var title_f37_38_38496="Clotrimazole: Patient drug information";
var content_f37_38_38496=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Clotrimazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/44/5828?source=see_link\">",
"       Clotrimazole (oral): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/37/41556?source=see_link\">",
"       Clotrimazole (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11610 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-5DB12175E3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_38_38496=[""].join("\n");
var outline_f37_38_38496=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/44/5828?source=related_link\">",
"      Clotrimazole (oral): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?40/37/41556?source=related_link\">",
"      Clotrimazole (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_38_38497="Patient information: Sudden infant death syndrome (SIDS) (The Basics)";
var content_f37_38_38497=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15898\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/33/26141\">",
"         Sudden infant death syndrome support groups",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/40/7811\">",
"         Patient information: Sudden infant death syndrome (SIDS) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sudden infant death syndrome (SIDS) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/sudden-infant-death-syndrome-sids-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H32868694\">",
"      <span class=\"h1\">",
"       What is sudden infant death syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sudden infant death syndrome (SIDS) is when a baby younger than 1 year old dies suddenly for no known reason. SIDS is sometimes called &ldquo;crib death.&rdquo;",
"     </p>",
"     <p>",
"      SIDS happens when a baby is sleeping, usually between midnight and 6 a.m. Almost all babies who die from SIDS are younger than 6 months old.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32868701\">",
"      <span class=\"h1\">",
"       What causes SIDS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors do not know what causes SIDS. But SIDS is more likely to happen when a baby:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Sleeps on his or her stomach",
"       </li>",
"       <li>",
"        Sleeps on a soft surface or with pillows, blankets, or stuffed animals in the bed",
"       </li>",
"       <li>",
"        Sleeps in a bed with an adult or another child",
"       </li>",
"       <li>",
"        Is too warm or wears too many clothes when sleeping",
"       </li>",
"       <li>",
"        Is born to a mother who smokes",
"       </li>",
"       <li>",
"        Is born to a mother who is younger than 20 years old or who did not get medical care during pregnancy",
"       </li>",
"       <li>",
"        Is born too early or weighs less than normal at birth",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32868715\">",
"      <span class=\"h1\">",
"       Can SIDS be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. SIDS cannot be prevented, and there is no test that can tell if it is going to happen. But there are things that parents can do to lower the chance that it will happen. To lower the chance of SIDS, do the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Put your baby on his or her back to sleep. Do not let your baby sleep on his or her stomach or side.",
"       </li>",
"       <li>",
"        Put your baby to sleep in a crib, cradle, or bassinet in your bedroom. If you want your baby to sleep near you, use a bassinet that attaches to your bed. Do not have your baby sleep in your bed with you.",
"       </li>",
"       <li>",
"        Have your baby sleep on a firm surface, and not on a cushion, waterbed, sofa, or other soft surface. Do not put your baby to sleep in a car seat except in the car.",
"       </li>",
"       <li>",
"        Remove pillows, stuffed animals, and other soft objects from the sleeping area. Do not use bumper pads on the crib.",
"       </li>",
"       <li>",
"        Do not cover your baby&rsquo;s head when he or she is sleeping.",
"       </li>",
"       <li>",
"        Do not dress your baby in too many clothes or keep the room too warm when he or she is sleeping.",
"       </li>",
"       <li>",
"        Stop smoking and do not let anyone smoke in the house or car.",
"       </li>",
"       <li>",
"        Breastfeed your baby.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Doctors do not recommend using devices or machines that check a baby&rsquo;s breathing or heart rate during sleep. Studies have shown that these do not prevent SIDS.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1526544\">",
"      <span class=\"h1\">",
"       How do doctors know if a death is from SIDS?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After a baby dies, doctors and other experts try to figure out the cause in a few different ways. They talk with the parents and look around the room where the baby died. They also might do an autopsy. An autopsy is an exam that is done after death.",
"     </p>",
"     <p>",
"      If the doctors find no other cause of death, then they say that the baby died from SIDS.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32868722\">",
"      <span class=\"h1\">",
"       Where can parents find help if SIDS happens?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse can tell you where to find help and support. It&rsquo;s very important for parents to get help, because a baby&rsquo;s death can be overwhelming. Parents can be in shock or feel anger, guilt, sadness, or fear.",
"     </p>",
"     <p>",
"      Some people find it helpful to go to a support group for parents whose babies died from SIDS. There are support groups all over the world (",
"      <a class=\"graphic graphic_table graphicRef63630 \" href=\"mobipreview.htm?25/33/26141\">",
"       table 1",
"      </a>",
"      ). Other people find it helpful to talk one-on-one with a mental health professional.",
"     </p>",
"     <p>",
"      If your baby died from SIDS, your other babies have a slightly higher than normal chance of dying from SIDS. Talk with your doctor or nurse about things that you can do to lower the chance that it will happen again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H32868729\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/40/7811?source=see_link\">",
"       Patient information: Sudden infant death syndrome (SIDS) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/38/38497?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15898 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-124.240.187.80-4AC29DC90F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_38_38497=[""].join("\n");
var outline_f37_38_38497=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32868694\">",
"      What is sudden infant death syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32868701\">",
"      What causes SIDS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32868715\">",
"      Can SIDS be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1526544\">",
"      How do doctors know if a death is from SIDS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32868722\">",
"      Where can parents find help if SIDS happens?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32868729\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15898\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/33/26141\">",
"      Sudden infant death syndrome support groups",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/40/7811?source=related_link\">",
"      Patient information: Sudden infant death syndrome (SIDS) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_38_38498="Intermediate case 16 answer";
var content_f37_38_38498=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Coarse atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 97px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coarse atrial fibrillatory waves are seen with an irregular ventricular response at a moderate rate. This arrhythmia may be mistaken for atrial flutter. However, the atrial waves are all identical in atrial flutter; in comparison, the rapid atrial waves vary in rate and shape from one section of the rhythm strip to the next in atrial fibrillation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_38_38498=[""].join("\n");
var outline_f37_38_38498=null;
var title_f37_38_38499="HLA TCR complex";
var content_f37_38_38499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53512&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interaction of the major histocompatibility complex (MHC) and the T cell antigen receptor complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 406px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The T cell antigen receptor (TCR) is composed of an alpha and a beta chain, which are linked by disulfide bonds forming a heterodimer. The TCR recognizes and interacts with processed peptide antigen presented in the context of the major histocompatibility complex (human leukocyte antigen [HLA] class I or class II).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Krensky AM, Weiss A, Crabtree G, et al. N Engl J Med 1990; 322:510",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_38_38499=[""].join("\n");
var outline_f37_38_38499=null;
var title_f37_38_38500="Ketoconazole (topical): Drug information";
var content_f37_38_38500=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketoconazole (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/51/34612?source=see_link\">",
"    see \"Ketoconazole (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/26/10659?source=see_link\">",
"    see \"Ketoconazole (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8120613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Extina&reg;;",
"     </li>",
"     <li>",
"      Nizoral&reg;;",
"     </li>",
"     <li>",
"      Nizoral&reg; A-D [OTC];",
"     </li>",
"     <li>",
"      Xolegel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8120614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ketoderm&reg;;",
"     </li>",
"     <li>",
"      Xolegel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8120619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8120753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Fungal infections:",
"     </b>",
"     <i>",
"      Topical:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cream:",
"     </i>",
"     Tinea infections:  Rub gently into the affected area once daily. Duration of treatment: Tinea corporis, cruris: 2 weeks; tinea pedis: 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Shampoo",
"     </i>",
"     (ketoconazole 2%): Tinea versicolor: Apply to damp skin, lather, leave on 5 minutes, and rinse (one application should be sufficient)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     <b>",
"      Seborrheic dermatitis:",
"     </b>",
"     <i>",
"      Topical:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Cream:",
"     </i>",
"     Rub gently into the affected area twice daily for 4 weeks or until clinical response is noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Foam:",
"     </i>",
"     Apply to affected area twice daily for 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Gel:",
"     </i>",
"     Rub gently into the affected area once daily for 2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Shampoo",
"     </i>",
"     (ketoconazole 1%): Apply twice weekly for up to 8 weeks with at least 3 days between each shampoo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Susceptible fungal infections in the oral cavity (candidiasis, oral thrush, and chronic mucocutaneous candidiasis) (unlabeled use):",
"     </b>",
"     <i>",
"      Topical:",
"     </i>",
"     Cream: Apply locally as directed with a thin coat to inner surface of denture and affected areas after meals",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8120752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/26/10659?source=see_link\">",
"      see \"Ketoconazole (topical): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Seborrheic dermatitis:",
"     </b>",
"     <i>",
"      Topical (cream/foam/gel, shampoo):",
"     </i>",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8120754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8120805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical: 2% (50 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extina&reg;: 2% (50 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 2% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xolegel&reg;: 2% (15 g [DSC], 45 g) [contains dehydrated ethanol 34%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical: 2% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nizoral&reg;: 2% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nizoral&reg; A-D: 1% (120 mL, 210 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8120615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Aerosol, cream, shampoo",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8120771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Cream, foam, gel, and shampoo are for external use only. Avoid exposure to flame or smoking immediately following application of gel or foam; do not apply directly to hands.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8120656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream: Treatment of tinea corporis, tinea cruris, tinea versicolor, cutaneous candidiasis, seborrheic dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Foam, gel: Treatment of seborrheic dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo: Treatment of dandruff, seborrheic dermatitis, tinea versicolor",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F12813375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cream: Treatment of susceptible fungal infections in the oral cavity including candidiasis, oral thrush, and chronic mucocutaneous candidiasis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8120604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nizoral&reg; may be confused with Nasarel, Neoral&reg;, Nitrol&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8120674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Topical cream/gel:",
"     </b>",
"     Stinging (~5%), local burning (4%), acne, allergic reaction, contact dermatitis (possibly related to sulfites or propylene glycol), discharge, dizziness, dryness, erythema, facial swelling, headache, impetigo, keratoconjunctivitis sicca, nail discoloration, ocular irritation/swelling, pain, paresthesia, pruritus, pustules, pyogenic granuloma, severe irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Topical foam:",
"     </b>",
"     Application site burning (10%), application site reaction (6%), contact sensitization, dryness, erythema, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo:",
"     </b>",
"     Application site reaction (&le;3%), dry skin (&le;3%), pruritus (&le;3%), abnormal hair texture (&lt;1%), hair loss increased (&lt;1%), irritation (&lt;1%), scalp pustules (&lt;1%), alopecia, anaphylaxis, angioedema, burning sensation, contact dermatitis, hair discoloration, hypersensitivity, itching, oiliness/dryness of hair, rash, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8120663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ketoconazole or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8120664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Cases of  hypersensitivity reactions (including rare cases of anaphylaxis) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: May cause irritation; discontinue use if occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Foam: Formulation contains alcohol and propane/butane; do not expose to open flame or smoking during or immediately after application. Do not puncture or incinerate container.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gel: Avoid exposure of gel to open flames or smoking during or immediately after application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Shampoo: Severe allergic reactions (including anaphylaxis) have occurred. Use may remove curl from permanently wavy hair, cause hair discoloration, and changes in hair texture. Avoid contact with eyes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Formulations may contain sulfites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8120700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8120659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8120660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were noted in animal reproduction studies with oral ketoconazole.  Ketoconazole is not detectable in the plasma following chronic use of the shampoo.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8120662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9771736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ketoconazole has been detected in breast milk following oral dosing. Although it is not detected in the plasma following chronic use of the shampoo, and concentrations in the plasma following application of the gel are &lt;250 times those observed with oral dosing, the manufacturers recommend that caution be used when administering to a nursing woman.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8120807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Ketoconazole External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (30 g): $27.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Extina External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (50 g): $239.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Ketoconazole External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (50 g): $215.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Foam",
"     </b>",
"     (Ketodan External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (100 g): $369.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Xolegel External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (45 g): $475.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Ketoconazole External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (120 mL): $27.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Nizoral A-D External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (125 mL): $9.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Nizoral External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (120 mL): $57.58",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Apodruff (IN);",
"     </li>",
"     <li>",
"      Aquarius (GR);",
"     </li>",
"     <li>",
"      Arcolan (BR);",
"     </li>",
"     <li>",
"      Arcolane (CO);",
"     </li>",
"     <li>",
"      DaktaGOLD (AU, NZ);",
"     </li>",
"     <li>",
"      Dezor Cream (MY, SG, TH);",
"     </li>",
"     <li>",
"      Dezor Shampoo (MY, PH);",
"     </li>",
"     <li>",
"      Fitonal (AR);",
"     </li>",
"     <li>",
"      Formyco (ID, SG);",
"     </li>",
"     <li>",
"      Fundan (SE);",
"     </li>",
"     <li>",
"      Fungaway (TW);",
"     </li>",
"     <li>",
"      Fungiderm-K (TH);",
"     </li>",
"     <li>",
"      Fungium (CN, PY);",
"     </li>",
"     <li>",
"      Fungoral (NO);",
"     </li>",
"     <li>",
"      Kenazole (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, TW, YE);",
"     </li>",
"     <li>",
"      Ketazol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ketoco (TW);",
"     </li>",
"     <li>",
"      Ketoconazol (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Ketoderm (FR);",
"     </li>",
"     <li>",
"      Ketona (TW);",
"     </li>",
"     <li>",
"      Ketopine (NZ);",
"     </li>",
"     <li>",
"      Ketozol Shampoo (IL);",
"     </li>",
"     <li>",
"      Kezon (TH);",
"     </li>",
"     <li>",
"      Larry (TH);",
"     </li>",
"     <li>",
"      Micoral (AR);",
"     </li>",
"     <li>",
"      Micosin (EC);",
"     </li>",
"     <li>",
"      Mycofebrin (GR);",
"     </li>",
"     <li>",
"      Nazole (KP);",
"     </li>",
"     <li>",
"      Niz Creme (ZA);",
"     </li>",
"     <li>",
"      Niz Shampoo (ZA);",
"     </li>",
"     <li>",
"      Nizoral (AE, AT, BB, BE, BF, BG, BH, BJ, BM, BR, BS, CH, CI, CL, CY, CZ, DE, DK, EE, EG, ET, FI, GH, GM, GN, GY, HK, ID, IE, IL, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, OM, PH, PK, PL, PR, QA, RU, SA, SC, SD, SG, SL, SN, SR, SY, TH, TN, TR, TT, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Nizoral 2% Cream (AU, NZ, PH);",
"     </li>",
"     <li>",
"      Nizoral Cream (GB, IE);",
"     </li>",
"     <li>",
"      Nizoral Shampoo (DE, NZ, PH);",
"     </li>",
"     <li>",
"      Pikangwang (CL);",
"     </li>",
"     <li>",
"      Pristine (HK, MY);",
"     </li>",
"     <li>",
"      Pristinex (HK);",
"     </li>",
"     <li>",
"      Reduff (PH);",
"     </li>",
"     <li>",
"      Sebizole (AU, NZ);",
"     </li>",
"     <li>",
"      Sporaxyl (TH);",
"     </li>",
"     <li>",
"      Sporium (CO);",
"     </li>",
"     <li>",
"      Terzolin (DE);",
"     </li>",
"     <li>",
"      Triatop Lotion (CL);",
"     </li>",
"     <li>",
"      Yucomy (MY);",
"     </li>",
"     <li>",
"      Zhoulixin (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8120707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alters the permeability of the cell wall by blocking fungal cytochrome P450; inhibits biosynthesis of triglycerides and phospholipids by fungi; inhibits several fungal enzymes that results in a build-up of toxic concentrations of hydrogen peroxide; also inhibits androgen synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8120709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Shampoo: None; Gel: Minimal",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Moretti ME, Ito S, and Koren G, &ldquo;Disposition of Maternal Ketoconazole in Breast Milk,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1995, 173(5):1625-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38500/abstract-text/7503214/pubmed\" id=\"7503214\" target=\"_blank\">",
"        7503214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9150 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_38_38500=[""].join("\n");
var outline_f37_38_38500=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120613\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120614\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120619\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120753\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120752\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120754\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120805\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120615\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120771\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120656\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12813375\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120604\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120674\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120663\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120664\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299555\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120700\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120659\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120660\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120662\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9771736\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120807\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961983\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120707\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120709\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9150\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9150|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/58/28585?source=related_link\">",
"      Ketoconazole (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/30/2533?source=related_link\">",
"      Ketoconazole (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/62/20457?source=related_link\">",
"      Ketoconazole (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/51/34612?source=related_link\">",
"      Ketoconazole (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/26/10659?source=related_link\">",
"      Ketoconazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_38_38501="Entacapone: Drug information";
var content_f37_38_38501=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Entacapone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/10/20644?source=see_link\">",
"    see \"Entacapone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Comtan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Comtan&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Entacapone;",
"     </li>",
"     <li>",
"      Teva-Entacapone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F165196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Parkinson's Agent, COMT Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F165170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parkinson's disease: Oral: 200 mg with each dose of levodopa/carbidopa, up to a maximum of 8 times/day (maximum daily dose: 1600 mg/day). To optimize therapy, the dosage of levodopa may need reduced or the dosing interval may need extended. Patients taking levodopa &ge;800 mg/day or who had moderate-to-severe dyskinesias prior to therapy required an average decrease of 25% in the daily levodopa dose.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F165171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F165172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment is required; dialysis patients were not studied.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F165173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage adjustment in chronic therapy with standard treatment has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F165145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Comtan&reg;: 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F165131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F165148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Always administer in association with levodopa/carbidopa; can be combined with both the immediate and sustained release formulations of levodopa/carbidopa. May be administered without regard to meals. Should not be abruptly withdrawn from patient's therapy due to significant worsening of symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F165146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to levodopa/carbidopa therapy in patients with idiopathic Parkinson's disease who experience &ldquo;wearing-off&rdquo; symptoms at the end of a dosing interval",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F165194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dyskinesia (25%), placebo (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension (4.3%), syncope (1.2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (8%), fatigue (6%), hallucinations (4%), anxiety (2%), somnolence (2%), agitation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Purpura (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (10%), abdominal pain (8%), constipation (6%), vomiting (4%), dry mouth (3%), dyspepsia (2%), flatulence (2%), gastritis (1%), taste perversion (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Brown-orange urine discoloration (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hyperkinesia (10%), hypokinesia (9%), back pain (4%), weakness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased (2%), bacterial infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Hyperpyrexia and confusion (resembling neuroleptic malignant syndrome), pulmonary fibrosis, retroperitoneal fibrosis, rhabdomyolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F165151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to entacapone or any of component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F165135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: Has been associated with delayed development of diarrhea (usual onset after 4-12 weeks); use with caution in patients with lower gastrointestinal disease or an increased risk of dehydration. Diarrhea may be a sign of drug-induced colitis. Discontinue use with prolonged diarrhea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hallucinations: May cause hallucinations, which may improve with reduction in levodopa therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impulse control disorders: Dopaminergic agents used for Parkinson&rsquo;s disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Melanoma: Risk for melanoma development is increased in Parkinson&rsquo;s disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome: Entacapone, in conjunction with other drug therapy that alters brain biogenic amine concentrations (eg, MAO inhibitors, SSRIs), has been associated with a syndrome resembling neuroleptic malignant syndrome (hyperpyrexia and confusion - some fatal) on abrupt withdrawal or dosage reduction. Concomitant use of tolcapone and nonselective MAO inhibitors should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension and syncope; Parkinson's disease patients appear to have an impaired capacity to respond to a postural challenge; use with caution in patients at risk of hypotension (such as those receiving antihypertensive drugs) or where transient hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease). Parkinson's patients being treated with dopaminergic agonists ordinarily require careful monitoring for signs and symptoms of postural hypotension, especially during dose escalation, and should be informed of this risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pleural/retroperitoneal fibrosis: Dopaminergic agents from the ergot class have been associated with fibrotic complications, such as retroperitoneal fibrosis, pulmonary infiltrates or effusion and pleural thickening. It is unknown whether non-ergot, pro-dopaminergic agents like tolcapone confer this risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rhabdomyolysis: Severe rhabdomyolysis has been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dyskinesia: Use with caution in patients with pre-existing dyskinesias; exacerbation of pre-existing dyskinesia has been reported. Levodopa dosage reduction may be required, particularly in patients with levodopa dosages &gt;600 mg daily or with moderate-to-severe dyskinesia prior to initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Catecholamines: Use caution with agents metabolized by COMT (eg, epinephrine, dopamine, methyldopa) regardless of route of administration; effects may be enhanced when used with entacapone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MAO inhibitors: Concomitant use of entacapone and nonselective MAO inhibitors should be avoided. Selegiline is a selective MAO type B inhibitor (when given orally at  &le;10 mg/day) and can be taken with entacapone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Body fluid discoloration: Urine, saliva, or sweat may appear dark in color (red, brown, black) during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Do not withdraw therapy abruptly.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F165190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     COMT, CYP1A2 (weak), CYP2A6 (weak), CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F165140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Substrates: COMT Inhibitors may decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: COMT Inhibitors may enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F165164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Entacapone has been reported to chelate iron and decreasing serum iron levels were noted in clinical trials; however, clinically significant anemia has not been observed.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F165141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F165153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F165175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F165154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F165152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Comtan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $504.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Entacapone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $395.48",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F165143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of Parkinson's disease; liver function tests, blood pressure, patient's mental status; serum iron (if signs of anemia)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F165155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adcapone (IN);",
"     </li>",
"     <li>",
"      Anxopone (TW);",
"     </li>",
"     <li>",
"      Comtade (CO);",
"     </li>",
"     <li>",
"      Comtan (AR, AT, AU, BE, BG, BR, CH, CL, CN, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IT, KP, MT, MX, MY, NL, NO, NZ, PE, PH, PL, PT, PY, RU, SE, SK, TH, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Comtess (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F165134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Entacapone is a reversible and selective inhibitor of catechol-O-methyltransferase (COMT). When entacapone is taken with levodopa, the pharmacokinetics are altered, resulting in more sustained levodopa serum levels compared to levodopa taken alone. The resulting levels of levodopa provide for increased concentrations available for absorption across the blood-brain barrier, thereby providing for increased CNS levels of dopamine, the active metabolite of levodopa.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F165150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: I.V.: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 20 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Isomerization to the",
"     <i>",
"      cis",
"     </i>",
"     -isomer, followed by direct glucuronidation of the parent and",
"     <i>",
"      cis",
"     </i>",
"     -isomer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 35%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: B phase: 0.4-0.7 hours; Y phase: 2.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (90%); urine (10%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Pahwa R, Factor SA, Lyons KE, et al, &ldquo;Practice Parameter: Treatment of Parkinson Disease With Motor Fluctuations and Dyskinesia (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2006, 66(7):983-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38501/abstract-text/16606909/pubmed\" id=\"16606909\" target=\"_blank\">",
"        16606909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8912 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_38_38501=[""].join("\n");
var outline_f37_38_38501=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165167\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165168\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165196\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165170\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165171\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165172\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165173\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165145\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165131\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165148\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165146\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165194\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165151\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165135\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165190\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165140\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165164\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165141\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165153\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165175\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165154\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165152\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165143\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165155\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165134\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165150\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8912\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8912|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?20/10/20644?source=related_link\">",
"      Entacapone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_38_38502="Cilostazol: Drug information";
var content_f37_38_38502=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cilostazol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/8/34948?source=see_link\">",
"    see \"Cilostazol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7885909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pletal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F151461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiplatelet Agent;",
"     </li>",
"     <li>",
"      Phosphodiesterase-3 Enzyme Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F151445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Intermittent claudication:",
"     </b>",
"     Oral: 100 mg twice daily (when refractory to exercise therapy and smoking cessation, use in combination with either aspirin or clopidogrel) (Guyatt, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      PCI (following elective stent placement) (unlabeled use):",
"     </b>",
"     Oral: 100 mg twice daily in combination with aspirin or clopidogrel.",
"     <b>",
"      Note:",
"     </b>",
"     Only recommended in patients with an allergy or intolerance to either aspirin or clopidogrel (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Secondary prevention of noncardioembolic stroke or TIA (unlabeled use):",
"     </b>",
"     Oral: 100 mg twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Clopidogrel or aspirin/extended release dipyridamole recommended over the use of cilostazol (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment for cilostazol with concomitant medications:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CYP2C19 inhibitors (eg, omeprazole): Dosage of cilostazol should be reduced to 50 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, diltiazem): Dosage of cilostazol should be reduced to 50 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F151446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied in moderate-to-severe hepatic impairment); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F151423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pletal&reg;: 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F151410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5582346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer cilostazol 30 minutes before or 2 hours after meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F151424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic management of peripheral vascular disease, primarily intermittent claudication",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F151457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct with aspirin and clopidogrel for prevention of stent thrombosis and restenosis after coronary stent placement; as an alternative agent to either aspirin or clopidogrel in a dual antiplatelet regimen when allergy or drug intolerance to either agent occurs in patients who have undergone elective PCI with bare metal or drug-eluting stent placement; secondary prevention of noncardioembolic ischemic stroke or transient ischemic attack (TIA)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F151468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pletal&reg; may be confused with Plendil&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F151459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (27% to 34%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abnormal stools (12% to 15%), diarrhea (12% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (7% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (10% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (7% to 9%), palpitation (5% to 10%), tachycardia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (9% to 10%), vertigo (up to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (6%), nausea (6% to 7%), abdominal pain (4% to 5%), flatulence (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (6% to 7%), myalgia (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (7% to 10%), cough (3% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Agranulocytosis, anemia, aplastic anemia, asthma, atrial fibrillation, atrial flutter, blindness, blood pressure increased, bursitis, cardiac arrest, cerebral infarction/ischemia, cerebrovascular accident, chest pain, CHF, cholelithiasis, colitis, coronary stent thrombosis, cystitis, diabetes mellitus, duodenal ulcer, duodenitis, esophageal hemorrhage, esophagitis, extradural hematoma, gastrointestinal hemorrhage, gout, granulocytopenia, hemorrhage, hepatic dysfunction, hot flashes, hyperglycemia, hypotension, interstitial pneumonia, intracranial hemorrhage, jaundice, leukopenia, myocardial infarction/ischemia, neuralgia, nodal arrhythmia, orthostatic hypotension, pain, periodontal abscess, peptic ulcer, pneumonia, polycythemia, pulmonary hemorrhage, pruritus, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, rectal hemorrhage, retinal hemorrhage, retroperitoneal hemorrhage, Stevens-Johnson syndrome, subcutaneous hemorrhage, subdural hematoma, supraventricular tachycardia, syncope, thrombocytopenia, thrombosis, torsade de pointes, uric acid increased, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F151427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cilostazol or any component of the formulation; heart failure (HF) of any severity; hemostatic disorders or active bleeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F151414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Leukopenia: Discontinue therapy if leukopenia occurs; progression to agranulocytosis (reversible) has been reported when cilostazol was not immediately stopped.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: The use of this drug is contraindicated in patients with heart failure of any severity. Phosphodiesterase inhibitors have decreased survival rates in patients with class III-IV heart failure.",
"     </b>",
"     Use with caution in patients with underlying heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with moderate-to-severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Discontinue therapy if thrombocytopenia occurs; progression to agranulocytosis (reversible) has been reported when cilostazol was not immediately stopped.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Clopidogrel: When cilostazol and clopidogrel are used concurrently, manufacturer recommends checking bleeding times.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP3A4 inhibitors, moderate or strong CYP3A4 inducers and major CYP3A4 substrates (see Drug Interactions); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Platelet aggregation inhibitors: Use with caution in patients receiving other platelet aggregation inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elective surgery: Withhold for at least 4-6 half-lives prior to elective surgical procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F151454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (major), CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F151419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Esomeprazole: May enhance the adverse/toxic effect of Cilostazol. Esomeprazole may increase the serum concentration of Cilostazol. Esomeprazole may increase the serum concentration of OPC-13015, an active metabolite of Cilostazol. Management: Monitor for increased cilostazol effects when coadministered with esomeprazole. The manufacturer recommends considering a 50% dose reduction of cilostazol (eg, 100 mg twice daily to 50 mg twice daily) with concomitant use of these agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Cilostazol.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omeprazole: May enhance the adverse/toxic effect of Cilostazol. Omeprazole may increase the serum concentration of Cilostazol. Omeprazole may increase the serum concentration of  OPC-13015, an active metabolite of Cilostazol. Management: Monitor for increased effects of cilostazol when coadministered with omeprazole. Consider a 50% dose reduction of cilostazol (eg, 100 mg twice daily to 50 mg twice daily) with concomitant use of these agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F151438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Taking cilostazol with a high-fat meal may increase peak concentration by 90%. Grapefruit juice may increase serum levels of cilostazol and enhance toxic effects. Management: Administer cilostazol on an empty stomach 30 minutes before or 2 hours after meals. Avoid concurrent ingestion of grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may decrease the levels/effects of cilostazol. Other herbs/nutraceuticals have additional antiplatelet activity. Management: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, chamomile, coleus, cordyceps, dong quai, evening primrose oil, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American), ginseng (Panax), ginseng (Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), St John's wort, sweet clover, turmeric, and white willow.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F151420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F151429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In animal studies, abnormalities of the skeletal, renal and cardiovascular system were increased. In addition, the incidence of stillbirth and decreased birth weights were increased.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F151448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F151430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known whether cilostazol is excreted in human milk. Because of the potential risk to nursing infants, a decision to discontinue the drug or discontinue nursing should be made.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F151431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is best to take cilostazol 30 minutes before or 2 hours after meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F151428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cilostazol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (60): $109.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (60): $109.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pletal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (60): $128.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (60): $128.46",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F151432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aggravan (ID, PH);",
"     </li>",
"     <li>",
"      Alista (ID);",
"     </li>",
"     <li>",
"      Angiovan (CO);",
"     </li>",
"     <li>",
"      Artesol (CN);",
"     </li>",
"     <li>",
"      Cebralat C (BR);",
"     </li>",
"     <li>",
"      Ciletin (PH);",
"     </li>",
"     <li>",
"      Cilosol (KP, TH);",
"     </li>",
"     <li>",
"      Cilostal (CR, DO, EC, GT, HN, NI, PA, PE, SV);",
"     </li>",
"     <li>",
"      Cistazol (TW);",
"     </li>",
"     <li>",
"      Citaz (ID);",
"     </li>",
"     <li>",
"      Citazol (TW);",
"     </li>",
"     <li>",
"      Clazol (PH);",
"     </li>",
"     <li>",
"      Colidac (IN);",
"     </li>",
"     <li>",
"      Dulox (CO);",
"     </li>",
"     <li>",
"      Lozence (KP);",
"     </li>",
"     <li>",
"      Pencil (PH);",
"     </li>",
"     <li>",
"      Platecil (PH);",
"     </li>",
"     <li>",
"      Pletaal (AR, CL, JP, MY, PE, PH, PK, TH, TW);",
"     </li>",
"     <li>",
"      Pletal (AU, DE, GB, IE, IT, SE, TR);",
"     </li>",
"     <li>",
"      Pletoz (IN);",
"     </li>",
"     <li>",
"      Pleya (TW);",
"     </li>",
"     <li>",
"      Policor (UY);",
"     </li>",
"     <li>",
"      Qital (ID);",
"     </li>",
"     <li>",
"      Rostal (KP);",
"     </li>",
"     <li>",
"      Sadoxol (UY);",
"     </li>",
"     <li>",
"      Silverstar (KP);",
"     </li>",
"     <li>",
"      Stazol (ID);",
"     </li>",
"     <li>",
"      Trastocir (AR);",
"     </li>",
"     <li>",
"      Trombocil (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F151413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cilostazol and its metabolites are inhibitors of phosphodiesterase III. As a result, cyclic AMP is increased leading to reversible inhibition of platelet aggregation, vasodilation, and inhibition of vascular smooth muscle cell proliferation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F151426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 2-4 weeks; may require up to 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Cilostazol 95% to 98%; active metabolites 66% to 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 (primarily), 1A2, 2C19, and 2D6; at least one metabolite has significant activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 11-13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (74%) and feces (20%) as metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al, &ldquo;Coronary Stent Restenosis in Patients Treated With Cilostazol,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 112(18 ):2826-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38502/abstract-text/16246948/pubmed\" id=\"16246948\" target=\"_blank\">",
"        16246948",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38502/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38502/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary. A Collaborative Report of the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2006, 113(11):e463-654. Available at  file://www.acc.org/clinical/guidelines/pad/index.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38502/abstract-text/16549646/pubmed\" id=\"16549646\" target=\"_blank\">",
"        16549646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee SW, Park SW, Hong MK, et al, &ldquo;Comparison of Cilostazol and Clopidogrel After Successful Coronary Stenting,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2005, 95(7):859-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38502/abstract-text/15781016/pubmed\" id=\"15781016\" target=\"_blank\">",
"        15781016",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee SW, Park SW, Kim YH, et al, &ldquo;Comparison of Triple Versus Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation (From the DECLARE-Long Trial),&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2007, 100(7):1103-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38502/abstract-text/17884371/pubmed\" id=\"17884371\" target=\"_blank\">",
"        17884371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8872 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_38_38502=[""].join("\n");
var outline_f37_38_38502=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7885909\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151442\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151461\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151445\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151446\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682656\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682657\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151423\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151410\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5582346\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151424\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151457\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151468\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151459\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151427\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151414\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151454\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151419\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151438\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151420\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151429\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151448\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151430\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151431\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151428\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151432\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151413\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151426\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8872\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8872|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/8/34948?source=related_link\">",
"      Cilostazol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_38_38503="Ampicillin: Pediatric drug information";
var content_f37_38_38503=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ampicillin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"    see \"Ampicillin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/26/11685?source=see_link\">",
"    see \"Ampicillin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ampicillin for Injection;",
"     </li>",
"     <li>",
"      Apo-Ampi&reg;;",
"     </li>",
"     <li>",
"      Novo-Ampicillin;",
"     </li>",
"     <li>",
"      Nu-Ampi",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Penicillin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11432528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      General dosing, susceptible infection",
"     </b>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012): I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Body weight &le;2 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA &le;7 days: 50 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA 8-28 days: 50 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Body weight &gt;2 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA &le;7 days: 50 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA 8-28 days: 50 mg/kg/dose every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bacteremia, Group B streptococcal (presumed or proven)",
"     </b>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012):",
"     <b>",
"      Note:",
"     </b>",
"     Treatment of bacteremia without a defined focus should be for at least 10 days: I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Body weight &le;2 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA &le;7 days: 100 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA 8-28 days: 50 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Body weight &gt;2 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA &le;7 days: 100 mg/kg/dose every 12 hours or 50 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA 8-28 days: 50 mg/kg/dose every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Meningitis, Group B streptococcal:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA &le;7 days: 50-100 mg/kg/dose every 8 hours for at least 14 days if uncomplicated; some experts have also recommended 75 mg/kg/dose every 6 hours (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012; Tunkel, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA &gt;7 days: 50-75 mg/kg/dose every 6 hours for at least 14 days if uncomplicated; some experts have also recommended 75 mg/kg/dose every 6 hours (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012; Tunkel, 2004)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"      see \"Ampicillin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      General dosing, susceptible infection",
"     </b>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Mild to moderate infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral: 50-100 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours; maximum daily dose: 4",
"     <b>",
"      g/day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.M., I.V.: 100-150 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours; maximum daily dose: 4",
"     <b>",
"      g/day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Severe infection:",
"     </b>",
"     I.M., I.V.: 200-400 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours; maximum daily dose: 12",
"     <b>",
"      g/day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Community-acquired pneumonia (CAP)",
"     </b>",
"     (IDSA/PIDS, 2011): Infants &gt;3 months, Children, and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     May consider addition of vancomycin or clindamycin to empiric therapy if community-acquired MRSA suspected. In children &ge;5 years, a macrolide antibiotic should be added if atypical pneumonia cannot be ruled out.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Empiric treatment or",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (MICs for penicillin &le;2 mcg/mL) or",
"     <i>",
"      H. influenzae",
"     </i>",
"     (beta-lactamase negative) in fully immunized patients: I.V.: 150-200 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Group A",
"     <i>",
"      Streptococcus",
"     </i>",
"     : I.V.: 200 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (MICs for penicillin &ge;4 mcg/mL): I.V.: 300-400 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Endocarditis",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: I.V.:  300 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 4-6 hours with gentamicin for at least 4-6 weeks; some organisms may require longer duration (Baddour, 2005; Ferrieri, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Dental procedure or respiratory tract procedures (eg, tonsillectomy, adenoidectomy): I.V., I.M.: 50 mg/kg within 30-60 minutes before procedure;  maximum dose: 2000 mg (Wilson, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Genitourinary and gastrointestinal tract procedures (high-risk patients): I.V., I.M.: 50 mg/kg within 30 minutes prior to procedure; maximum dose: 2000 mg; followed by ampicillin 25 mg/kg (or amoxicillin 25 mg/kg orally) 6 hours later; must be used in combination with gentamicin.",
"     <b>",
"      Note:",
"     </b>",
"     As of April 2007,  the American Heart Association guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. Routine prophylaxis for GI/GU procedures is no longer recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Intra-abdominal infection, complicated:",
"     </b>",
"     I.V.: 200 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours; maximum dose: 2000 mg; maximize doses if undrained abdominal abscesses (Solomkin, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Meningitis:",
"     </b>",
"     I.V.: 200-400 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours; maximum daily dose: 12",
"     <b>",
"      g/day",
"     </b>",
"     (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012; Tunkel, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Peritonitis (CAPD):",
"     </b>",
"     Intraperitoneal: 125 mg per liter of dialysate for 2 weeks (Warady, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Usual dosage range:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 250-500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.: 1000-2000 mg every 4-6 hours or 50-250 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses (maximum daily dose: 12",
"     <b>",
"      g/day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cholangitis (acute):",
"     </b>",
"     I.V.: 2000 mg every 4 hours with gentamicin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Diverticulitis:",
"     </b>",
"     I.M., I.V.: 2000 mg every 6 hours with metronidazole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Endocarditis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infective: I.V.: 12",
"     <b>",
"      g/day",
"     </b>",
"     via continuous infusion or divided every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: Dental, oral, or respiratory tract procedures: I.M., I.V.: 2000 mg within 30-60 minutes prior to procedure in patients not allergic to penicillin and unable to take oral amoxicillin. Intramuscular injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications.",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Prophylaxis in total joint replacement patient: I.M., I.V.: 2000 mg 1 hour prior to the procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Genitourinary and gastrointestinal tract procedures: I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     High-risk patients: 2000 mg within 30 minutes prior to procedure, followed by ampicillin 1000 mg (or amoxicillin 1000 mg orally) 6 hours later; must be used in combination with gentamicin.",
"     <b>",
"      Note:",
"     </b>",
"     As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Moderate-risk patients: 2000 mg within 30 minutes prior to procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Group B strep prophylaxis (intrapartum):",
"     </b>",
"     I.V.: 2000 mg initial dose, then 1000 mg every 4 hours until delivery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Listeria",
"      </i>",
"      infections:",
"     </b>",
"     I.V.: 2000 mg every 4 hours (consider addition of aminoglycoside)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Mild to moderate infections:",
"     </b>",
"     Oral: 250-500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Sepsis/meningitis:",
"     </b>",
"     I.V.: 150-250 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 3-4 hours (range: 6-12",
"     <b>",
"      g/day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Urinary tract infections (",
"      <i>",
"       Enterococcus",
"      </i>",
"      suspected):",
"     </b>",
"     I.V.: 1000-2000 mg every 6 hours with gentamicin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants, Children, and Adolescents: The following adjustments have been recommended (Aronoff, 2007).",
"     <b>",
"      Note:",
"     </b>",
"     Renally adjusted dose recommendations are based on doses of 100-200 mg/kg/day divided every 6 hours:  I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR 30-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 35-50 mg/kg/dose every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR 10-29 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 35-50 mg/kg/dose every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     GFR &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : 35-50 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermittent hemodialysis: 35-50 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peritoneal dialysis (PD):  35-50 mg/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): 35-50 mg/kg/dose every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute: Administer every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (20% to 50%): I.V.: 1-2 g every 12-24 hours (Heintz, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times/week, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peritoneal dialysis (PD): 250 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     CVVH: Loading dose of 2 g followed by 1-2 g every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     CVVHD: Loading dose of 2 g followed by 1-2 g every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     CVVHDF: Loading dose of 2 g followed by 1-2 g every 6-8 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F134931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium [strength expressed as base]: 125 mg, 250 mg, 500 mg, 1 g, 2 g, 10 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: 125 mg/5 mL (100 mL, 200 mL); 250 mg/5 mL (100 mL, 200 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F134915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer around-the-clock to promote less variation in peak and trough serum levels. Administer on an empty stomach (ie, 1 hour prior to or 2 hours after meals) to increase total absorption; shake suspension well before using",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Reconstitute vial with SWI to a final concentration of 125-250 mg/mL; administer intramuscularly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V. push: Reconstitute vial with SWI (see manufacturer labeling for specific details). Doses &le;500 mg should be administered over 3-5 minutes; doses &gt;500 mg should be administered over 10-15 minutes; rapid administration has been associated with seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermittent I.V. infusion: Infuse over 10-15 minutes at a concentration not to exceed 30 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F135012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Incompatible",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      10",
"     </sub>",
"     W, fat emulsion 10%, hetastarch 6%, LR;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, alprostadil, amifostine, anidulafungin, aztreonam, bivalirudin, cyclophosphamide, cyclosporine, dexmedetomidine, docetaxel, doxorubicin liposome, enalaprilat, esmolol, etoposide phosphate, famotidine, fentanyl, filgrastim, fludarabine, foscarnet, gemcitabine, granisetron, heparin, hydrocortisone sodium succinate, insulin (regular), labetalol, levofloxacin, linezolid, magnesium sulfate, melphalan, meperidine, milrinone, morphine, multivitamins, oxytocin, pantoprazole, pemetrexed, phytonadione, potassium chloride, propofol, remifentanil, tacrolimus, teniposide, theophylline, thiotepa, tolazoline, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, caspofungin, ciprofloxacin,  epinephrine, fenoldopam, fluconazole, hydralazine, midazolam, nicardipine, ondansetron, sargramostim, verapamil, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Calcium gluconate, cisatracurium, diltiazem, doxapram, hetastarch in lactate electrolyte injection (Hextend&reg;), hydromorphone, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Chloramphenicol, colistimethate, dimenhydrinate, heparin, iohexol, iopamidol, iothalamate meglumine 60%, ioxaglate meglumine 39.3%, ioxaglate 19.6%, pantoprazole, procaine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Erythromycin lactobionate, gentamicin, hydromorphone, kanamycin, lincomycin, metoclopramide.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Lidocaine, polymyxin B sulfate, streptomycin.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Store capsules and powder for suspension at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); after reconstitution, suspension is stable for 14 days under refrigeration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Store intact vials  20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); after reconstitution, solutions for I.M. or direct I.V. should be used within 1 hour. Solutions for I.V. infusion in NS are stable for 8 hours at room temperature (25&deg;C)  or 2 days under refrigeration (4&deg;C); solutions mixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W are only stable for 2 hours due to  inactivation by dextrose at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible respiratory, gastrointestinal, and urinary tract infections; bacterial meningitis, septicemia, and endocarditis [FDA approved in pediatric patients (age not specified) and  adults]; susceptible organisms may include streptococci, pneumococci, enterococci, nonpenicillinase-producing staphylococci,",
"     <i>",
"      Listeria",
"     </i>",
"     , meningococci; some strains of",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      P. mirabilis",
"     </i>",
"     ,",
"     <i>",
"      Salmonella",
"     </i>",
"     ,",
"     <i>",
"      Shigella",
"     </i>",
"     ,",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Enterobacter",
"     </i>",
"     , and",
"     <i>",
"      Klebsiella",
"     </i>",
"     ; has also been used as empiric  therapy for neonatal  sepsis or meningitis and endocarditis prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F135014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ampicillin may be confused with aminophylline",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F135011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever, penicillin encephalopathy, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema multiforme, exfoliative dermatitis, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Appearance of a rash should be carefully evaluated to differentiate (if possible) nonallergic ampicillin rash from hypersensitivity reaction. Incidence is higher in patients with viral infection,",
"     <i>",
"      Salmonella",
"     </i>",
"     infection, lymphocytic leukemia, or patients that have hyperuricemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Black hairy tongue, diarrhea, enterocolitis, glossitis, nausea, oral candidiasis, pseudomembranous colitis, sore mouth or tongue, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, eosinophilia, hemolytic anemia, leukopenia, thrombocytopenia purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Interstitial nephritis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Laryngeal stridor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, serum sickness-like reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ampicillin, any penicillin, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; dosage adjustment recommended; use with caution in patients allergic to cephalosporins and asthmatic patients.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious and occasionally severe or fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria). Administration to patients with confirmed penicillin allergies should be avoided; in patients with confirmed cephalosporin allergy, consider skin testing to rule out cross-sensitivity to penicillins. Epstein-Barr virus infection (infectious mononucleosis), acute lymphocytic leukemia, or cytomegalovirus infection increase risk for ampicillin-induced maculopapular rash. Appearance of a rash should be carefully evaluated to differentiate a nonallergic ampicillin rash from a hypersensitivity reaction; rash occurs in 5% to 10% of children and is a generalized dull red, maculopapular rash, generally appearing 3-14 days after the start of therapy. It normally begins on the trunk and spreads over most of the body. It may be most intense at pressure areas, elbows, and knees. A high percentage (43% to 100%) of patients with infectious mononucleosis have developed rash during therapy; ampicillin-class antibiotics are not recommended in these patients. Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Seizures have been reported with rapid I.V. administration (over &lt;3 minutes).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F134924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May enhance the potential for allergic or hypersensitivity reactions to Ampicillin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atenolol: Ampicillin may decrease the bioavailability of Atenolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: May decrease the serum concentration of Ampicillin. Management: Chloroquine prescribing information recommends separating administration of ampicillin and chloroquine by at least 2 hours to minimize any potential negative impact of chloroquine on ampicillin bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Ampicillin. Management: Administer oral ampicillin at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1045176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food decreases rate and extent of absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F134927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F134941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Ampicillin crosses the placenta, providing detectable concentrations in the cord serum and amniotic fluid. Maternal use of ampicillin has generally not resulted in an increased risk of birth defects. Ampicillin is recommended for use in pregnant women for the management of preterm premature rupture of membranes (PPROM) and for the prevention of early-onset group B streptococcal (GBS) disease in newborns. Ampicillin may also be used in certain situations prior to vaginal delivery in women at high risk for endocarditis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The volume of distribution of ampicillin is increased during pregnancy and the half-life is decreased.  As a result, serum concentrations in pregnant patients are approximately 50% of those in nonpregnant patients receiving the same dose.  Higher doses may be needed during pregnancy.  Although oral absorption is not altered during pregnancy, oral ampicillin is poorly absorbed during labor.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     With prolonged therapy monitor renal, hepatic, and hematologic function periodically; observe for change in bowel frequency; observe for signs of anaphylaxis with first dose",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial cell wall synthesis by binding to one or more penicillin-binding proteins during active multiplication; inhibits the final transpeptidation step of peptidoglycan synthesis causing cell wall death and resultant bactericidal activity against susceptible bacteria",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Into bile; penetration into CSF occurs with inflamed meninges only; low excretion into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 15% to 18%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA 2-7 days: 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA 8-14 days: 2.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA 15-30 days: 1.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adults: 1-1.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anuric patients: 8-20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &sim;90% of drug excreted unchanged in urine within 24 hours; excreted in bile",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: 20% to 50% is removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F14800138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/26/11685?source=see_link\">",
"      see \"Ampicillin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take at equal intervals around-the-clock; preferably on an empty stomach (1 hour before or 2 hours after meals). Maintain adequate hydration, unless instructed to restrict fluid intake. May cause nausea, vomiting, or diarrhea. Report immediately any rash; persistent diarrhea; swelling of face, tongue, mouth, or throat; or chest tightness. Report if condition being treated worsens or does not improve by the time prescription is completed.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1045174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Sodium content: Oral  suspension (250 mg/5 mL, 5 mL): 10 mg (0.4 mEq); parenteral (1 g): 66.7 mg (3 mEq)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Some penicillins (eg, carbenicillin, ticarcillin, and piperacillin) have been shown to inactivate aminoglycosides",
"     <i>",
"      in vitro",
"     </i>",
"     . This has been observed to a greater extent with tobramycin and gentamicin, while amikacin has shown greater stability against inactivation. Concurrent use of these agents may pose a risk of reduced antibacterial efficacy",
"     <i>",
"      in vivo",
"     </i>",
"     , particularly in the setting of profound renal impairment; however, definitive clinical evidence is lacking. If combination penicillin/aminoglycoside therapy is desired in a patient with renal dysfunction, separation of doses (if feasible), and routine monitoring of aminoglycoside levels, CBC, and clinical response should be considered.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007, 55, 149.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baddour LM, Wilson WR, Bayer AS, et al, &ldquo;Infective Endocarditis. Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association - Executive Summary:",
"      <i>",
"       Endorsed by the Infectious Diseases Society of America",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(23):3167-184.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38503/abstract-text/15956145/pubmed\" id=\"15956145\" target=\"_blank\">",
"        15956145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boguniewicz M and Leung DY, &ldquo;Hypersensitivity Reactions to Antibiotics Commonly Used in Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1995, 14(3):221-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38503/abstract-text/7761188/pubmed\" id=\"7761188\" target=\"_blank\">",
"        7761188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38503/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown RD, Campoli-Richards DM, &ldquo;Antimicrobial Therapy in Neonates, Infants, and Children,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1989, 17(Suppl 1):105-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38503/abstract-text/2692934 /pubmed\" id=\"2692934 \" target=\"_blank\">",
"        2692934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow MS, Quintiliani R, and Nightingale CH, \"",
"      <i>",
"       In Vivo",
"      </i>",
"      Inactivation of Tobramycin by Ticarcillin. A Case Report,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 1982, 247(5):658-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38503/abstract-text/6798229/pubmed\" id=\"6798229\" target=\"_blank\">",
"        6798229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daly JS, Dodge RA, Glew RH, et al, \"Effect of Time and Temperature on Inactivation of Aminoglycosides by Ampicillin at Neonatal Dosages,\"",
"      <i>",
"       J Perinatol",
"      </i>",
"      , 1997, 17(1):42-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38503/abstract-text/9069064/pubmed\" id=\"9069064\" target=\"_blank\">",
"        9069064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farchione LA, \"Inactivation of Aminoglycosides by Penicillins,\"",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 1982, 8(Suppl A):27-36.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferrieri P, Gewitz MH, Gerber MA, et al, \"Unique Features of Infective Endocarditis in Childhood,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 105(17):2115-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38503/abstract-text/11980694/pubmed\" id=\"11980694\" target=\"_blank\">",
"        11980694",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, and Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38503/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2012 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"Antibacterial Drugs Dosage Tables,\" 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012, 808-16. Available at file://aapredbook.aappublications.org/cgi/content/full",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shaffer CL, Davey AM, Ransom JL, et al, \"Ampicillin-Induced Neurotoxicity in Very-Low-Birth-Weight Neonates,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1998, 32(4):482-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38503/abstract-text/9562146/pubmed\" id=\"9562146\" target=\"_blank\">",
"        9562146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Solomkin JS, Mazuski JE, Bradley JS, et al, \"Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2010, 50(2):133-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38503/abstract-text/PMID:20034345[PubMed - indexed for MEDLINE] Free full text /pubmed\" id=\"PMID:20034345[PubMed - indexed for MEDLINE] Free full text \" target=\"_blank\">",
"        PMID:20034345[PubMed - indexed for MEDLINE] Free full text",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2004, 39(9):1267-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38503/abstract-text/15494903/pubmed\" id=\"15494903\" target=\"_blank\">",
"        15494903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warady BA, Schaefer F, Holloway M, et al, \"Consensus Guidelines for the Treatment of Peritonitis in Pediatric Patients Receiving Peritoneal Dialysis,\"",
"      <i>",
"       Perit Dial Int",
"      </i>",
"      , 2000, 20(6):610-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38503/abstract-text/11216549/pubmed\" id=\"11216549\" target=\"_blank\">",
"        11216549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson W, Taubert KA, Gewitz M, et al, &ldquo;Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/38/38503/abstract-text/17446442/pubmed\" id=\"17446442\" target=\"_blank\">",
"        17446442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12683 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_38_38503=[""].join("\n");
var outline_f37_38_38503=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134956\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045166\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11432528\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045158\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134931\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134915\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045170\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135012\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045162\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045169\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135014\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135011\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045173\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045157\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045156\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298748\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134924\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045176\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134927\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134941\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045165\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045155\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045172\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14800138\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045174\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12683\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12683|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=related_link\">",
"      Ampicillin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/26/11685?source=related_link\">",
"      Ampicillin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_38_38504="Viral exanthem close view";
var content_f37_38_38504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83682%7EDERM%2F54205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83682%7EDERM%2F54205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Viral exanthem",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFDAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0e3ywB3ksP5dwavtGpj+UBtwHyMOh9vf3qpZpiYiQdV69fzrUKKkZ8sA46r2IryT6aW9mVUJfgkr2BPHSplEbq/mxsy4wdnB/L+oqpeSPGDLbAOVySh7j/Gq0V9vjR5A6HO1W65HocfzoLjSclcs+aI5o1kfCE5V9vH0q2gUuHXYWPII6MPeqcrx3MJ8rAx1jU5/EVJbQIEVfLjlHX7uM+4/woCVPS5K81tAx3TIjHBA3AlW/2cfyqK9X7XDIkMJIcYLSgpt9Co6kg81ZEMJhICxkEYyoCsD657GoTI8cRjuHJI+7KeMj0PbNMy5dTJtleWITSMXmGRKu35VYcH5alVmZkYEMYxnHBx6H3qy0Oy783cf3ow5HUMOA2PccH8KhmstyI5IDoeXQdR3BpHVGS6l2xKSW0iSISmflDdVPt7VZkiDxtli4x24zn+tQWcLKiKhB7gr/ABDHb1HtVuAYbA2BAdrA8rTOeoldtFCIyxgxy4kjUfL2xns/v71o/N904UkcEH923tmmtG24Mh2uThXYfoRVVnaG5XcuIs4dT1Gf5ijYi19i9LI0I3NFmL+ID7yfj3FPdy6q7MRkcOO31HeiJi8QaMZCggHuP8RUDMsDM6/dByQR938O4obISuNMflkFPlwOoGQRnv606NBG29mJXGQVxtx+FS+YY4llUEqecjnb/wDWp0Jinj3xD5Dz8p7+oPr7Gmh3Y13ZFBQ4Zsn5P6ev0piSZhVlQEEEMCOPx9KSRG8osrluSCu0EHnt6GoIzHsZpC8g6q3QY9170IErrQuMTJiOGVoj2bvjuPf69qhbbDwgZFQYKr/X1oW4Vx5ZUFVUEgfeFVr5sKXSQMOu/NO5UIa2Y5JTHIDlhuUFXXgfTHSi8Yy2skiSKJY/nxnawx1OO/frVcEq7YUZPVR0P0p72f2i3YwMUnVTsY8En+6fY1O5pOCWppIx2jOcEYV2HH0NOIeJlVRgkZ25/wDQaqaY8txZwM8nylR8+wenQ57jFTGEyFd7s/PKq21T9MdDTOd7loyKjBSSG6gKMsPbFZepM5e3lfaiLKNyJ1YN8pyfTkcVZMUQZQkajnIyuPmHf6iqeszo1g8bb3IljUgjDLlxjPt70X7Ciu4+WYNETCgjVTxHjH5eg9qzy/2d1uIm5QgsP4CDwcg9DWrJAmxgm0tuyA3XPp9KpTW7kTcMGClShGaTOmDjaxq2hLK5Hypn5T0H+77fyqy6gEu+QeqknkD+orO0+4aOCN2UmPYCR1BGO3+FX45Yp0VomjKNyNp6emKs5pxakRyEJICQdwHVD1qKSMSuTEyjK85H38dM+/61LLLHtw7K56EPgN9PfNZMUXktI2n30iRE4aJlEgU/Q9qHoJK6NbeMYnBVjwBIOPoCKbcrHEmZG4H3e5P0H8X4VVSzu5YSH1RuRyqWyKR7jJNVPs0Nm/nM89xwCxmkLFf649ulK9ha9CCe2iaUsN0BbrHA2ZJP98DIH0P4mrkf9oGP935LKeMlfLcj3AyoNXbMRGNXhSPaTu+T5c/THekuVdwzRnEqn7pGeKNhp30ZSZpfmU2swcg/vEkWRs+ucjmoftkrIyajbySqFysyxk4x3x1U/TNTWt39okNrNmG4J+4e/wDtIe/061NcsqAecyROvRncKM59feluXaxVRoZE3RmYx5+6wLbf64pk8s4xJbL54HDRlcM2OmCe/wBaPtKtgW4eZx97YmePUNUpa6uE3IkA3cje2W+oxjn2JoG9Blte24xIN0TMPlDIeT6H3pxv7BP3n22zhk6ESOCrewGev61Uu7NnPnC5uZjnEif6sN7soIz/ADqukKpIqW0EEcpG6SIgAOvYhsZz7mm2Plurj0u7NTmG8jQnJYAkhj2P/wBfrUk1/CcMSzTAfwKzBh+XIrQsZLe6dokJSdOPKZQrj3+nuMio75JInljk+eNRuyByPf6/SpsCepgxMxZZI0uPtBOcEBVb2rVDNNCxEaq7dMt82fbHanRypOSquj4w5C84B4BpL6RrW3klIGEGCCMk9sDHBJNNFzlzMoXAkXZbK8a3Dn5EAAYerZPb+uKuW8UUaqgV5MADY7YJ/DpVGCPy5nnljU3U64cFcsqDog45A6/Wqb3T2sil4We2Y8yoC2wehH+FCdjT2d9zoI7qMwsqqqoTtO3A591HSqkl8+n3SiWQG1lO2GXphv7jemexPB6VTTb5wuYmEiH+Ic4+h71JM9vJby/a2UxMpVg+CkgPbH+HNHMTOglqazKj/vXYxqq5Ytzj6+lUQnmBAgGWf7S6tnIX+EZ9en5VUguJF/c3nmLZgEweYv7y5x0jceo7d2GM9DV6IyRo8syB5JSGkcDDRjsvuAP60GFjShHzncQFP3SV6VODhVT7jZ+UjoT3+lUrWYu7ROuM8DPQj0+tW03oqnAkUj5x39jQjecbalKdQWLAbcHBB/hP+FQNFtbMSBQ/bGQx9/Srd7E+7cCC4GFxwD7H/GqBf7PKyyIWgJBZT/AfX6e9I6YP3dB4jSSNNoJ2HAP8Sn0qW3QpJ5ZYhCPlb1/H1FSJG2drsFYnKueQ3oD71bhhzGqT5BJznPQ/0NFiZzsQyKUCqo2y9MnhW59e9Ok2lCHABbgA4K8dj6VI0LKJIyuWP3l65HqKY4MbKYyMMdpYj9GFMwvzEFpEJAQMkFsEOcEf7rf0qzCVbeCxWU8MD0b0NRiIjJ2cEcNnIz6f4VQu55raQTtH5kQ+WXB+YD3/AMexoFJXd0baKsJbH3TjchGSn+0DQQqFnC70bqR94fX1FRWsqXEEcscgkRh8rZ5/D/CpImJbG7DL/F0/76/xoMrDZGMZRoX82Njyw+Yrx+opWgDqw+WRG7Hn8CfSmlgJwuBHL94oeNx/z3qw24hmULz1PT88UrA2VEE9n8ke+SPHCscuo9Ae4/WrEVxDcD5WAdcdVAPuCD3pJ5PJiIm2mMYAbH8/8acY4Z0UzRpKdowGwc/Q9cU9NhPuWfL8vIQFe+xenPpVEWvkzSNbELCxywQ4we/FSQW0QJjSe5gXr8shYD2wc8ehprW00YyLsk5OC8an9RiholOw4I4VjvBbHIPBPvkcGqVyhDttyN3zbRz83t6Grnk3JUFmib0YIyg/r1qrcugIS7lgUjnIkxn+uPahmsJWZTvJQlq207JCN24rznpkenXpXO2Wq3bIFvcLID+8cjG4dsEcEV0U/lSBQsjS45yqFjnt2wf8KoGzQTFkt5EYcgsBwfUf4VErnTBwsXreTfs3R8EZO3g49R+lbSSKttJJ8p2g5OOG9ARWLbIiuRIUgZl6NlQfdM/yq7apKs3myCUW2QeOGz03Y7KP/r1cTGs1JaF62i+zTGMZQSADGMrvxyPoev1FR3U8cEqpKnEp+Rzyuf8Ae7H61YntoprdsFnDch954PY9apLDDNBIk0cZIIEgxkZ9QB0Hemc0Fd3LS7uDgMucAsOD9feqWqRmW4sYQCsjTeZ/wFAWxnuM4GKli3Wb7FZpI24Cv8zAex/iHsefektnF3fTzKNywIIE46scM3XofuikO9mTxylI1VkVz0KZ6fT29qiPkyI0kCkjB3Kc/KR+oqyybo84BI7qevv7VTukmSKaSNQ7bDld2C3YEH1/nQxpoWzhH2eBsk4jHA47D86iuZFRicREkZKnGHHsexqxZyRr8ob5lAHIxg4xhh2+tUPEKNBE9xCvzodzoeQ4zzg/T+VF7IqOsrMiSRJXHlgDqAc/d9B9KtWs7FxlflHUKcEds8VQi2PKG8vDADbt4+X29auRttbHTaAV+Xr6YP8ASpTZ1TgrWLzrgKAzbFAKsD1HsanYbj5h6f38d/U0kOWXBYgjnIGcevFTIuRjAD9SFbAb3rSyOGTsZN1ZKJ3ZA0JI6wPsPPt0NQJFNKCv225OwfKV2hh7H5auXj+Up25AzjDDjP8AT6jiqgJEQMZ5wVz/AJ96lrU2hG6uNutPjmQC8kurmEEMQ03X0OFx+dOj0mCNy9nKcddsqCbr15PP5GnecVxngjkYbGfp6Z9DT1uQ25sFjkZBB4P9DTugdNkN0t7CvmOlvMg5DIxUqPyOadZTXDx744VZXPVZlIPp2z+FWiokXZJuUkZyTggevvVSSCBJpDFKQzcboCQT/T86Qr6WYyczH94bbHf/AFoIH5UWySOwLW0alcgM0uSM9iAM4ppm1BC5gthOndp3EOPYjn+QrMuptajImRVRG4eKKHzWC99jE8n2xSvYWttDSnt3lUxvBBKqdArtuT3DAAimQLdMJfs2oLLsIBjlj83ax5GHBz+HNJarZX0YMl7LdEEBo559rKT0BQYx9CKWe2nhbzNPRY1QkmELtST1HsfQ0XFa7KjxajHIW3Qh5c5eBwm8+6uDk09Rd+cZJbe5eWPlQREQvuAGHPv1q0JYrxHeMlZxwylcFT6MKsI7GICRUyRgfL1x6ehoTK8zEkkucrvtZGXJ2kKE2n25xUEzSGNkCEttLhtwB49+49q0JEkUlx+/gx9z7rofb+99DVW5kt50MET4nkO1UYbXQnvg8+ppWOqE7oYbcmRbi2uY7YOMkwrnPHRlbgn9femqgtned1EjxjP2hiXVV7nafuj/AHaS5K2+17kGOU/Ki7M+dx0A9T2otojLtnvInWJTmO1HJU56t2JHp0Hv1plNKxLFPb6tLHHdl4GA320XKMxA/wBYCf4x1A6gHnqa1IJZMuZtvnQ7UdVGM8cMPYjkfiO1VpiHjRXj3kEEbxlgfUH9KaXRSZ0DMY12SIpIYp1PHt1H40GEqdnc2JrNZOQCjrg7u2fep7bgZfAcDhx/X2pba4SaXGNkqj5kOenYj2qYxbTiNeGGSoPQ+xoJc29GROu44wVfHPcMPWqk8OTvTBHQEjn6H2rQR8RjsM9OmKrI+ybEUuCGOR/CM9sGgcZNbEMUOxRjcqAkYxnYff1HvVuwuFnR/MAjnXhl7Edj9D6037QCSeV2dQvUfh3FQ3EYdVdHCuvEUqDoT/MeoNFyJ3e5aCjJVlZgOnc/hVe7DSsHjkVZ1GcA/fHv61JbXADpFNtjuCMqp+6xHdD/AEqrdXRFwRIojlU/MCOCP7wPvQ9RxV5WLVpl0KFwjYxsI4YelNkgTj5fl+6SByvsaS0l85CeGwcnA+ce/wDnrUpkIf8AeErx8kgHDexpid4tmSITY3DizUeUctJbleHH99R2I7gda0YJxI6EthyMrnkOPY/0NVW3Nc7J0AkXDhc9vUGpY42adCqiRGydo+Ug+o9D+hpIqS0uXJ7d3Cso+Rh8hHPSqcV8sF6ttcBYpG5QnhJc+h6bvUVcikKghJ3CZwwOCB9Qe/fNMvojJAY7hbeaE/xEcH6+lP0Mk3sySSNShUrkYP7tjnPqMVmra+TuS2MyRnjyxLjHqBnOKkeKa2iAW4CRjjEz71X6Z+YD6Gpobi7bdvs4nXGBJ5m1H+gYZ/Gjcaly6CPYPNF+7vrtZIjlW+UlT78dPaiLLN5ck135mOAsvyt/ukAflSvPcB8OJ0x0aODdj2Jzz+VQz+WxPmC8VjyQ4YZ9+B+vWhkrXctJY2jKcp5mT915C2PXgnGabJbw4XZBDGf9wKG9/Y1RuJwu7yZ7qOYc7JkLDPp9DSWV9M6GOeB2Ayx2jOfpSb6Fxh9pGlEpbIlZ2GSF5yfoQaje3jkTY271LRE8D1HpUQvA+WMN0Yz38kn9aka5JXJtLlv9rZt79yTx9aYrsRIowhEwWUqRtkbkY/pWlaMwUgfNGez/ADfUZ/rWXJLI8i7LbaTnIdwCfy60+1uJIrkRMUhDj5QMsM9KFKwpR5lctSjEjiP5HI54yD/vD+oqFWYAyklWj4ypyGHof6ZpbqGTfu3ytg/dixk57A/rg1Rmh5V9xdj0Jc5wO3PFDbHCKktC7dTrDbGVtrFRu8rdgsegAHqSRUQtZLaONrZsz7dzo52+Yx5JDdjnPqKzLa5gk1ARhMQ2Z3FSBnzSOAP90c/U+1dEjJLFhlVgeoXkUb7ClFx3IoLpXUDJSbPzROArH8OjfhRI8bfJuYNneyN/CR7ducVFPANrCZUkhOeWOfy9DVWS0crkSum7GFcsQvoFb7y/TJFImyJpw8jgkRgAZLnqw9velL+aJI2zjG1gfvAf1qsrXlqzC4t0lA/iTuPXjp+VVX1JHk2pb3DY+6QQWTPtwWH0FSWmtiayhzAhKqwUlGIGCCOM/U4q4g8sr93YDjdnHHoay7O8gW7dbhXOX3JK0bJ1GSMY4I561qrdxRkjzFaNhnIUqR/wHHI+lNFSm1uOvwJYAoaWKUHcjJwVP9R7U2G6nVR9qt5GG3AkhG4H6r1FIdSs4stJcxCHI4IOAfbj9KWW9gDfubkHGSpCkY/SrSM3roULzUoFLF0uduBlWtnJ9MdP1Fc2JrjTtQllittRubGXkoybDGf9nJ5HtXW3Lx3GEJcEjj5DtOevHpWb8xVo3JRV+Uq/3T7Z/UVMjqpFR57y5jFxbxWSQsfv7/MJ98DAH0NRi1u7pvOi1C4jnXIXylCIwz0IHJH1NWBCAWwrwytg71IKt/vDo3161Y33K7TOiRLzieIGQN/wHqPxpWLcklytE1j9njAFzbiGZRzJkyIT67jyPoattKkzhQcKPvOBwT2FQ27RTKW85XQ8lQQoHvgf1p08HkKWtEJYL/qwcK/tjpTOZqzLJLszb9wLDh8g5H+e1REB0MKuA2MjBwG+h7VBZ6lFcwkBWwOqsuTGf9of1q0jLw0RDxdAMhh+FArWM+eCC6nH7mQTjgOmFkX2yR8w9jkUjQz26ElRLGDndA/lMP8AeQnb+R/CrV3LC0axtKm7Gdq53D8OpqKJ7oInkxFowP8AWSkJ+Y68UCavqZ16kbzJIJ5raVeA0sOxlHoT0Ye3SoJtbSyBF4baQZ2iWJwAR/unoT7VtzZmtzEbnz+n7m1jyxH+8TXMazZzS2rxnO1WypIUTce+OPpUyTWqHB30ZpR6zYTxMN5ZiNyogLFz7Y6fyqncvJdIvmwISPkV7hciMegxyfxxXNaQt7b3TeZ89sedzqQVPu39elbdxdsRBLpaSTPgmSA4G4dzHJ0J9jRGV0acriy9b6XGoIinnE+zDM7b1Pfo3Cge2Kr29zdWNwBK63OmOTi5ZSu1x2OM/L0+fp6+tXrYi5hjmuZoriDkbIwUVW/uOOufrx7VqRt8jbYyTx904B9sVViXIYAxRXa0LR4OCkinj+oqk5SOZZTDdK+cb/KOAO2SM09ZHsJH+wwSPDnJtuBtz3j5/wDHenpircd8tzCkkCARsfvmTG09CCOo9OaA5maqxRyssu0iRejAYYfX2q6V3gBiUPYZwDVLcbaRfNlQKTxhf09TUtxLI0b7cooHcfN9R6VRErt6FDVpmjfag3OBuHqv19qoxy/aNoLhwwDBvU+pqysisHEe7rliG3bvf3rHuQ9pNI9uSc8+XnKn6dwfaobO2jDozZt1B+YSM7ISDk/Mp/rV23YSyZACFhwezfhWLa3SShN5MMp4w5wG9s963Fi8yEFsx59OcH+8Ka1MqysNmjBGycDyR1PZSOhHoagmi8xY2lfco+5KOSPr6irSCRVKSoZO25cfN+f51m3U5j3pt2kN124DD/PejQxim3oPs1MUw875SDtDg43/AEPf6VemhZ4mQr5gblsKef8A69cs0lzBKY4mWaAg4inG7HqCa0LG7vd6G0NuEUgASyPhR6ZxkfjkUJpmk6clqaTQyxxo0a+egHyqWw6+wJ6/Q0+yuoXZhCB5qnDwONrD8D3qnLeX/mMZo7a0bOD8jSow9cjimXNnbalAHuLuWdhwqq4XaPouCR7ZpmOr0YurXVvFMrRTFLgDG1B5jfQqOcU61uLySUxzRrY7hld2JGYf7PYfqfaq0UMtgFS1C7Mj93tHP0YDn8eav+eksAWe2Mcbt1UkqD7EdDmkaSVkkAgggdHUkScfvZH3Pz6E9B14q4ZCuRMN3qmPvcdqbCQ0RRiksZAUZ5wPemvIsTKkw2gcAlgRx70JmW+hSmvzZXabgstrL8qZzlT/AHD/AEPtVyN967l3fKcj1A+n9Kg1G0ivIJDBMpk5KDI3bxyD+dR2TiWCGXeVLJnbnlD3x6jPY9KNblaNaFgjJ2spLjlSvKkemKRUUPHs3BRyAO349Qf0p8tu0vzxuEONwkQcZ6fMO1LHOwDGXiRRg45GPcdx71Qk9NBpcRl2bJ2gZZODjHJx3qt9rLLujdSezqMhh71auAIirrkR4zx2B/XFZRVY7l5ICBE/31AyM/3tvb3xUmtOKeppowRcjYAwztLZDH1z2pXWKYBHXdyGIYYIPrn+tVHVgFX5cHO1SeCPTPb2pFkfJIADp8uT1BPY0h+zvsW2llRGjEiyjPG9tr59z/U1Q1KeWG3LPbSCZyFjGAyl/U4PGOv0FW7eIeakx7gq4PG3Pt3FS20fmytPKCVCbIAeqJxk/wDAv5ACq3M37j0OdKQx2yRx7iy5xI8ZDEnkkjHOT2rT0S6kQAMXbZx905X2Prmp7hEeZki5cAZjP3h7j1FJGhiTzFwzZwG6H8fb+VQlrc3coyhY0t5mYEoyBTuAfo3+0fp6VVhud108TBo5hyIH43e6Z65qW2cyx4kUsM5O3oPoe1JcQpcJtuFDRDoWGcf4H6YqmclrOxGoWVd+fmDfxjgH0wen8qju5UuHaKbYZI8ZSXkrn3pxiuLdVCSefF02S/eH+zu7/wDAgfrVO68t3DNvtrtM7DKNoYHkqT0I/lQUrXBdOt5J5WaPy3wMbGKqevUDgH3q/DGyoqCa4Xn7olOD7r7+1VrSbzA5zjnayEcqQOdw/qKl8wCFfM3Kv+zyp9j6GhDkriTRTK5ktby4jkfszAhvYjH61WW7ZPkuXngmJ+67KFJ/2TjFXWkbB85gyOc7woweO49aiYfuzgpJERlkbmgEhYleWMlJZmUcjbIDu/LpTPsRebaAX+UcOef8D1FQLY20qefFbRLEy5UqCCfrjtTBawiVAzTR5HH758DpyOelA7tbFmW0baxIKlcFSB1qsJpIyYvLKyIc7SDhvceh/SnTQBWA8y5Ldv8ASGyR6deRVJ9PglYF1keMHALSsSD378UPyNYa/EXUEUqu9wka7SBufGc+hP8ASpPtNmjMqBsqOGiZsZ9j0pltZW6SApDEkyjh2jzuHo4PUfqO1Pd9rlwu0IPnj3fdB/iXsV9aNjKTu9SnfWRvXWQLJHKOVl37ZPwK/wD1xQdPvzt8rUVA6uksQy59ypBNasSYUAsoXoMj5fpxUMk2GLZbYPlIHUf40C1eiKcdvqEcLYMGVPzCDEZA+pUkio4xLvJnt1kdjndNMzD6kYxWg0+UUglv7rDr7c/41UF26BmOFLZG4g4B/wBodqNC403JFiNrsxkB7RY+oEaNz6EdP0qO7tku7dkuZTKrjAYJgfj3BqJpJChkttgmx9zJUSf4E1ahuBdweZGQyyDJXH58evanoQ4NPUw7eBYrjE0A+0RHaSeR7MPqOfzprs0odBlufnjI4Oev0q9djypRLyuchlPUj6ex6fjUESrLINykZBPXueh9qk6aa6mLPZslyZrKae1uSMZ6q47K4PDj34NXtO114pli1CBbeZ8bZVfdDMf9luMH2OD9avTWjShtrbufuOgzmqEcRjlK3eTbMdrqVDLj/aU8/wAxQimoyV0bsvlyxAycSnk7gVP1FY1/FLAJ5pYzvHzCeNgG44yw78cHqCKkhie2ULZySC2H3UI86Fx7AHcn4flUU11ZPcLa3FnJbjHmSMMyIQOi56gHGSCOgptHM247nW+Uijftw/ZupNV728IBjYqZVXIPQN6Z9Kl8wNJtUCRXGc549x7H0rMvYWVgzOxUHIPc/wCPpSbNaUVKWpXu/wB4EkAMM0f3cYA/3TjrU8MguwBMPKmHVeRn6GokUbMYVu4jbuB7+tNeUzukdoA7KeJzwqHuM9WPtSR1NW0ROFG9llRWXOTnlW9/r61owgjHkExHkg9V/wC+f6VHDGBCY5FEm75iemT7AcVi3N3cW1yE+aS1Y5DE8qB1/EUN8phKPtDoG3LETMZpmc8qjfKT6hRzWfdrERmSMEMMbgD+TVet5opbUlWyeu/Gcj19qzp1MiyJJgtjactwx9f/AK9U2uhFGGrKk9uY5A0busTdGzkDjoe4xUtrPIgckHegLYBzx/UUscpGBJncBypGeP6ipDtEgiYKJf8AlmSeHH19aR1S00ZciuN8cTgCJl6Ov3Qfb2oukS4ud7RRCVRhlYAE+hU/nUKsAdyxlFwMr6+ufellhWZjEvB3duo+h7/yoepzOCvdFuGCEzACJA+c4GR+IHY+1XIV8tC+UwehA6H3FVbaQYELSbpQoPzfx/8A16l+07gzSKrbfTg59x3qkYSUnoh96IBblnxt7suQQfUd/wADVJJYZI2MLByBykg3YH88VHdTSBSuMwyDBVjymemPaq9hbNCHO1iw52N1H0/w79qht30KVNKOrNC0lZiPMQLIPusCASPT3qvEixT3CMWVY33DjDKG5zj65qd40u7RohJ5iq2AyNzGw/z0qmr3aXiec0cpZNoZiYzweAeo7nrTJt2LdlcyfaXicKrbc4X7kq/3gex9fSrU+1RlwQAOueV/z61nSOQhElndI8Z3Dy1DEHuQVP696eup24gUStNGcDDNC4z9OKaFa7uieaJyhIAYHoqng55/A+1R21tE7eZ5jjjjAwy+x9R+tZc2qQRTmSK5WSFjjYAUKH096lGs2HmBzdeWeCBz9PejqbcslHQ2DhR95V3HlT91vQg1nXO4ZK5iYDlSOPxqObVbWaN2tbq3eTPzRuSokHp6A0+K/s54A32hFZflZXB3r7H3ptkxfK7jVAuJFhhP3FzL/dYdQo9Se5HQfWtD7QchJN6N6f3fcH09qqwT2wG2Jl8s8qAuOfUehq1KqvCE2SSRdDxgj8f61ISa6hNAblY3lVXKk7GHBB/xpwjZUASWVSOAD84P4HnNRRPcxMIlg81eieYyqce/UGnTzywsfNs7oHIXd8rj8RnrTRlf7JVntLrf9o064ht70gcPu2S+zLnH4jBqVL2+V83em+duABNrIGB9RtbBz+dQC7clSUlaIclQhP1qeO7DsWTds/65HBHp7Ur9i3TZC+uW0VyIza6nEMY8qeApj3DZwasQ6hDPHtS0uJo2/veWM/UFuama4baY8M6n7qv7+/emCC3lkWRoYnlHUOgy2Bwc4p3M+Vme9rdRv52n2syFciSJnUh1B7DOQR2/KpRfShFeW0LxNx5kTBwfw6g1YktbUKQsWxuvysQw9+D+tU5LFIm3JJMqN98LIwIz/EBnB96Nti4tvcrWt8YbgkvI9uwJCMh+U/XuParkMsUquttKJUYY2qfmQd+OuPaqlzp5Iz9puNx5A8zv6Uy0h3uVePzwfmXdlXT2yOc1GzNWrq6N2NFEQCjYp4ABwMY/n2qtKpBVJE3KMkbhyD702XzkiBt5nyy8xXDFt30Pf8M/SoreVGcRSNLCx4MUjDGfRW6fgcGrZjHuOMRKbSfNjPOQeR+HX8qXDEEvliowHAIIHv8A4GrjW4Ctu83zPTdhl+nqKaoKqriXcQOijJFDRSlcWFnkGQRjPbo2PbsfekvIxIn7zPmLkoeAy8dR2I9u9RXEE4UXFqU3H76DgOO/0PvU0Esd3AA4YKThgwxhvQjtR5E+ZjWF5JhrV2AmjyNoGFkUdCPfB5HUfSti0KOrBtpyM5OM/l3rJv8AThJdXK7XD/I6lD8yEAgFff8A/VS6XL9og3MxNwh/eBRg5HRlHYHnilsatRktBt5bPazmezlDbiA9u7YX6q38J+vB71UjvILm4fGY5ANrRSja4P8AI/UVtTzF49s6b1YY3hfx/wAmse/s1YrgApyFkGCw9vp7Gk2aUn0LEqhjguoPB25OD71PZIscjBSRvbevOMNwD7dcfnWVbxXCn95I2R0ZQWA+o6ge4yKtmWMSojkRupDE9VdW4JBH1H9aaFWtsWdXikERmUklRlj/AHh34rLspBMwWLCyrycocj/9fpW/LGWRHf7vOSD0PTIxVN42aYwTKDuX93Ih64/9mH8qXW5NOpbRlE3X2WZGkDmN/wDloDkIf9oVPIU+9IQp5IZT0J96juQ7nZKvKjDDbyRjrj0NQR2724jMPCA5Af5lI9x1H1H5UXN1bcsqfIjMpOyMDLYPPv8AhVqEGOBGm/dzTcluSuSOAfwwKz5buK4nt7edDDGT5kjINy7VPTIHGWx1HatsKklqDCUkDckjlaZzVJXZZMC3EZUkBj91wMfMOn0NUbm5VbfM4LO52rGgy7uOCAOpNLNdiScR2samRBmWRnwsPoW9T/s9enSnR2XlXbuN8sky4e4fhpPYf3F7cf8A16BKTizJa3lu0XzR/oytjyEbOfZj398cfWrLqZJVlt2O5AFaIDCso9PetfywUHlIPLxgrjBQ+lRCFHb5CCc4x0z7g+tB0KsrEcMnmQnYCQ3Qk4zj0I71CYcyKZQQWzhscN7H396teQ24tBhXcZbj5X+o7H3HNNkuLVIWa6cQDp8xyG9gfX9abM/aWKtxusrVpSPLZ+E2DGDnr9MZ/CmojSSF5FALjI7qRjg+3vVlBNeKrTAiIgCONhhlGeh7c9/y6U6W2dIpBGAWTqQMMD7D09qSTCFS25ku6krI+DGD8y91PqMdqsoIsDdh1BIPp/8AWp0MXnRs20F93zxkdD65qpcYiITyuGHyn7vPof6UrnVdS0LaTOOUIwvJ55H19R71MojzujOxeisDnBPv6VTLzLMssQ5A7jJXjnPtU8SmVlkiCpkkunYZ9Pb2p3IlEkljEytHN1HOU4ZT65qCO8fzvIlx5oXgseHHr7/0qbzCwPYjgZ4IHoahks0u1mV/mbO4cZB98f4UCSS3JHZnXYoLDrtzkkdePX+lTQEgIYnMmwYXJz36f/WNUbM3FuQnzTYGTyPMH+6Tw30OD9a2rFYrmMyQkN2OF/Rl9aErmVSSjuWIWjaSQpGqPnL8Y3nufrVHVIi08G0KCWKjdyCNucH0+vatCVFPzMGV1O3cDnB/2vWqFxcu13bJsRpVLcFwob5cdcYI5qmc0XbVD7YSSRbgRlTlefmT057ikZ4pQY1JjuAN4UEjdz2H1p0VwsAKzwXMO08naGA/EZ/wqCaRJD5hWP8AdtuBDdVPXkfdJHP4UnoVe7uinJO24ZLBxnIPUH3P+c1JAzDJBRRxg4wv4/3TUs0eQZEHK87sZ3f7LD39aqxMqQmWIkgk5XPT1Uj/AApHVGXMrIuM27HmMCMfMG6j3FVxHJDeCW33/aCoDRlseaB29N3ofwqAoUlQlwYXOAD1VvTNXbVgHKNyqgDaRg57/Wi9wnHSxpWrC6i8wDKMNp45yOoI6gj0NCjB2r0AynOOPT3qCRJIW+12245x5oTkOPX/AHh+op8jkhSFG1uVZfutx/OqehxpX0JY447sFVYq8fG3oQfXFQ3jEDyZcAgbd3X8v8KiuNy4V0UyIMhxwSPY/wBKrLdFpFUSAS4+4y5J+nc/SlfoVGDbv0KbyN9paGeJY2bLK6nCSDuR7+1W4F2bv3pjB9Tlfx9afcW5liKtCdnb5ufwB5/Oq9jFLAixqSSowUkXqP8AP1qbWZ0qScSwgVJ9kpMOBkEcq341bMoiXLBSG5LLyOfX396qICJXKK2DkhG7H2IqylqlxGSyDPQrjHP+P6U/Q55K24SxiQqZEK/3HTk/Uf4Vn2DywXRs9TdGdiTBNjCzr6Y7OO479RV+KEorfvHVFOCgYjH5025g+1xsHLOowfXoevTrRYm+o5oY/M8uQsEY/u2zkg/3Sf1FPaKOLmTCMTkSrwD+I71SgMuGt2KsWHKE4EgHIZG7Eeh6Vat7szO1rNGI7raWUOuPOHsc4LDuPxp6EuTWg+XbtKMUb+I4IG7+maoXVuIpEaAB1n+SRJD8pb+E+x7flV1SY25bnuNgwPbHf60l2pltXjlDGNxjB6j0PqKGPUgW5Ee0KWKdDEx+ZT6o3f6H8KuffzIGDKRw4649/WqsbCazikfa0RGDxkA9CCPrSxjyJc28n7l2G9Gydh/vA9aNw2LiPG3B2KrdWHQ/UdqqTRyW8hljQnoGQHPmL6Z9R2J+lWGTewdEAckgkNz9feopJ5oYi00fmI3IePqT6Eev0oYDLcrKZHiYPBKwVGPTgf45qG9tUkdri0cx3KcOUPLc/dI7jvz3780lm0VvIYTuUSAyKWVuHz8w6dD1/Or58kwsfncEZHyMdp9jjpSE3YoP58duPJjhuNy7kMbGMn3weP1qjaMsELpcRzW8h55jJXPfpkVppI9s7RzRSeQ7ZRsYwcc49BjmkV1jIILPjoykZ/H86GtblxvbQqQ3FokiFbiMEHu20fTBxRqVrbXds8n3ZVyweF8MMdDnoen41oB1mfouQMvuHDD3HeqV+IY4ZFWGENIjAbVxk/40A22RSSXVhK5KhoM5WWJf3fI/5aIfun3BxUc2opMiJMyW8uC0WOFdh0Ab6evr3q2yKgJjMiEfxI5BAx0IqC4sN8EhiuYwCpYiSIMrHqCQOM/gKNQjpuTP+8UMX+bAZG7+uCKhyse3kqGOSV6H/Cuft01CxjihntJJrdUBLWshdl752tyR7DNE+s28+2yikCvcfLFNnC4/jBzjDAdqDbQ2NMBaWW+hx++bCoTwUTgfQnk1dmghvI/NVBDcDnemVb9OtVoZlW3EcRgEajZsz0x2/KpfmxvR1cZwYgD+YPr70IxkLBp8UEESQNsRDlE2lo0Y98DkZ9STV6W6Kx7LuN0Uf8tV+ZQf5qfqKnhaEklCqkHaVz/OoLu5hiQlpIirHkbxkY+hp3Ke9iBL4s9rLCySeazLMvXoOvselXi8RjQoMHP3T/ng+9cveT26avueRFKR4OwEOxc8EAcngc1Yk+3XDBfN+zwcHdtBl/MZ2g+vWlc09n1NW6vhCxWOJ7qZxn7NGPnPu3ZR/tGqaWrFhPqhS4UdI1yUgz25+9/vGp7KO2sEbyGaLHzNk5ff/tHq2fX+VWVuBPuAzG4ALDOQQf5/WghJ3KzxiFc2kzKm7AX76c9sHkCgXUhiHnozJ2MbZZPp3xUqoQ5DDgjkY6fQ9xUMqtE5l6gY5TjPtinsaqMWIWEku8MUlI+904/2h/Wo5eG2SKC5HO7lSM9eOv1FG/zY0kh3GMnG4feT2yOn8qmQbmIlIUjowbp9KXoXrEqqTHciCYCNyco27hh7N6+1W8GMHaN0Stlgv8J9h2pJoJJEKBVbuARnJ9Rnp9KWCNmRlG/y84K7iGB7j0P+eaaFKXUe0ISQvDluM7Oo/P8AxqWKFNoaFck8lSefw9KrBws4A5BBG3kc98f4VoRbdw2gqp/ShGc20hjxLtC7RtbkhhyPamCNVkLuWcdBNH8ssfs394fWntc7lYGAEhsZY5WT/wCv+tVZriMjysgTBfuk/NjPb1FF+xnyOejRZeeZAGYfaM/8tEGCO2GX/CqiyQSXjygZhSIRluTgk5Of0/Oq8l2kUZd2K7ccdT14HvmmwrLExMj+VcSEyO398t1B/vAf0ovc0VJomvZmYhdwkTsQfmHpg9x7daI4GeBTHKHb7rNt2nB7MOlV5IvN3wzx5jcEMBnbj19vqOKlsbWVAEgvZkk42CVVmDL/AHecH6ZNTy3Y5+4tC1ZlzEsbkho8oexBBwMHoQeKr3pSzug11DKIX4eSOPKg9iw9ffHNSRRX/m3CG/gRdwK4sxg5Az/Fx071Yn0+4MOJtTnZMf8ALNUjH0yAaq2hzqpqU5J9P24kuQYWzlgjjHpnioxq+kiSNGvIpJl4QIrsQe3QGrEWm28XMvmyj/p4lZyp/PBFXI4NqBIFWMYz8q7Vf6EUrl80urEgvgwL2lreS46hYfLwffcRVcTTwtg2jpDK+MOy/I57HrgH9D9avxOVOZG2Pjhj1P496juEE25JCf3gIyOuPUf07073MluUZhLIT5oUqOVPmFiB68daiWJ0G18PEDvwBwQemD2q9bI0wZJG2XMbYfHRjj7w+o5qtK6xo8sjCFQMHPIY+mOv5UWOmnJEbzTwKBLK0kXARyBuA7BvX61P5ykBmkLOcfwjcv09ar5BAEqmLd0JGPpSIyqQP3a44Kn7p989qRbgmjVQZDbDGSvOehz6/jVgTxSSBJR5M2O46j3Pf61lxylZI1QkELlSBz/gabdSLcRqlx+7IbMcqgjYw9uv1HpTuc86V2afHnlCOVGOuMe4PSq1wJEbzYgfkP3VUDePTPY+9RwPIYMqN5GFeM9fqD0PtVuMh1PlyEhjnBHI+o9PpSWpGxXaS3u7cPExCk5RuhBHb2YehqqwFzbtDeLuQHIK8FWzwyjsw9amu0JkMtuu6bGHjHCygd/Zh2P4GqIuN/zxiQop2kjh0I7Y/pQ9C4Q5lYuwyuH+y3MqeeeUcjKygen90+q/iOK0LnCAMNwTO0YP9e1UUWKeFYbpVZSMo69DjofUEVMZJIYwrFpojj94g3EezL/UflQQ9GVrIZ+1xPgsshIw2CQQDx+ZqpdSTWrRN/rLVm2SN0KEjg+3PH5VJLc27XN0zMvSMowP3TtPf+hqabd5DLckzxupUunO4HsR/UUMrXcmtp98KvIVG9QxOOnHJIpTHLcpuB2x/wAAfkPjv7Y7fnVbTj9pUxsweWIAKoPyyD+FgfU+nTINXmKr8qnaP4lA5B9x6U0S9yhNO8ZjYbkKupKvyCM4JB6Ec1pwz7TgkgryQSQOfft+PFU74JLbujZ+Zfm4JXOf0rOurttLdHn3S2u4K0ydY89Mj0o2Hbm0NK5umLOqOxCckHqPp+lUJrpckxE7s/Ngbsev1HtTpiZ4lZXU5+ZTnr69OlU0kzIzR4UAYznoff1pN3Z106asXfPCrnlSem05H4Z/lUl0yz28cT7cTOq7sZxg5z+lUVkG8/Jh888nBqSKTF4uAmyMHdj7vPAyPpQTUpK2hfLqY0Dglj1yMcD09vrWZdyuqNFlvMlBxt5IXuSPTHH41cuJEdBtVjcNwqA5J9z/ALPvVUWZgYzSbjM2N0o6cdAvoBQYxSWhNHdwgF9w8pQCSf4aoTacJnkvUiYOxDeSB8wH94f7Xf36U42bT3KzF9sCEFVXne2f4/b2rS8x+csEIJy38P50wk10K1m8ToqxAAv93YOG9x6fSrAPzBye+Aw/lWbqTi1dplGbd2/fD+6T0cfj/nmn2F7LK0g2ZkQ4Y9s/0pCs2jSis4ZJGEdpYJKByhQuw/lx70kulA72huJUkYBSEVYlbH8OAP61YkgLzCWJwk8Y+XI4ceh9quxSJLB5mAMn7rcZ9vqKa1E9Hc5sWMMULRwRGMsTuByX3epJ5NMd5jaEw481MFTng9se1at8r4K5U+hY4OOwb0+tYRimiuXKkNER80b84J5yP5VDO2lLmWpcglS/tVd13gDIAyroe+DU1sv2eIgl5JIM7HI5ZOuOOvH8qyrd2inZLddpUblU9GU/w59j3966KFRcwE7tsq9sYAx6HtQtSa0UtRokGUYYMTYKtk4x6j/CopMlTJF8wQYbnJSo7lvs4OV/cOcSx9o3/vD0zTCwYl0IUdCWBzn0b/GrYqeoRwl2DxMEJ+9tHU55JA6irluqkgnEcvYjlWPofY1nuDImYnCMF+4OCfcVYs5PPba7leeSTg/T0zSW5pUTaNKAHyGRyrAfgy/TPaqsxGnwedKX+zqMszDPye/Yj9RUjSLCzPKWMSE57duuex9qlndZYfMh+6RllKg8e4/niqON3vZESwRyMZFcyQBckDnbnnPuKfJsjXKbCWGRzlW9vY+9Y+lv/Zl2NOdmWFhmykX5sr1MX1AzjuV46ir9w+0lScZHC9AwPcEUiknJ2Y92iCkqSjngqTnJ6Y96y7y3SdAzKUKHKSL96NvUeoPpUsxDR/MQ6/xluMkevviiNoo13KAyepBBX2/+vSujpjGy0I7QSSszzKgli5EZBxIf7/scdBzipWYP5kTLgKMtG3p7U2diqEghcDKyZzt+p/rTYJVuWUSBVmHCSBeMd/rST6FW6kiu7AI+7Yh+XnOBVyCIAZB2kdWGPnH+0O/6VEseC2CDIeoJ/kfrVjPlxeW0Xm5+b3B/nmnaxnNpqyGiSU3dyroSoCFlGeQQeQas2MuElADGHlRIARnHXIP8xWZZ3jJq1zC2WRhF5bdwdpJT2P8AOtlB8qMm6NQcg9V/H0pryOSSsrMWS33L5ik7eDx8w/EelNR1hZQ42I7YBBO3d7dx7U8EsT1UqcNt9/5ikkVZImB4DD7w5UY6H14osTfuOmZZI3VtrKeckcj3x/Ws6ZmhkRQGfPI7Mw9vUiriSebH5n3WUYZQenqV9qz2YgAF9wUg7wMMT2OP73uP1pPUuCvsWI7qOW4idWLxSnyX/hIPO0n6HI/Gi9tiJYrhdgK52SY6f4dxms6SUGC6c43YEhK5A3DnOPcjt3rbIW8gBQbS4DbSeHB96adw5fZyv0M15VcMoXaOCyeh9R71X/jbOCvTBOT+PqK0Uh+YqCxaPjBHT6iq95bEkGMsCoyWXuPQ1K11OqE47IgVzGpyP3B79QPao2y6gF9wzkMw5/4Cf6VVbUGt75LWZdolH7mcH5ZT3X6j0PNWR5nKjKjORjjHuP60Gij1L8OAAfuH+8G+Vh357VZt5NxPlgMc/Mnf8v6isuMzKAyruU/eA4/T196rX0lxDGJrTlIx8xi4KjuSP6Ur2OeVO73NG+jE43wTNDLnAcDlfTg+tYcjzreFrlEWbABePJjkx691P51s6ezXMR89V8wDcJEP5ZoubZyc4zngkHOPqDRvqEHyOxHprLNDujyNrZKn76H/AB6fWtK3crl2ISTHLJ91vQ4/nVSKzWQhov8AXoNuGODj+6T1H17UlxJ5VuZGaTbFkyBz93A/nmq6GcnzMasQuL27lBETmXAdTj7qgde/JPFOt5Xy44AjfYVYcZ9cjpkHIqvpXmJaojEl/vOpIyCeTx35P6UoJi1NBuOy4HlMp+U715X8xkfhSsFraDriOW1f7VGm9eRLDnkqeT2+8MZFW5d7xRyIwEo+5Jk/n649qlnTy4lIyy9fcfQ/0qGyaJImi4aIdCeu09D9ex+gqjN9ygl5cTyLY3wMN4eQqfcmTqWXue2R1H0qxcIhTYwwuO5BU5FR6hbC8iwQ0gXlQowyH1B6g9MEVkNdTRyiC6fcXGIbj7nmEDo3ZX469D2pGtNISJvKypYKucCTOPw9j/OrazkSopPsTtGfoar3OFOHG4HJdSuS31H49qihlFviOdwsJ+VZJBkH0Bz0+tSdjslcu3CqIXWcEpyCAflx7H1plmkigrEXZ2zu8wZUE9hwCcce1Wba1W6mRsqyL82w/cc9Mj2FXdoZcOu1eflJ6fSqOadQhht5Yrf5HQMTl38ss5/3gT2qe2XLtHcSH7XjKszblb/cPb6danSYJhXORjvn5fwptwUkBYFQOo3euOooehzXuyhqNvPDbtPYBRIh/eRsciQD+R96jjmLRo8IKPgcMM49qttOYo8TlnT+IqM7Pc1nwoGQvEGxGxQOO/8A9bBoY1dkdy1vO7W8xjEjxlmiTn5O5IrK02KafbcG6SYKSiy2+RwnHzepwec0stzc2Wq3EyQ27LdqgIkmWFsqMfKT29utWvC8ge+1Bw8PnSP50sMRysR2hcZ9eAc96LJgpuLsdYZYv9ry4/7oO5Ae/wBPalSWLz2KyKyHaJiBlQT91j6H1pHwFLIoVR83HbP9PaordhE0kP3TzjPRh3H1H8qexUl2Jb4lQ37vzHA2vG3OR7VjGIOySRuduMISM7eehrQuXc23ynEsf8HfI9PbvWdC5fex+4x2lh/X8ahvU2o6Ec9kFk8+3PkyBgxKDMbE8HIPQ1qwi62Hc9riMY5RgV9jg8io4YneNd4LBvlBB4cf0p8R82GPaxEoGFYd+2D6iqWgVHzaXIb6K+m4cWaygdMu25fastBfWr+XLcQMjcIfKPI6YOT1/nW+XfbiRW5H3ehGO61CYkmiZ+CGIDgjIOPX0P0pNajhLlWpmR20okwbl5IGGSoCjYe4qwsKhyzEy8bGDdWHp/8AXp19E9tskK7gp+SU9weqn3xUbt5YLRltpXoDhl9vcUG6fMXbct5QDnbE42sZPmUjHRqqmCWzwto0ptVYfuxhnjHqpP3l9qYLtUXKMBuHJx8v4irFqrxgfxooyf8AZz7elO9zOVNLUieNbq2OCJVc7gUO3GDwyehB5x1qxHIbiIF5NzEfN2wf7y47etRXlpIhaayYxPIMtgbsgeo6Nj8DVLewj8xBsmJO0bso5z/C39Dz9aL9CN1dEl1ARNtYcE4YL0YeoP8ASiKJlIaPG9eme/t71ctnS5tVlRCUYndGRgAjqPbvVO5WayjSaFGmtW/1gAyyH+9t7jsaTVtTZVL6E6hXwYshs4aL/A0nkFywiKpKrb8Hv7/54plu6TBCjblPykZHy496uyK5EZY7gDw2en409GDdtAiaO4VFC7WVRkgdPerBDjCTRhnA+U9mB9D2p0IJjBeLLDPz47buoFSSL5S7nDNERwcZHuD6UzlctTHEETX14joGWQRFudjIcHke4IzVu21RLdzFcArOrDdv+63oeOmRz6UKpXV9zP8ALNBgOPmU7W7j6NUOq2TgxTI6IwIU8bkcH/6+P1pPTYG4y0ZoTySoolsf9YDuMbHG4d19j+hqe3ming81HaMsflwvQ+nsR6VmW0EwR45DJHLjgBs/k3pVWS7mtLwuqeW8hCyox+WUdAwPY+/ehPqyXSvojS8wW948Vwpj3jKybflLDoQf51DfWhJygAxzwenuP8KnlkF8qRQfKoP70kZ8s/3cf3v5CnRsDCpkXGPlOD8ue4HoaCYSaZis7zPLuXbcQttb0YY6++Qc1saNKTYwbVP3FJTt06j+tVrq1CzsckrPE6ENyMqNw/HrV3SY0NoiEZ2qM84ZSByf0NCTLnNOJemhR03I3zcAN6H2P9KoSlmZlPyScjIGNwqwGWNwGlznoHGCR6fWql/KiYbMgKjOemPUU+lzOF76GTf2cUsWySPfGzc/N37H1B9O4qn581lIsN4V8k8pckfKPZ8fdP8AtdD3xWzaXcdwyiQI5fgSKOH46EdjUssQjfKgiNsBkbp79ai19UdKqNaMjtYAJVK7g2OVYk5B7j296muIhv5UhiOWHr7+tVTaS2WGsTutwc/Zm6Kf9g9R9Pyp1pfw33mJFhZFbLqw+cH3HeqfYzlJyH20QcmM8TpgqY/4h2/lzVoSnJ835WBBBB4OKggUmUAhY5ScFN+Aw9RUzMVmWPPlTY3LkZU+uD/SnYl72Ce3BkEq/K5HzMD17jB7mqWop5kvlqhLBRJNt/iUH5Qf9rPP0GKvSzxwZUKTI/yrFjhz6D0+vpUUIW3L+YfMkLbpXA5B/wAB0HtRYi7Kot0xHNBIGjcfeHIYetS3MMlza5ddzrhkYdnU5H+fepnCQ5uYFD2xy0qqvA/6aKB+o/Gpyw8xXhKhiAMdQR2IPf60Dc2yrJukhjkjACOC4YZA9x/n0rK/f2Z+1ruKAHzIRj5lyMsD0961SCHmii+U/wCsQjsCeQR35zWTHfOspt9ShS2lkbCOpxFOD2z2Y9Cp/DNSwjtqXg6XSuYnYSKfmjJKlfqKq6gkVxDJDdqrpIMOj8q/09KjgKbDbypuktzs8wk8f3SCOemOParkdrJcxfNOsm0Y2yDcOvboao0Vo6nPxTz6ftVYZLm0T7oY5uEGOmT98ex+apYza6nHKIzG8L/I6cjI9COq1elhEG4yRJjn94pyPxB6H3qCexS6ljlA8mbGRKmRuHbkdRUG6kug7QZVtJDYvuITCwycgMuMgHPRhyPfHrW9s3biOQw+mOK56ZJ4mj+1qJ4eEZ0OxgCeD6DDY54rZ067iCtDO3lzJwRJ8vHZh2IP86qJz1H1Q9QIyrglsjng5X/GoIJm8xoiux2G5D/A4xzt9x6VfnZFVjONqH/loG4FZF/avIn3uFIdXAGQeuR6/wD16HoRHXUmkWYFjG6+YR06dR0IrNinXTZbgSr/AKMzKfL6mNm7r6gkdO3XpWlbOHQgDJT+8ck59Pas2aFJdSljlYtGbfAAOCMkg/pxUlNaFLUrLGsXk99o899HIibHWNWVcD7vP55HemaVbKLi4ltbO5swgVACoDqcZPH8Q9qkg0S2y9sJb5mC7k/0hzsQdjz27e1T2GnvpUj/ANniW5j3h5Emclzkc7Se/tVtozUWmb7vLFCFRA6bSrxlvzCn+hpx2XkC+WwaL+Hd96Nvr1FTXEXl4eWNSg+Use3se4+tMuRj+PDEYDgZz7H1NLyNbp7FaK4E7yIg+dMCSPPzKw7rQkI3B227ZMHcP4h7/wAqr3olh1C3l2nBTZIF745DKfz4rU8zzUVwY/mG71Vx60DUrKwimOPKS4XJ4IOPoQfTtSW2cyxkcrITnGVYHnnHTr1p4RVBR8FSejc49MH+tQRL5N1MmCQdrY3YYNgjj8qCR93GSgxnCcFT1X0P0pyAxfO4Cuw5K9x9O9WW2OoLnzEAx0+YGoZy8EZDp5sHGDtyU702Cm2uUZcKskLxsBsbIznhjjg/Ws5opEEcbqWDgCOQHJPcKT6j9avpOAWX5GRhkrnAPboehqnbSqlookDzRYC8cOvoP/r+tS7FxcovQa8JUebG3JBJcfd98jsafbyhUfAMbAYKN/T0pz3UcUfmHzM4I81RgsPcf3h3HfrTfPikhygVVwSJFPH/AOr2pbPQtSb3RNEyCQozFEf7rZ6H0P8AjTbq3V0baiOX+U443enHY+9VdphViAWCgZ9Bx1x3+tXbN47hAPnaNlxn+Jf8RT9RyXL7yMqzZ9OvgV+WK4OxwWPyy9geeARxg98c81otebXbIMeSSVZeh6Yx6e4pNQtPNDrJtBlUL5g5z6cexwao2reZEBcBWfPzRgcjHB5+oz6UbaMIqMncvG0iLeZGGQn+OI7WX+jD2NPdbiBAU8m5jPGGBib6ZGV/AgVBFueQDPmR4xuHGfdvX6irMKzSSJsblRl0f+MdskcH60yZIntrnyNonguo1XuY920/7y5p02o2mf8Aj5Rec8g4+pUj+VWYT5KYUMQf+WZ6r9KhMx2K6S7FU4wOcenFO9kc9m3cyjdQW88DxzRGBJMbN33Fb5W/AHBq9eGF7eVI25ZdpQDOT2P16GnXRVo1jePCucP6YYYP0pbAs8G2dSTGdj4JyGHf6EYP40ou+jLfdmfHfPMiNHbvNhdxVwE2nucnk/hRKst0Cs8iCMj7iA5+jZ/XApAha2RgxMahisijBX5j1pgeRSNyFo+MOpxn2x2NCl0N6cV0G2cb2rq1ryI14RWyCPb1/nWrb6hDLOXBWPcQkyMMYJ+639M1RjQFi6ZdfXuB/tD/AAqvegHbIwZWwQrjqueo9/oaSugqUlNmtqm1HtkXcGM67oyMgjnOPw4pDMgUNGxQ7iCe6nPA5/kaxItRlZ7WDUCFn3jZJ/BKgHBB7NnqD3rS5MgZSVYfKT159D7UJmUafRlyW7Ro2DrHvPPqre49DWfeOrsgjZo3UAgNyoz3B/pzTJZPMDEKQrcnH88VWJZ2TYBNGScKpw2fp6e9Dd0bwoxQkVtIL6NhiIuS8oPJ/wB7I9+K6GGMtbKNuWBwBnn8M9RVO2hMa/vgWL4JcDIX0H0FX7fd5uxFJA5yBxn0+v6UQVjCr3GpFCeQOQMA5PH9RWbqFgJbje7bJ1G0TR9XHbPY1sTLG+HRgrgYzjBH19qqvk4RzhjgA4yD7Y702jOMjJ+1T2vy6jC0qDgTx5OD7+n0P5mr8dzBc2RWELcDPygf5+X61YeJy65Vo+ABjrj0Iqi2n2iTtMV8mcf8t4mKv7E46/TGKY200JLE0UqyOxkkI2jknYO+09/601LoD5wCf9vqR7/T2qJre5DIftUl1EO+FLg/lyfpSJZeZllups/xKUCsp9SKnU2i42sy/CrxN5luu4Hlo0bGfdfQ+x4NVTcRWgZ1Il0+Q9AP9Sx9R1Az1HY+1KsE0IUsZLlByUMnr3Hb8KlREnJezRRIo2ugO0kf3WU9/eh36GTSTItXna3iS6CsFgbJZupQ/e9j6/hWRrLvcFbiNBOI1xPblcieLOdwHcjqO/UelbcHlxxgNk2bcAsvCHptYdh/LpVK0X7BfHT35Ea+baHruj7rn+8h/NSKNWK6II7aSERSWEyPbyKF8q4YlMEZXa/3l9Ocjmp49QS2ZYb5HtJG4UyfdJ/2ZB8p/HBq9eKsyMgG3P3geNp6/wD16qNO00QidVcNlXTg5YdcD9aLq41qXeoQyKHjYYJAB3j+X4VU/s/7HJvsJniQ8mPrH9Qp/piqUdqIBvs5J7Uhvm8kjGfUqeKnS7vghAlt7n5vlYqYSfrjI/lQ2gs0WpC/2aRXhVyBkNH94fgefyJpk8cd2rSQgeeh3Lu43eoOeoPoaqzXkoUm5tZLbAIyWDL+YzU1nfCQbiAy8AEMGHT26UkxWIVWOeRWBOGOOhRl9QcccdKdFbXFqirYzSmNeRC5Dcf7JPTnt0+lMmJhvi0TSQ+d3Iyu7t+Y/UVbS5dWIliAcEBWVhtYHnn0+lO42hVmQyJumWK4AJIlQqx/DoR9M1SSXzNZUsRuaFkODkZUg5/EGrcySTxkSQxvGOdpk/MjvWPqFtdQFJ4Sji352u53AdDzjnA7HnFJk20L+oTQWyuQ6RPbL9oxuGVXoSfYjIpmmTNeySXdtdF7d2xGGIG0Y4HTOR7+tYN1Lv1kW19c2ltHfSQSlXJ8yTZ0RD0KtxgnA/Gt3w6iG2vJZ5o3nmuXLeRyg2nbgfQAZquhKlrqbksoZjE8oZX+cHsw7g+hzTJkEYLR52YyVHzY9sen8qy9RuCLX7Q5cOpEZJXlM4GCPUHFXxc+XFhzwB/rRnnPGTQbKNthksyvbEfM2wq6qMZGD1XP40/zFjLNHH5kTnLxD1/vL6H271UuXVEMgTzYskNGv8P4das2yxzRRSRSBQwA3HGPcEdj70kOUEieJ8uU80ywKA6E8nb3FNBZJ2CRCVJI8FH46N1U98A0s2YCZFVlbd80ZHGe5X/CnSyiR4pohlfmyO2cDt/hQzMsJgurrKw2gfvQMMuD3FTyzI+zACyZwdvQ/wCf61UjwtzgHLNwVc/ez3BpkjiOJpyGPGGUrkqAe/qKpMTSvdkF7bKssjBcEfN5ZyAwHU+oNGnKy2iB0LIFAKkZZRj9fwo1A7Ym8gFlYgFCxO3Pp7VVin+yzLHKzSW0pxE4Jyp/uH+lTomaK7RomMMjBn3QyY2u3qO31qAWy2yl4wMHgr1A+nsamSeISssYM0eRvGMf/Wpks58xShBVjjGQQQexPqD+eaeglzXIdp+9FyCe+Dk9wD/Q0/T0eGU+WAjZ+7jjPr7UZxKyhld/Tb1Poff3pYJ089UkldVbgNIAR9M0GzvY08efE0RQ4Y529Mf59a5+eBrTUJ02swLLMrHhkBGD+o6VvRnzdsb7nI6cce+PU1Ru9sl6EkPJh+VweD82eDQ9TCnLlkZ2SRneFzjDqMjr1PpU1tK8Dh1QrGTllH/oSn+lMmWWOQuoI7MQBg+5FWkARURUwDtBQDOfp7fWkkdUpJo0tvmKvLPEed3AK01BlsfJubjeeM+xqtBIttH5PLKrYGf4e4+n0qxGA0e05JJyN3H4e1VuzkcbDLiNo0J+4xO3Bzzz+nT6VD5vly+bGShYc5OORyP0yKn3g4SR2xnHK/MPYjv+FUNTgMsKwoQZJuMdsd2B7Uio66MlsPntImwqTBQWHrnnGO/XrTrm3UKfKRcP1A6H6dxUFqxngWQLtGSH2gBo3HB47/SrlnMipkFCM/MP4W9x3FNdmUm4u6Ft4cKAWVsfKSeCM/5/GoJ4BG6sVypJGff3Herty8Txh/M2OeFcevof8DWe80gyXG6Hn94vAyOx9KHpoCbb5jKvITJKQkausfPlnGDuPQflVnSp4Lh5LaR5AykhXPDKR1Vx0yPXuKdIqFllldFnc7hxnoOmenAqOSCOO7jvVJB/5aY5xxgP6HHOfY+1TsaSV1cvlCCVhWNg3JfHyn3A9aorb/2fctc26s6SEGePHzn/AGwP5jv25raVXIHyowI5C9/pSyxgx8bmKjoR8y/T1ppGftLEay74FuIVEoYA/I3JHt6/SrNrLFLGJ7aTcjLk8dT+P8qyJI3tTJLa4ZnG4xl8Bz6gn7rfoawbXxFH/a0sKrLaXDNuZZFGc99w7+oI96JTS3IUXPY7tGEq7vMK5BKtjIqvPuZD5kLFhgk9c/h6VW+2TxxebJEjZAOYzwfqD0/lSm7GMrHIq4+UHJ/IindMhRdxsnnxN+6kWSFzykj/AHD9e34jFJLcRFglwjxkcFZFyAfZhkUwXcTqThWOSQTkMcf3getPtXhaElflx8pRiMg+2elFkXytasplHhle4sZd8RIMsLEMCfbPQ/ofrU5uI7rMhG/HykqDlD6HuKlmjiZciNVK9WAwwrPvG8uYyOWilH3ZUXtjoR/EvqD+FK1iknI0kU/LLHskGCMtzx3Abr+dU71VEu5kdGAIV1PzDnsR2+tMXUVgx9pg8tZP+WyN+6P17qfrxV63HnMQwQxDlSjZI/TpRa5NmnqV0nmiYlwLiGTh2UAPk8AkdD6HHtVHUo47iFYvO8po23wyFSGgb3B6r2I9K05F+zKRy0GNuQMlc9/cZqvLIZUjdyvzDBcAFTzg8etJoSXM9CC3vHvrIeYogvoT5cqEkhXxkc90bqD3Bqijhp28xFE2MuV42sMfzGDUWo2fk30N3azC3mi+Rm58uRD/AAsPTPpyO1NkLy3kWTPZy8RyxF9wKnhWU/xKDjn37VMkXFcuhZa4V3AUBk28OD8w9veljaUTiTcGDAAswyuPcVQmJg1KETStEGOflYLuI6npW/8AZUPzqkuGB3pI3BJ78e2DxUxfNuXJqJGJmQEsAVztxnIPfiqsLWjsI3VBKpztK4cc8HsSKvsIogPkwp9OVOKz9SsGcpcW3lvdxDMTMflYd0b2P6HmtDK5Z+zl4mjhmb5ufLl+YH8eoqC2YlZlnwCWK46jjjH0Pamaffx3yEQkx7hks5GUxwVB/vdvap5o9jrsOFcbAPRh0Pv3FAvQhdpjcBY3xxkd8gdj71NMH3KxAXjp1z+NU4pZYSpkKkg5DjgqfQ+1ab/vY2LMNrAMo7EUkkOVziNeiW1vZYnspLiCeWGSN4wMxBSd0fPY9R+taHh6G8sTqEseYoJZ/NCN8/kgqMbsdc+q9O9ZfiLT7ePWruXU4ZJLVwhjRixXGPm2sP4s9j+FZfhppbPV4o7RZUZ7hti3G5WeAKPvKfTjBqrvqRZN3R3+pLLdukqMotCCFkfgXDD7pPooOcE9TyOKv2M/mQMWDIcAMjjsQOnqM066Iu7WWKbZ86gblPDDp+BFUdBfdZRZzK0LeU3XPH8+MHFJ7m6ulqSS7owwfcQoOHB6+2e4qTS5/wBzGB8ylcFgPlPsanuo4haueE3ZxjoT3Hsc1V8trJWlfkKoDKOuB3I7/Wi2tzZSUommuGR2LSFMjtnZjsR3HvVdkdJme1BBUEtEDlWB/UGrFs0P2cFGG7bwcfMv+IqJ2MVyJI9pDjBAOQe2R/hTsjm6jY4Vm+cL+6IJKkYMZz2H9K0YiXVWcA8HDjHzjuD6n2NVLa7Vbpo5N0YLEru4KnuRV53IZhEwcnkqB+poREm9mjKaT7E4EwP2JSSGHWE+h/2fft+tMvbZHV4ZFDK3BLHhgfXHGfcVblLnOxSjt8xQYw49f/rVSi863Zvs8ZktxjzLcdUH+xnt/s/l6UM0i7amRbi6tb9IfNZioOFduJV9cj+Id89etajNGyllXDE/dPY/zB/SpLyCC4gWVCWC/MsqjBHPQj+lECCSHPAcHbmPjB9M/wCe1So2NFPW7IJpH2KZGURs2VJP3vr6H6VaVhOqLKQyHj7vH0/+vUCR5Lq3zxsMEbe/0pFk8nbGEZx02kfd9qaN7JrQ09PkkXdGWGwHOS2SMdD9P1qyP388xl35XADKcZ75B9eaz1nja0DBjuzhFHBz7DsfWrFkSsSpKOBktIV4bPcjtVHHOOpHeRyRtuXy2mHboHHcH0P+RTLKZbyI712EMfMik4ZD6ZHUf/WpbzzlbduXbnYHDZPqAc9frVS4lSCYSblTolxERlcdpB9OAcdj7VLGk+U0GjEVwBIfMiZch+p69Cfxq4kqCMoMsO6kZJHqPWqKFyvO541BUjPI/wARUQk8iIKHbGSdo5ZT6gd/pTTE1fcuM4RN+AYh827oVHqDVaRQxEsyn94P3bHjaPQ+/c1CZ2d1lfC5PymM5U/73vWnb/vImMi53cHuG9vY0W7A1y6mOsbx6k6uWKXI3JIOodfX14xz7VJax+RLdhc5MmcD7vIBzg+9aV7bJFZtJGFzAfOTd0+Xkj24yKjRTtjkI2rP+8A+vIGfpjrT5eo/ap7FO5VoyQPLAPOFJw3uPU+1QSSLtxyYuAVI6mtC5tyqskh+TGcE8j6j+tYr3DW1yIpQ0ts33CF5H+yR39QRUvTQ6KU+ZFhwhZlYjI/vcc/0PvV2EyKgKjeO4wOlUNwufmgO5OnUE59M/wBKtWTBmLlgZB/Djb+f+NBpO3KXIJfspKBQtkRlWZuEPcY67c/l9KsKwkyYyCe6H+hp0MIRWx8wIyyEZP8A9eqS27WjsYjm0Of3ec7P/rfypu5waXY+5DorcgIAd6vxgev0rmtS8PwXk8YkAVQd6vn51Pbaw7e1dLPvnKeXIvyjlWHOP61HK32cCNox8uOCcEAmplFS3LhJpaDbeK5t7JYN4ldQUywwwP8AvdD26/nUUkiQgA5hLcFJDwT6g9KsRFoFDbgWPXb0x/nvRMRcKUBUY4wy5H41VhRumVZFbAZgw3EYC9D7/X+dQyojvKdgA2439Tnvn8KFKQHyiGjf0U/Kfz4NV7iVlKtgFQSODj2I96TZ1xTZbt7khwrOPmOAw4JGO1LcrjDp/qs5JXBx749KpweWshjByx5Kt/Sr8ESMm0szDqCTyP8AEUbimlDVFWJSpYBmKY7EZB9Ks6fAgk/dl4ZR128A/UdD+lTx2QU8qsgJ4bJzUqJ8+5dxJGMryRTSaMp1FLQWSR3QxXEQEmCQ0JyCPUD+lYjIVecW75CyAkHkHIzyvb8K2oXjOTKwBGQHGQP/AKxqjcxn+0HKkPmMHphlIJHX8aDGm7Mo3M3mRt5igBjgoeQR3AJqn5TPafZpFNxbZO1GPzxk/wB1v8fTrWlLGfMwDmQ8/P8AxD3pzQrGFKxlATgshzhiOKVjeco2uQ2kJvraKdGhnbGClwvzI44PI9/arru8JWMR/uhwNkgwp68ZqhbW6h5gjDzI3J+bhiGAPH4561cnJYDecqFBBUfMp9x3/CmYPXQmaSWYOqokcrDAYtlW+oFUpYJFUdX7tEAQp9h61D9okEg2q9yuRkJ94Y74zVlNTt5g6R3EbdykjhWJ+hxzQK1jMLRbmu4G/wBHziZQuNjdA+OxHcdxz2q9FK00JSORSzgeWV+6zDp9Dx+NRz2zY89HXzsYMu5SG9nA6+metUxe2+nERXDxwwPyELg+X6jryue/UdOlJF3Vi1dL9otAyD5z93bwQ3TH4GrdjJ5dgYJ12zQLy/OWXs4/l7GqMN1FJLstjJLCcyKcbVD+m4/nVu5gMzQzyyJHPEd0IXonsf7wPehKxL1MLVJLkyXri/ntREYXWCNgA8bHDOeO36VFpEUV3aaja3Uxvtt2xWZ23FuBgg9se1aRv726uLyK0Sxg8oCM/aULOzP1Uf7Pv3qzaaYyWQila1Gz7gtk2Ko+hq3sTDSWpYMzAOMBZVGAAAQfQ47j3qFY5rK/N1Gn7rb++ROSV/vD3HXHpmnyyKJYWmZNwyofPT6kVfyedu0OpDRuOAR6Vmdk9h98UkiUx7XE2MN1R89/Y4pjowiQAM6htrIRhlHt61TlMNnKsUh/4lspG045t5D0U/7B7eh47itNVK2zCRSwHBbpg54zVHPeyKumfNZlpXAeFjE20YKEHg47cYzUqtHhkMgSZlwuT8sgHp7jriorZhFqF+iyGORikgfHB3Lggj/gNSXUMN7aCK6RVK8g7uY27YP8J7g/hQKzZPNEJ7IswBkwHjZjypHTJ9D+dS2spkiVvugfKNwB2+x/HvWbbXk1uY7e+KrPu2pL2k+nYH1U/hmppbpRO2GwpOWdf4T7j9KVxKDLtzbxTIVlwHXlduQ6H2Pf+tVJZGhCC5InK8CVOCB7jv8ASrNvIspWKRSHXOB1GPVT6VHd4Z8xyfd7MOR9fX60xRTTsyCNg2fKYB8EhuQHx256GqqBoJl7QzMIXB6A4O0H0OeM9CCMVKqbiWhUZPHlk8fVSe49DVe9je6tpI7dws7JtC5+UnqA3cc457GgtrsSzOiS4di0Yx8xOdvs3f6GgxgzZQsyAY91Hv6+xqWxuY7yzjvRlZXXDOB/F0ZWHqD/APWqWdxAjOVG3IXYB0yR09qRpGpbYghjImD9xgAdCR/jUl9dNb/O4xESAWXjb7+hPamPJsD7QDnPynofp3FVPPEw2E8E5aNu+ev+e9F+hqoc7uTow2gq5KYyRnrn0z/Kqk0Xmb1CZRuqscc+3p3pyJGvyx48ogDZIOFPce3rU+xDGyrmMj+BxkD/AOtSL0juVrOci1Ec80m+AmLHAIx7+uMH3pTA3n+dayOyggAjAb9f5VCVVNSnjDbDPEGZCPv7eCVPrgj8qfAwEchRmBQkA5xx6g+vtQ9SVHqi7Gp2s7korHmQcEezD0rQtNwUFG4Yco2QGHqD/nFY9tIxn2o69Sd7qcg9wRWzajbH+92Iw5GT8r57g9qIsyq+7oXJ3hmZIAxw/Mqtz8o7fj0/OobG48uAQSN/q3aIMvIIB4/DGKbFGUXzJOPMbI9UHYfT/GmxIWlulYAiRlYZ6Nxzg/h0q7s5lFILh12v5jHBH+sHII/z61nXCqybipMYIxyd34H0q8VbHybWY8bGOPy9P5Vk3CNE37sbTnDRlemfSlJ3Oqm1shBEOHYss5PEqfI31Pr261bR5xh2WO4CjG5PlcAjv2I+lNiiQR4YNk8qM5z9D61ctYmw+/8Ai6ZwDn3ApJsVR3J4L+ORljZiknZHG1vwzV6dFXjgA4+bn9aoJFHtYJHuU9UfBx9Ae1PdSiI8O+JMYPcDt909Kd31OWS10HRQNDKTK5yTlAeh9we30pkq+Y+H+aRSVUcb1P8AWpS8gh5CyxgAll+U/XB4/lVOe6hK4kbbjg7xhh/j+dOw4ttkLSfvPLky7dCp4JHt7VWkdo23A71U5Q/xD6dyKmumjkTbMFx1EyDGD7GqJLqEVSH29iO3sals7Kcb7kszpIkjOolR+eD93/Cmwxx+SUlxju2fuk9iP6il2R7SVzkjocEGrNpArncwZCvTJB3CixcmoogFuYo2LIJVQbhjlvr71oRRCSGN4yZEx8vO049jVpFaJsDAbHAz1+lV2DQTy/ZlbOd0kecA57j0b9DTt3OSU3Iek4tI8su+Mn/WDsf9oDoPepVInYj5gcZx1bH9ajSZZ03wkkEkEgcg+hWqkSGBixYBAMgIfu574/wpPQjlv6li4+QcjaGO3cM4H1FZtxJ5NzC0kYJOUOCSORnj8quzMPLIBAUjBViQD9DWXdoroSzESRMJFYd8df0zzTZrTjpqW/NypLqSgyFZeq/X2qVVE8TRjCSFflI5J9CPxxVeIASARkEdM9iMc0yVlidVfMZxlccK3tnsaSYTSWw0OpmkkVGlzErlQDuB5BxSCdLiBWG5gflXPy49vbipI5ANSljeRSVhDLuOOpzz+OaLiON385HQF/vRg8E+opkJ2GJhpM7CGII+U/MPcGmzhX2iRYp0HG2VBuB+uMfpTHjhhLunlvv5ZmOGzjGQfoBVC8vZ7dj5kMbRZXFxnIX/AH1HP5UFxjzEl5FaK26axhUNjLNEo5+o4IqYx20Ns+IYfKOc/uxyMdyKhSSOWIPF5brnPytlSfwqOIpPc+UT9zBdc4LHsMe1K5coJIjR5LJdxDS2owdqndLAQOv+0uOvce9an2mG8gSaCVJUYgJIn07VGWEGTwGPzdOAK53UrRoJHuNMujbrcf66LP7t898fwn3FFyIpXuVtUXdr81zc6ZcXpRVUbUO0ADlByOe4P4V0Xh+5tPsZNpZPYxlt3lyjazHuVOT+XtWBHp1m7RwzyahDP23XJ+Ydip6GrOmxvpTy2yebMrEyHzGJLD2z0I9KfMXGnd3sdLcWS3kAu4ZDE5w4mToW9HHr71LBM1urGRPlbADAfL/wIdvrVbSXQPdwhlA3mRQRwyk8/ke3vWpp6AgOgwVBUD1Ge3+FLzIcmlZkdwpVfLKpIk4OUkAKvnrj/PNUYrl7ACFnaS0bKRuxO6PP/LN89vRvwNXJM2rOixkwP84jHAyDyR6H2pLoo8bylA6up3NuyQv0PUetDYlZ7laGQJqUitGdrWyYweANx5HqDVnzdy43K8i/LjPUf4fWshXkjvo1bJItwsUvtv8AumrC3YExVgEG4jKkFc+hFFzWnHm2HTRfvJcRtPZS/ejds7eOh9v8KgjhIdNjmeADYm9sMB/dV/6N+dWC+E+Q47AoTx7E+n1p8wVYN7YyeCeMke/07UtzblS3Ni3KyRKI1ZnQZCkBWH1HbP8AOkdjITIzlQrYV+4+vrWHp9zNG3lzP5rRn72MNjt+Y6dsitqO82APIS6Mc+YRyPZh396e5yzg6b7jRHu+d8Mrfe3AEHv+X8qryWiMVljyl6oGWwTvUdiOje3cVfumSMCS2ZcNyVP3T+NMHzoFxtBP3WPf2P8AKgjV6mLpcrW7O4TEYkeOYL0Chjhx9M/l9K2bmJ54Y1bOxZFd168Kc5B7gmsuyDYkLgFHnlY5PuR+RxWnp8kn2do3yssOUO4cEDBB/EYpoJK2xHM8c6yA5Mi5GGGCPx74qjLA2wvgjIyHPT8D/SrlzukuXQqUduVX0PGdp9e496j3lW5f9y/AbsD/ALQ7H3pWNqcmloZvlkHcSCOgOD8p+hqVGBYGZ2jU52sozg1JP8km4BUfv2Rx6expkQ8xT5WSmTuXHIGe/Y0jpcrq5V1MYksjJhlMjBSo4OVOT6g8VZgUqR5wDBxuQ5xgn+tZk5ktr21tJHL7JJHjYn7yFT1+hOPyroLRBMSgVcsCuR0pbsmTtErBXbAwUlH3ZMA/T61pIjTRRo52HHzsgADY6jB6VV0ImOzWCcmRkPIbg7cnaw9R2q+m5/McqTvA2FR27Zp2OWpPm0JyyGMsrBR/eH3T9ajUh1IlG0Z52nK/X2+tPh+WMqylJD97uGquxeLEtvGWTOWj6Ef7v+BpmSJBHIxYSIzrjn+8vuKZLG8kQBUyIDkOuMg+vrUkckEm1RI0Z/hJGOfQ9qWQuZGLlkfABcdB9famCbuNtwoOSA27g84De/1qwVj3BhlT0BPIPtz2qt5TrGAYlU5xu/hY+vtVuOQBPLb7vXYx6Y64Pekgk+qGyBpHAdODjHHcenalDbAzgZx94Iw3fkaYyeW5a3XMZPzxN257UPHE/IbYfXpj2pkFWZctI8WQrcMMkZ7dK5HWLue0lZclWQZiJOUbn/8AX1rrL3JjZWbbIV+XnH456fnXON9n1BHW4kETkFS2MY9iPyqKiN6Wmpm6bqX2hjHLHsuDyfKbIcE/eHqPrWyWZ490Mw3Z/wCWoHP4jpXPx6RNp16BbAFSd2FbPP8AsHtn0NdNbwtMgMpDDptf5SP6UoX2Z18yIzeIrj7ajwEceafmRvYsP64rehYS/KoypGQQQVPHasmG0OXVN2OcqOCB6Y7imwQxw7vNQIQcEKT+mKtPuRNKWxpSvc2pI8sSRdSSOR7fWkMrTYYjEfqwzj8aq7UYYgM0iFeMytke3X9KqGGOPHySSJj7zNnbnsTnp9aZnGn3L8e1ZTLDLGzkYZS33x+H8+tXJStxHkKwlC5wy4P4/wD1qzo8pyMow6FVwRj1xxTzegtvkQKwGAOgI9vx5pX7kSptu6ESNgrq5Z1f0IBX2z3qsWeLMbxHyWHyyL8zbe+R/h61oJP5qs6tlgcMn8Q9KiuYhNEWVidpyV5ypxxQtATaepQsmQskeBcAjg5IYr6474rRmhtZrcqYldn4GBnI7nHbFZ0sMFzb/wCr2yxkEOONvvnsaq2t3J9qEFwXhuyNoJIbzx6g9z7dfrTuKXvMvwRrFqRMZVgsQTbJ2+YkYP4Vps8LIApKHJ+8On0NUrb5jMSA375FBB6bRjv9TTpfLhmeZGZkI+eJRkEdiue/86DJ7kN2fKYhiFyRhs8H6e9V54mdy0eCpGA3I/P0rRaO2uYAEbMTjIxypqhdzT2DhBEZoCOQh+ZfU47j6c0MtStqtzOEMglzFAGuWyAyjaSR3bHUD3FLc2AltFTAWaM7hK+clj15Hr3/AArVtpRIgkgjjmRxwyHJCj09vapCEeDajDBPHOVJP+elCjpYJVNdjHtrmYEpcCRmj4cFckN2JA557EcH2qR4or2zmeGVHyMYTDBf+A+tOms5FuI5LdvLu4xiNivBH90gdVP6dRTY4IL+5aO7hCXyjcyPw/8AvKwxuX3/ADpJWC5yV7IdNuPsdxq1xcxcMY1tVcxg9CP8OtaWnZvLMvY3st4m7928sewow9COcdjmq+r6Yy6hdwQ3ciPLHHOqb23I6Hgn2NWvD0IuIri7lupi1xMXZYpCqhsAYJwDu4pvaxcZ2ZuzxiBpriP5lgnLMqrjKsBuwO2Bz6cVsw75Gl8uQPG+CGI+8Mdz/I1FY+XJcXbQbZcSkkZyeFA/GqVsPsMyrE5AhcoUPeJjlG+oOVNFiXI0p0ZoQNu5h1U9Vxxn3qusnyyx7hvPRSMq5/8Ar8VcnfDMzZ4xudRyPSsu/W5ilWWEgyqQzAfxj1+uM8ikJX6kasItReJ4sBo1QqT90ZZvofaq10v2PU423AxXX7sHAAEnYMOgJHfvUiXKTXs/nKzRvtXchyQAM/zNLqNu17bNBMTLDIpVJAOv1+nH0pXNorW4/DMf3owwGA2TyO2fenp0ILjcDyuTgj/PeszS5rgP9k1DmeMEFxx5gH8QPr0zWlLEN7Zl2FT8pxwD6MP60HVdCyCJLxSAyiVTGV7bhyCB+YqazuJYZjaXKM8bgmJgMng8ge4/karzyYgXfnKsHyDwCDg/jzTrsFkwmfPibdGc4Ib+uenHrTM3G5eSVIn8xCCmcNGBkMe5A9fbv9as/bIvszNCEkCKTt6h/QfnjpWVFKLmFG3OPMy24dSR/Ig9vakhffeIoU7DJksOA0nt6ep7ZxQYyo3Rf5sLNGXzJLVRtmGcsjdS3vg9amhkQSy7MbGCN8p9uMelPin25MrjzVG47vlPP8/pVW3jW1Vgu77O55yMmLP8LL3Xt6j6UGG2jJL0yKmWxuU7lIbH1HseazLuQQ4kklxuIG5QPvdgR3B9auXe5EZ4sFlXdtHzDb/UVjXAaS2lWVGEhQ4HUHAzj60NnVSirXNNJUaNN+0g8lM/IfcdxS2cMiuZBksTjbnDD/PpVKxQHy3iOMj5VPIJxnitmFHdQ2NzH2w349jQtSp2S0MnWLVrvVLOO1YJJDFJPtY4XPCgH2bkEVehn/0EzQgBv9X5Un30k6bG9wcc+nNJZYnuJ7wndvYIjMM/ImQMj3O4/lVTUIXkmW/sFy0Qw0a8rdY6lT/eUcD15FD7nLzO1jRnBgigkic7Ix5UjAchTwT+Bwa0YD54Xaqr22nIAx/KqVqEubUebIfJmXaGA4wR6e3pRZHe1uXbEhR4mJ+7uU9/yP50K+5DfRFsuyyBGTaRztJyR/8AWqZkSYZVzu6Fe6j+ooLblCZCyDpt56VA02yQJOAGyTE/8Leo9R9KaFe5WuITGxfeQ74UEfLuGPT1p7lhGPlDsOemM/gaR5VlBV8SR8jZu4YeoPrTvORUG9maIkD5+Sp7c96Vi9SVGMa5UZAHzJk8D27/AIU9Jkky8Wxx0bHQ/UetR+blN0hJA5WQ/eH1qhdje7vuCN1LAZH/AAL/ABpt2BQ5maX2hAzJuxyMBvvD6Z7VBcTSx5kXLgDkoMkexHpWXNdGVABtLqCCAd20/XqM0pw6M7yspA4YfeU+nuKVzRULblibZdBlcbW64HQj2rMOntGxflkPy5B/HnNSC4xIgkYOB0OcN+FaEbo6BHKsrDG4HBH19/elZPcuUXDYr2EW1UDnziR0K4ZfU+9XrdVeNs9zgnqD9fX69aYQVjVnj+VSAJB1GP5Zq9HGflYjryHVssf6GqsYSZUeCSMrJDyBwAx5Ge/vUE6KwHmtiQnh+/0NahjaMFkZZCewXr9R2NUZTFcswRtlxH8rI4wR/iPehoqE9dTPkAE4IAMnO11OCW9COn51GXkklAVdhI54xk+hqYAmUhEA3clc8P8ASrFup3lGXcCOCDyPw9qm1zq5uVXK7RvHgI2wHpu6D/PrTrhMJiTh/VeVPue/5VZuIUWEl3ZWYfeXkZ9cVmMJ0KqUbb2PTA9/ai1iYvm1COKRHRoHCv12OMhx6Z61tRPFcoN+Y3IwAR39PesZ1ZEwp3MoyAnXHuams9RclpUw0ZyHUc/jj1H8qOZIzqxb1Rbmt1cjABYYABznGeorKvltwhXVIt0Lg8k4wfXPY+9bkkiKkc6lcN0LdPwNUr8pcDyZABG/3twC5HccetNmCbMjT5ru0iSGUm8t8bw6ndMnfn+/j1HPHQ1dkvYmtxKJYprdyQGVsnPt6Gnx20MZaOSIPEeQxX5l/H29ak+yRC4V7fFvc44mhAAkHo69GP6+hoQc1noV4fOKiSxAUN95ZciOQ+uOob36etMiljl86IM4nUjeJgAfxHp7jii+iaCTz3YWc5+Uy5LW8o/uuOqfU9PU0z7ak5SG+jZSOVJYH8VYdRTuVTfNsNCG0m8yMvAw5YZ+Un6f5NWHnFyC52xyHrIgyrezf4/rVXdKqgSDzlUcZA3Yz3HQ/hUdjKwd/swAVG5yCNpPY96S0NZQUteoR3T2E4S9YvDKdsU5PCH+6x/kT9D61c1BIpoy07NGYvnDFtjRe4bsakaPz12hEVmGDtPyvn1B4rKuJjpcXk3SSXNkTgSbdzRA8BSD1X0P4UGJm393Npeoys9xY3Ed0qMzSS7GGBwWx2I9qs6LGIxcXa3cMr3MnmP9lbdEDgAL+Xemwzz6pqVx9ifTzbxJH880O9iSOn0GMfpTrH7Ut6FY21uWuWtZDax4G8LuDFTwwP4EVVroXNyvyOjhWF3eVmPmmVzvX5dwzgAnscD8aNStUNul3HIdiZVnHZTjO4eoIz+FRBNllD5v7xY1EUmTySO5/n+NRNcGGRCsRIkJR+e4Hf14zzUXNVBSWhoQ3SmOOV2EKFtofGdrDqMf3Sen1p0mydjGz/PncCD8o9x7fSsqznNvK0U43WzYjlHXIP8Aq29uPlJ9hVm6lkt9NngdAZCAkZYYyWO1Tn15/SnclwsQ6NDvt1mkjP8ApDvOpXoQWOQP0496uvEJG2BjsbK5XqmOh+lUTIunqyxFmtY2Aw/WF1HQ+xx1q7JOkjb0+44DKynCknnGR296EOKbM57Z3hjMjfvYzt80f8s3HRiPQg4OOze1WUnE8CTN8rN8pONxjxwQR3ximXrYmR2WUQMNsyDqg7N+HrVMrP8Aa2JKCUn5wx272AyGHb5l5464oNoJp6lmVgkDAMWjdT8w5HTsD/Kp4ZfLh/djJdRhA2f++SeKzoNRtVRZBLGu4ksq4LEeo9/anqyS2kckUxClQVZUOzPuOx+lSbPclgDLNJGR+4lJl2KRwf4ufyP51ekt2+yblRyFHytnBU9ulZ7PK8fmPsWSNtxK/dYgdPxHFbNo0oUeUu5VxkDCuB6Y700ZVJNIkS3mnhS5WQXHRlGNpHvj196kkd48tKzMSQDIB09yB+VV7KcG3KxRTI8Zw0RXIU54/wDrHpTnuIpIt8coVweVfjB9wenpTOXV7jbpG2/IfLueqN/C/Pp6H9KqApeKr4LScKuOufT6dRUc2rqLqK3eHcsyttI52sOShx37j8asu6ROZ42VEOGcO20Z9j2b+dLmLjzRINGt8aZAwffHsxuUYZRkjB9cetaEw/dmDzVRtu55hwFT1PbJ7fjWfo168umxR2CKrHcRcTjaFBYkYXqx/IfWrkNqisEYNJNnewkA2se5x3Puf0ppIhylPRkKsbhlRonghRcBo15kXsFz0X361MiEGNBtCZ4A4Qjtj0Iqy7o7cKScfcB5A9R9PaosJwhlcMDgHoD7MPX3pjIoYpbO8MUADwyszBGHRurKPr1H40W8sbXMnkkkiUsUfqMpyp9eRT71Q0IhkcIBgrKpBCkfxH6VSs7wX2oSSjBZYQsjxncC4JBI74x68GkKzRslgigbSQMHA+8n0PtUd2uIy5+ZR1c9/c47+9TDCRrvYNERlWHIPr7iqxaS2Zgqb4DyQTyn4UPYIuzKG5y20NhOzD7pb145BpzMkJRlOFUghhyB9R6VOI4SrvagShQWeMA5A9fUfSq8coutjRz5QgsDnOeMdaNjpi1LQ0LVi6lkeOMsTgjkH2NQ3MIY7k+SdeoXuPp/WorSNkZnXKMWy5IyGGfSrdy4SPLZIAzkcleaEZu8ZaGRGUWZ8IySqSpUjg/WkQBoAQAVXO1M88elF1KftAXAIZByMbWA6fQ1FCxVRs9cAEj5R9OxqbnStVdmJrK3kKmW2JMWSGDDP4H6VFpl3LFNH9ocrngHoSPTHeukkhmB3dVIxn19iP60z+yIJZI52P7pT1Xqh/HtU8t2KU0tzRsbl2HljYRkEKe3qK0Yd1vIDEeM8wMf5Gs+K3SJUjP3CCQQePw9K0IJYnjAKllzwTwRWiOWrbdE0k8ZU7w0LE4wwxg9+e4rOvE+0qX3o8i/dKtz+B7fQ1bkcwMwZvkzw45x/smqt4I5XPKRsxG1tuR/9amzOCsyNWJjLSPvjC8kryB7jt+HFEfMaruyjdGXLA57etV55QT96SEoccev+fwqCGdhONhbbISc54zjp/8AWpXOpQbRbYSJjcxCnhT2PsaY8JMhY7sZ5CkkeuMGpo3L2+MHb1yOQPbFCsqg4J2EAHnBX6ev0pohya3KrRpKQdg3KCMH5SD9aqrG0cwYttPfbziprh1znYBg8ueDn3HaoiXYYZA5BDBg3IzUtJm0U2tS2Ztgk8rGT2Y5JB7j6VDcEq6pKjRsxyMHKfhnp9aglmWaMPHtMyjqAd2enPP40thqf70xSDeSBx6fh6U7rYydNpaF+HBJi3EKAOSMfQ+47Uk8LQkFFJDcbB3x/dPapWaOZEGdu3gYOCD0/KqbvKpaPcrsDwNuM+3vTMLNstQzrNu6lsbTn5T7gg/rWZd6cqiT7H5aDqyFN0Z+q9j7rimS3AuZA0LvHLjLcdfTrWjBe4xHcx7Rjgjv7/ShWY3Fw1MgvJZ7RcwMiPnB3fJ/wF/6Nj60PGLoLLbfPNEcrngkEcofT/HFaN7HPGS9o6SIwJ8tgNsg9j6/pVGG1hLpPZt9mbd/qzyjHurDt+GPakzRVNNS0imSCOWKRGiIDBZepPQrnsR702QFopY7iCTafvIMED/61OjlWG6KXC+SlycMDyizdsN6OPXHIz3p18727nzEV7cqScLlkI/i9xjr6daoyUrs4XUUW31VzYwiSFQqTTPM0XX7qMR1I/vfnWzoslr8jJbJbT2jMnlmTeqswBJ98g9etS3+nR3UrTW1zNCZkVZAgVllXHB54PB61Q0ACBJ7WRpHkjnaMzyNlnfA4P4YovoaKnZ6o7Vtsl267BuZRvjJwcjg4/Aiojbu8UiQvieJsAEdGHQfiKdJKxEE+SrqwDFupXpyfXkflUk4cEyyEqSMOSMqwHqPUUgjpoQzlDFBdqRHBLmGfC9A3TcO2G4P1qIg/bre2lUMLZTI3OQ5OVT8ep9OKgumWF5re4IVblSxY8DOOR75GCPcVPpLC704TToWumcmcAfNGVGMD8AOPegTVtSS4ukdMPtBUZU9ePQ/jWNZwJNbyrHAB5ch3JyGA6jGDyOfrSz3Ya7kjkUrcFN8Lj/VzJ0J+o6EdqNPYrJdBW53K6AZPVecH8OlS9zphFWuiZ7W3cCR1Yx4AJ81iMH8aopBZ211a74EZPMEbbwTuXna3PoTj6Gtq325OCiB/vFRkAnruX0NZmsW58wCIf6uNmKA5UgjAx+R4pMuyehZtlt4rONFRF34YFV5z3OR39aLSUW9vbuxO11xuHKg9j6iqNhPKtqqnYXiwrL0LcDBI7ZFWNLX/QbfdEGUr/EcgexoL5Ulc05YvnJJCsQN2MkMP6D9an0qbdbbJQA0W6PPfjoffgiqGjoluJrTdxE24Ow3/Keme/HTPbirduSuoTqVTyZFV8YyCeVJ9ug5pnNOV9GX3CPbbpgRIFwHU8kH0I6fQ1RvImkfyzdu2VBDmNScejZ6irLzxwpGsiGS3J8onrsJ6Z9j60jwq0aIm5kOSpAzt/8Are4ptGOiMO6003McgllkAGCdo8thjkEMP/10/S2e2dvtpD3aqZFaQZE6j+JM8AgdV7delbkkCs8U0bYYfJlR8sinoT9OKg1i3jurRY3H+skHzD7yn+97YGcGlyg5p6MqW+JBblWySmzg4bPXB/pVi1umikFtdKJeSYZI+M57eze35VXt4XhlEVyB5n/LKYDhx/Q+o/Lir8gSaICRAWIw/cHHofX/ACKSB26E8biXcyrmMgkeoP8AePp9aWVTG5Rijbs4J4BP49KgtnZJfKklaSUqfLkI5dR1B/2gPzHNSzk48pwrRHkOM4Xj7pHbirQk9TNu4VlhKM3mQbtxgPH4e/06VnW0n2TUfPhPl2UzJA+zhQwHyn25O306VoXts8a/uT87MVVgc4brn6Ad6oRWzvA0M+9Y5uSegYHpn9DUNM6vdsdPa3CvI5AKsTho24/z/KpJnLJwrOg4+7yKw9JL7PIuEeVo/vbjzgnhgf8APINaMrzwgEOXiPQ/xe4NX0MHBOWg9DlVaUcfwyKeU/Ed6rS20luzSxvuilbJXofcnHU+tTlo5BvjIjzw4HQn6d806MsdyxsRtPCnkfUd/wAKQuVxdxygeV8yFePlKklT9T6VDeP9nj3IpA7EAELnsR6VLbmRS2wKhzuKN938KlliWSIlFO4H5kz0z3/+vR0EpWd2Y/ktJsaNRgg7h1H/ANartpbK+xkk2djkcNis69ttl35luUhnAxvzlW9sDj1rQtmuYot89pJJnq8PzZ+o6g0JGk6nu3J3VduwoRyeT0apYgvAYhZD90Y6+9Vlv7N32C5j25HyOfLYH3U4/MUiPNhQOY2OB3AJ96exjfmWgt1FcJteMZXJJUdvoO9W9MYEFkfBYYJ9fY+hpvmFZ1UqcAck5BH40qgh0JJDDrxjNLzFd2syeX5HJ4G442sBjNUZvN27YFEkajnnO38KluInchkG+Ijhccj3NVNoKDym84KfXn3pNhGxV+zKdzlXAHSQMDyexFVZYmjKrIu+NhuEiHIVgPTrW/ZjcoAJLDuRgj6jvRNDtZdmFk39f4W+voaduxoq7RiQyAx+asgAP3lIIIPetFVJUso2huCRnOR3waJrfddeYVCy/dIQd+3tUgKxgZAQnG2QMSD600EqqkjI1CRbVy8jJ5o5HON/tWbeajbrCGXMQfnZ95W/EdKu67avdwt5aM5PAIAz9CD1rz2W42XIt5ZnMQO0ZQhlI6H/AD2qJSszWDujr7DUreZt0fU8HpwenFaDKrXCyKFDj5lZSO3fvXmQvTDNuAlDIcE56c+3H/6673RLo3kIxtbC4V0GCvpkUoyvoa7K5txXIkk+cKcnJkHb/PpVu6hWWNo3Y4xgSL1Udj+FUYYBMvBCsvUDkE+taUoMMRdJd0rnGw4IZjwMY/WrVzmqtdDJ0qTzJfstwcXB3bW6eaMn5lP8xV50IXy7g704IcDayn19vrVK704GIQOuYwAQMnIP99SOQfcU211CVQlvfMzsx+S6bjdjtJjo3v0PtSW9jOTdiyHKyrHJ9xujgAKR/tYqK6VrZ2niG5v7ueHHv+HQ1cRk8zy43/fcEqy4JHr9Peo7q0KJ3kRjkjuD6rj+VOxKauVt6ajayyRA4K7JFP3k7g49jyD0OKZJHcTafvg/duAVPcK46kD68+lS/ZSpDIfJmUYWUcZB7H1FR/aWsDJNOjeVtYsV7OoyOO2V4/CmkD8jCNlqaKfsmoxMc72tvsyrj1Kc4B/Q1Z0i1Ag1APcx3XnSh5SR5bxkqBgr2IxUV/b6pdNHqFsbGwn2hgh3NkHoGxx+VVbPUFu57trmNrLUrdhFIY3DKMKO54KHPfp7UbGtO7aOotpVuLeRYpfMhnUhHbgk++ejA8MPX61oWV6s0cSSDY7L8x7Z9Pr1rMvFgtZGurZstIA08Sc54/1qg98cEdx7iqmkPLOrwQSiSSGcgpjIiB5Uk9wQenfpSd+hmtdzT1O0E3+iqV2KBJuxuERzkL+P6CqNhM0V/cKSA0qidQp+ZHX5WznqPun3retoSql4COSd2453MerH0z+nSsDWY5LW9s5kxbq1wEYnGF3jbz/stx+Ip+ZUZdClrFsbiNN0gV93mxSqcFH749Pp+dRaRc+TczpfMiAlU8zBEbtjoCfut7H8M1pyMJhJHIu1v4wTynoc+noapW8ebCbfgF0dnDDKyA8gEH2AIqTsT0NOVGVldG8thwQf7vuD1FQQMkloYpfkmncLt9OeB+AB5qWyWOOGJVLtZPhkV+Spx0DHnH1+lPMMF7fRRvlGgBYsBhkJ4Xn6ZNFmEpJrUrX0a296C5BWWNgGzjBxn8as2EBS2iXYrYRcYbjoP85qLW7eQWNzBcN86r5kMq9GYcfge1aUNrL5CvCuEAHKjPGPSjqZe06XIrk+S63cEXCAeaR94L3bHfHerpSM3Uc0JUpLEQQhBBHBwB6c0trIiS+W2Y5MB1O3g/Q1WKm3u4Y5cfZiHKMBxEOMj/dzzjtn04qjmk3cQ+WYZIZXkweC45ZfQj2/wqWwnWeECR0W4QlJePlLDufTPBB96jcyCYjbGxHOeuR14NQbR9s3IFInU5BPUjkc9jtP6Ujo5UacZOZP7xOWWTjn1Df5FQRFZdSZWKp5AK5Iwd7dQR7DHtzQZVtrQMUaQ52xqeu49B9CacLQwwRhvmH32Zf7x6sO/XtTMZWTFmUTQlMbdh5Ur0x3Vvam2LhJDA8myRTwxHyP6fQ+3Q1OF2qodm2dwT8p9x70skcZwUj3ttIeOTnePp6+hoIfkOubcOjo4McmQyyLj5SOhB9QapNdFozK37qeN8SnBKn3+h9KsvIEWNmLyWuMHefmT0z3x/tDp3qhdxm1kaZ8PCgy7H+4eSffHWhjiQXLS7xAVx9o+RRnhE6tg+p9D6gVplBNbPE8avERzH0O32PrVGCJwXuXQywSLhUz80aDoMe/WrcFzbSLtikWQ4B8snDEe3rSLlboVbVjDPkDzJI1LDPBlT+JPZuhz6j3qSV0kBb5zAvzAkbTtPrjr9afdp5hjkBKyK2FIHzL7EVQsbmOSS5tpMxNGcx7uVweqjPPByR9aT00HHR3LC7mbCMMMv38ggn0arlsRGqq+/duyC2P0PrSwDaTgBSw3AAYRx6+xpL2T5B5JLqcZjccj/62aLWVypS5nYsxujHI2tkYznIPqCKfBKHO3DhQflPG4e3vVBkljKSxsCrfeQkce1WRKNjujbps7QAeGPbI/wA9KaMWkWJYVk81yFyTsyRlW2/y5qlKk8JZrYl0GCY2k5OfQ96njmkx5MfLKuDH39/r35pJE86MpGQrKBgP+v4fWixMVYQTRXUZ8wqXHWGVR09wapCztVfMKur45ELFCB9Bwal8lDlnTaV5yc4A/oKay7pWMbkpjG4nJX/Gi7LSS0HmKTZiK8d4yOkqq+Px4NNsLi/QSjdaXEaPtAO5GAIB96kZYUhMkpTB6sc4J9CP8moNLeLfcOhbZJJ8qkfNgADI/wAKQnbYtiaZSrrZTpk8mN1kX8RwRVa8MkU8tzDbyxh+ZImQgP7g/wB7+daIlIY/MxJGS23AI9xUksh2AFNkp425+Vvx9adr7kaooW9/bCFiZidpwxIAZPQEHpVxLtJCCZA6EDBODx/nvVeS2hKn94Q6ZwdwDr7Z5yPrUMSvbkiHy5iOSQQjkZ7r90/UYppgxuqqssXmWc6wzI25G3fKT6Mv909OOe4qO11Rbny4JFC3X8Ubn5sdCQf4l9x+OKluJYQp89fKYcYlTbn6Hp+tZ80Vpc5d/IlOePmCt9QR0+opNlKCY/WT9jiMoikeDPzqn3091HcewrB1LQF1K382IpMpGAwJDdOoHqK6WOGUWwVpJbmEDAJP7xeOnPDfofrVSzlURoySoJWALH7p7ffQ9/f9aHG+44TcdEcG3hW4FyYZYizqMgq23OPX6Zrp/Duj3NncoZFcpyoBYA+3IrcuLm1WMLN5W7jLx5JHsR1FCko6+WkhB6NIMDHcY7/jSUEtTX27krEc7xxoXZi23gKnDHHp6/jVbT7oyPvnG3aMJgZAHckdiemaWe2DtlnkfI58zrjPAA9OvAqOLEQJhcEYxgjacDtz7UN6migmjVe3W6RN67e4YHkH1HvURhR02OzZXuB0/wAKW0uN+TjIfjB4GccfSmSzGyO+WQxxv0bqAD2PtT03OeUXF2ZXFrJuE1uwhuIDu2kZjIPGR3XPcDj2q3Zagkr/AGZpPIuCobyXOOP9k9Dz3FSTwv8Au/KByo3KSfX39DVN7eK4Rld2Dhi67kBKtjsf85ouZ2uXmjDeZEwDDoEb068H9MVj36/ZoJ8K0toynfG/zFVHoe4HUA8/yqzJLdWibHcCIjAMgzGT/vdYzz0OV96huERnVbt5IWbkJKcKRjPBHDD3FMcbbM5iWXRHgD22sz4C8wwXB/dY7c9B7GmaVplvPYI8dxHJGrM37tiRvbnDk/ePTIPFWbqbSLUl7OO8MTvmaS2t2Kxxd2Q45APYg8E1pTzefZi4tRHcwt9ya0TGcdd8Z749PypyWg6UmnYvNZiMbrWRUUHPlyJuQH6dQPp+VUZ57iwkknitjbOO8QMsLA4ypwNwU+uPlNbdvcFFaGUxOACfTAPt+tSIIij/ALs+SzHHOcjpkev0pAVrLXbC63qk0cM6ABoZG2yISO+cbl9CM0/WbX7VpN3GCyExFlbGcY5B9+mRURghkmiScQybgVt5Jk3KwGSYX9D6GqF7p2mw2rztasi7SCkUjqVyOowcEe2KAUuwkr5CklY7jGyVm4UjjOc9iDkfWql9qtpFbXDrKSzRlSkJ3fLjuBkAg45qa906ygdLlI4nXaFkZl3EL2YepGeT6U6/t5EtwIBEVkkWFGUbepGQQPUA1Op1xldaj0nmNtH5FtJsVAWMpEYwF7g844zmm6b9omzM+6GWRtzRqp3pwAEOeoAx2pke6e6W1CMsJ+farBjt/udu/OPStJpFEhO7c4+8OQwH97HUEfyo8zTRonMzbVW4VDuZUEoX5W56HPQ+xqxp0KvaIHQsyEqSjEY544zjoelR2vmGPfPtkQqfmVPv9c5U061WSxeR0VpLcBGcA5KHH5kcfWmclSKRaudOt3i2qJEYAsrJIcg/ifSqM5kiw1zPIViUYnUbwpJ/iUjI47itqWSK4gEsbId/RVP3geQPWoWt4nibzwobOd6ZByeuD/jRbsZX7mK5KBW/dmMdfKORj1AzyOhwDRwbYyQxkbH84gcg474+maV7M288kIYwupyrhQUYH+8vT8Rj60iRtFuhlCwF1CiSNt0bDnIB6gemelI6VL3TVs1aW7jlQ77ccRZyVYnq3uOw/E1ZjRobpoomeLPzopHHuD7e9VNPuV/s62wQiugU5wQcccdux4p945ky6M2VOQD1H09eKpmDTb1LLyCZQqHDtzsb7j/T3psUTC3ZwMpnG487D61W+0KZWRvu8HaCCAeCD04qyjuSwjO+QDoeGH9KNxOLWhAR5Lhl3uvTf159v8DxVKJ1kkxA6PYN80oQHbn+6e+0nr6dKvxst3JLEuEkX/WAHjI7Y9azZwNMd5CdtmR8x6+Ux69Ox6+xz2oYWvoWIFI3W8ka+YjeXnPDrjI59ccfhVRzHI8kZUsFOdmMEe47j3xT4fMS+MEu0K6BsfeHynjJ+h/KqWr2I0+9hmJ3W7yBc53BGPTJ6gHpUybsaU7LctwkzKqSAl1wQwU889x3pL3yopEkkRSVbax2/KVb0PUYODVwvAjRhsKeRgjH5nvUV3JFPavbzqEDjaSDnA9j2P6VVrGnxbIPmj3FGUsBn5V2qcdsduO44pIr8PNsbYr5C89VP4dRWYk5REWdkOBsZ1H3gP5GrMkazIG3hcfwgk8/zqbvoaqnG2pry5BBQKMg5QnG76EdKa2GZHCbGGBhuo9eO+ah00kkxyFgBghQeo9atNbx+eTLneAeQOQfcU1rqc8kouwjEFl81TGOgZTkg9QR3qzZXW1ys+HfGSc8MOxxUCKo3ByFdVzk9/ofSo7zqrRkkkDsOPx6Ee1NaEOPNoWrkIMNExViRjAOQPTFVIZVDyLfeUAnzeYo4ZR0b29DUMmoqSYETzZ8hvIU5b6qew+vSontVvJka5wpQhxbOx2Mf9o9z7dPrSYuWyHRI2pTIyKI7Y8hjz53sCPryfTgUy3lEcCrPgNLIzKMcDLHHPbjGK0ZZB5LSQDY0YLFQMjAHcf1FQWggkt44mAK+WBsc5B4ycHvRYSZZ2mNCpUyRjo2ckj+f5VJC48oocSxsNwwc4qnHNLEhHmExjH7wjLp9R3A9f51NPgIZAcbxn5G+Vh/LNMN9xo+RgIwDH/tAZX8amJBUAhQ+c5HDdO3bH0qKKRmUshDAfebGB+I7fWo7iYLExl2ZbkHbnB7ewo2K5W9ETJL5ileMjhlyRn8B/OszUtPDLugURSJ0XAbt+oxSC6ZCjTuhPIjkXIPptb0/lVy2uFcZiyevDHn3pNJj5JRdyh5BgtmO2MNjcNqZDDHT2JOKqzGNIBG1sjSbACWT7wHv1H4VrEJPIltgDYPMZH/AEH171Bf2vmlWR/m6cnk+3vRZ2CPLze8ZFleTQALaTOYz8vlSANtP1HJH1NaweaQGTyVI6lVcYb6DtVVrOP7UCpx/tjggjqDjpUltK0bqztlWO0dFLfj0zSV1uXKHVBLdwyI0iH5cE/McY46exFVVjU8tIoLfdVmwenT34qS6tllYsHJQ8nd94H1qNNPDokU/wC9VQGVlG0j3FG5pF2RatAI5CAj7yeuPlIHP5e9aBKyxK3yqQMbG64Pb/61ZF1utUxIyuQcCY8jp3/zirmnXpZAk4bHoR8w9SKd1sZT95XQ14Ps8g+xu3lYO6ORjt9tpHK8/X6VNFOjErImwScFJOuR3Vu9WZIw67d0apjdg+v+NZ11KsaDdlApDEM3B9z7Yo2M9y27NahsM0sRGCNuSP8AEVkzwWs+m3KCZ7WFlKOAoeJg3fYejfTFabAbBghFI6g5XH0rLvYpr6CXbxEyMsE0Z+82MBiP7vp+dNENLZnKpLremjNtHZXEWFR1huSwCj7oKfeX3AzSeHtTitbq5tpJ0WWZzIYwCqoe6AHsMDnrV42SfYIWtIo7LUbf5QGIGSOCGH8Sn196i02ye/hvl1K2WIST+akUuDtbaMOp78j8RQ12NoaJM6WVftUazo4WZcbHXkj6diPUGp4pHhh3TqqxAYLop2Aj+8P4D78j3qF4baeWOS22wvvwSp24bpgjp161ZgFzE+0SwHd3b5ST6ccGglvsV71ory2xLmPzB823o2OQwPqDgioLa5a5aO1vMC5wH87OBMg/jHpkjBXsfakv40ETNaq9q+758rmLPuB0PuuKynVlCvORA+7fDcbt0bHoQT2B6EHHrU7MuPK/U0bxJbHD2qLOrZP2dzg5PUD/AAPWqOn3wuLiK1bJMSM6o3D88KOeu3nn6VoRSM1sXJYsr7ZIXGHiI5xnoQOxPUc5rOu4o5bX7WYQI5G8wk9YV6A+uMfzoNn8Ni7FOTcvFI7C4DCRZlUfOezbfboR2FbcVmt2gmGElzgsDgg9x+GfxrESyluIAY52kKNuUNhmQ+oPDD9RWhYXc9uFeaFHVhh3jYbX7Btp5B7EfSheZnOVloW7XzH3W5dIpEbYzKcAn29Dir8u9JAc4zHjzFPOc9/8aqxNCty0gWRQw+ZZEI5q3FLG8rIrjO1QV6Z5z09faqsYOXcbbILWYSZUK+MuDwp9fp6j8adfZ3gkKrHllBwGPt2H1pb2SJIW2uSvKlWXgexrNeQRKIpwxXh0xywx6ev0o20Kpx5ndle8utsqncUz8oGOeec+hx7UyJxJ8p2rJ0K5yp57elQ3durxiSVm5YYBOMDPP9eRUMgAmheNmZhmLPAZlzxn6Hv71FztUFbQsadJttpEjkI2yyKyMOB8x7e/860BMpWKGWTbsJPUYcYIGSen+IqppK5tIZP4n3MCOoBbJFakccauI5yvm9DxjK+gPcD0NUjCVloU7lHaOMrIomQDHYn2z3qGzvZmkAcS7CCuFwGT1B9voe/ai5tJreUm32jPIjlOFI/9l/Ue1VWQrM8gDo+4GWEkDOehHbPoeh70upajFrU3VMM8IdAI5YhtLx8DHYj19KbM7SqRIVHrnjd7fj71lx3QmRgo288cYwemMfwn9Khuo3WMwIryR7dgXksD2JJ9+9PmB0UWdpspbVrXzGgXzNqDmSHgZX/aXrx1HvVyZIru0YEmWJ1PQ4G3syn2OKzLWWSee0kJIURM2M/MDwCPwIPvWtCiurfZm2SfeZSMqw+nYj1GDQjCUXEytKeUhrZ5cvEPnjkHDqTw4/L8DxV2Ta4LbflAxhuQp6fWqd82+4/0gNHdK26OZPmIJ689wfQ0W975zmG4jVLgA7jGcqw/ve4/Ud6Wx0U0V76OVAGtU+ZDgxbuCOOh9evXrVjT3hf/AFT7Jxxsbhs+mPWpZTHhcNlD1wOPTnNQPBAWRLlBKM871yR6fN29qXU12VkawKmJU8zY6HOSwGOOue9Og1CBW8q+ni+XG0hgx/TmqA0+zB8preF1zmOQKM9Oh961bSFbT5oYI0HHMaBT9eKrqclR3RBPM8rK9vFcs2fvuvloR6gnk/lVG2E0zyJfTRRTKxHkplVYZ4O49fwroiHdSyZZWGSuMqfp71n3cTPE8ckYlXd9xuo9xnpTJhKxm4jUnyk8kKSRjGVPTdnvSX9yLiDy7iRVmADblPKkdHHqPpSzQ2wwj265J+XswHpiq7xR27sBCNxztxxj8KR0K0yo2qyvauVViM4yTgj1/wA981padOu9oJmUyHlYwPlPfp3rn9VhcGF7ZT5kjcr1BI9R6VZ0YzRjbcglkORuI5HYfh61F2tBuEbHWysXkU4EboQBt5H0qRg4y0CgJk74W4Un1H90/oahsiZI9kiDgcnGcD1zSxsiSNH5rPGeinqK0OWUbaFS6EkUbzWMbOI/9ZA2d+3v+Pp2qOeRLhRJbklJFB3J0Pqcd/p+daEqCRsPv3p/Epww/wAaybmB7S6eRTt8wgydlY+oPZ/boaGVTdtxivHLOflYNypJ4/Ks68dLV12h97DaPLO36Mw9OxNaczNKRJb52ONvmEHb7gA85+tV2jSKOQKpbcP3jMM5P0qbHWrS2LFlI8cUYLxzAZYycq4Pqf8AEVdvJJ44GL25lRSPM2yA49x3rOsPMCKZNqlMqx/vHOP19KtM6+SUUMp2lGjwDgnI/wDr01sYTp3egNMrxA4dH6hyOW+p71hag5aUBsDpkL8ufQjHatq2xPHESWUlRvBGQT2J/wAaS4t4ywW4Q7lICyKc7R7EUPY2pS5CnYAnafNjJXkSL94fUd/pWlDMPn5UkjO0dTz6VC6ARIyIkiqPmbHOT7d6gWzt5JPNQBeBjYcFD70bEy9/Vly68p42B+Vhw2FBzxVa2mO8PuDbhiMZ+YAdh7frQ8LMnE8hBO1W39DjvVG2VzbL5cxBVfusik7h2zxSM/ZXWhtW0olVvMwdwzg9T9aLlo2gKOQQy5XOMY+tYdxcyiMBjEZyckLuDNjrxzn61ZsZQ6rBPA8aNgopYMCO3TrTvcycGtGV/mgLA5fSlbJjAIY+pUf3M9V79uK2y6yw71ljWIrv81eigD+VQzlT5ezHXbuxyo7H6fyqk9pIlndxwsypKrb4gM4J/jX691700hNaXKN7NJLbvLLa2jWq4BMsuGUH7pPHyZ7Z9eaWGGJ4yYmmhkQlGjd8+Ww6jB4PtRJdD7PdRmS0iF1kyxzKwdSwww2gEOP7uD6CmafAxsJnnDL84Ta4+bCgKucdyACfrVNWFSbk7MvTW8Qv7hAg2lo2I9yxB/QVchjQ2rnYuQ5A46YoorNDlshtnyVlPLuFBJ5zzWcpKS6jEv8Aq0nZVB5wBziiiq6i6mTdSPbeJFtYGKW91bL5yA8N8y8ew5PA9a6adjLAd4Bw2Og9cfyoooNYlSwHkNbiLK5aROv8IPA/CtCbm5CHBSVSHXseB/jRRUxM5bho88r6YheRiY96Kc8gBsAUutzSLKZFc7/OVN3fGBxRRVPYzW5t7QfIYjJY8k9+KwdTY28ieT8nCtwO5JBoopM1oblC/dop5URiFCkgZzj6VDOxTTppV4kERO78qKKlnavhZr6VIyhIwfk8roea0dQUCKcgcxhXU+hooqkcctyGNjKVWT5lKsSD9M1k33+oklP+sQqFb2JOR9Paiihm1PYinjVLV51GJk4De3ofWtazUSTSBxkKVQZ9MZxRRREr7bM/TRuvJg2SFU7eenzNV3VJHhhE0TFJBKq5Hp0oooRlPoUb1i8TFjzuJyOOag12JF0tbhVCzLCZVdeCGAByMf5NFFT1NY/Ci/ZDfpsbNyXhDN9SoJ+lIo2vEw4JRSfqaKKGVF7mrCAy/MAcgg1LpTtLbp5p38d/qRRRWiOSoSBjE7LGdq5HH40upxr9omGDgKpHJznNFFJbGMdzD1FFZJSw+ZYS4PcMDwc1XDNNaRPISWMSuT05NFFSdUClHI8jW0rsTIivhj16gVs3saA2cgUB3Q7iO/FFFPoEtzRtFAbA4wueOOafOT9pB7svJ9aKKfQxl8RJdKBBdY48r7ntwKx4kW6ijkuVErF9hD8jGPTpRRTYqRBbO3mTDcSEdlGTngEAU+dFMEjkfOucGiipex209ilaSOkdyVbBMpB/SrUqKpYqMFCu32z1oopGqIgSljEUJU7McH3NFnIzW0RY5LAMeOpoopdQfwiTqCnphuMHFSRk5DdyOaKKpmb2HQgeYsePkOAV7dCelVWgjL7cMAW52sR6elFFIOjGQgRXCiMbd+7ce7YPGT1p0KrIybwDubB/OiimgnsPLEB0/hWXaM88Vo2qhScd/eiiqOeWwyZ2W4uFU7VWJZABxhi2Caz7pQZJ2xgmQA44GNg7UUUBR2P/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous macules are present on the skin of this patient with a viral exanthem.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exanthematous (morbilliform) drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous erythematous macules and papules are present in this patient with a morbilliform drug eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_38_38504=[""].join("\n");
var outline_f37_38_38504=null;
var title_f37_38_38505="Early repolarization";
var content_f37_38_38505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Early repolarization",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/38/38505/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/38/38505/contributors\">",
"     Andrew Krahn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/38/38505/contributors\">",
"     Manoj Obeyesekere, MBBS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/38/38505/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/38/38505/contributors\">",
"     Mark S Link, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/38/38505/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/38/38505/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/38/38505/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24315018\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term early repolarization (ER), also known as \"J-waves\" or \"J-point elevation\", has long been used to characterize a QRS-T variant on the electrocardiogram (ECG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/1\">",
"     1",
"    </a>",
"    ]. Most literature defines ER as being present on the ECG when there is J-point elevation of &ge;0.1 mV in two adjacent leads with either a slurred or notched morphology. Historically, ER has been considered a marker of good health because it is more prevalent in athletes, younger persons, and at slower heart rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, numerous more recent reports have suggested an association between ER and an increased risk for arrhythmic death and idiopathic ventricular fibrillation (VF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/4-11\">",
"     4-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While some level of increased risk of sudden cardiac death has been reported in persons with ER, the relatively high prevalence of the ER pattern in the general population (5 to 13 percent) in comparison to the incidence of idiopathic VF (approximately 10 cases per 100,000 population) means that the ER pattern will nearly always be an incidental ECG finding with no clinical implications. However, a primary arrhythmic disorder such as idiopathic VF due to ER is far more likely when associated with syncope or resuscitated sudden cardiac death in the absence of other etiologies. (See",
"    <a class=\"local\" href=\"#H24316877\">",
"     'ER syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This topic will review the genetics, prevalence, clinical manifestations, and diagnosis of ER and will present an approach to the management of patients with ER and idiopathic VF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21542558\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of early repolarization (ER) on an electrocardiogram (ECG) is based on well-defined ECG findings.",
"   </p>",
"   <p>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21543526\">",
"    <span class=\"h2\">",
"     ECG findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;On the ECG, ER is defined as either:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A sharp well-defined positive deflection or notch immediately following a positive QRS complex at the onset of the ST segment.",
"     </li>",
"     <li>",
"      The presence of slurring at the terminal part of the QRS complex (since the J-wave or J-point elevation may be hidden in the terminal part of the QRS complex, resulting in the slurring of the terminal QRS complex) (",
"      <a class=\"graphic graphic_waveform graphicRef83883 \" href=\"mobipreview.htm?30/7/30840\">",
"       waveform 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most literature defines ER as being present on the ECG when there is J-point elevation of &ge;0.1 mV in two adjacent leads with either a slurred or notched morphology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21543262\">",
"    <span class=\"h2\">",
"     ECG classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on data associating arrhythmic risk with spatial distribution of ER, a classification scheme has been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/12,13\">",
"     12,13",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H4191980\">",
"     'Prognosis of ER pattern'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type 1 is associated with ER in the lateral precordial leads. This form is common among healthy male athletes and is thought to be largely benign.",
"     </li>",
"     <li>",
"      Type 2 is associated with ER in the inferior or inferolateral leads and is associated with a moderate level of risk.",
"     </li>",
"     <li>",
"      Type 3 is associated with ER globally in the inferior, lateral, and right precordial leads, and appears to be associated with the highest relative risk, though the absolute risk of sudden death remains small [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type 4, or Brugada syndrome, is marked by",
"      <span class=\"nowrap\">",
"       J-wave/point",
"      </span>",
"      elevation in the right precordial leads. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=see_link\">",
"       \"Brugada syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While this classification system would seem to simplify categorization of the ECG patterns, it has been criticized due to the controversial presumed common pathophysiological substrate across the four types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21543378\">",
"    <span class=\"h2\">",
"     Concealed ER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ER pattern is not always identified on routine ECG due to the intermittent nature of ER [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/16\">",
"     16",
"    </a>",
"    ]. As an example, among 542 persons with baseline ER who underwent repeat ECG examination five years later, ER (&ge;0.1 mV) was not observed in approximately 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/5\">",
"     5",
"    </a>",
"    ]. No systematic evaluation has been undertaken reporting the prevalence of concealed ER in the general population, and the clinical importance, if any, of concealed ER remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21543506\">",
"    <span class=\"h2\">",
"     ER pattern versus ER syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, ER is an ECG finding. Two terms, distinguished by the presence or absence of symptomatic arrhythmias, have been used to describe patients with this ECG finding:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The ER pattern describes the patient with appropriate ECG findings in the absence of symptomatic arrhythmias.",
"     </li>",
"     <li>",
"      The ER syndrome applies to the patient with both appropriate ECG findings and symptomatic arrhythmias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Persons with either the ER pattern or ER syndrome can have identical findings on surface ECG. However, the mere presence of ER pattern on ECG should not lead to a classification of ER syndrome in the absence of symptoms or documented VF.",
"   </p>",
"   <p>",
"    Rarely, ER may be associated with the primary arrhythmic disorder idiopathic ventricular fibrillation (VF) in the absence of structural heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/4,16\">",
"     4,16",
"    </a>",
"    ]. Given the prevalence of ER pattern in the general population and the exceedingly low incidence of idiopathic VF, the diagnosis of idiopathic VF due to malignant ER is a diagnosis of exclusion. (See",
"    <a class=\"local\" href=\"#H24316877\">",
"     'ER syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21543802\">",
"    <span class=\"h1\">",
"     PREVALENCE OF ER AND INCIDENCE OF IDIOPATHIC VF",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21543845\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several population studies have estimated that the prevalence of ER ranges from 5 to 13 percent of persons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/5-8\">",
"     5-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 10,864 middle-aged Finnish subjects (52 percent males, mean age 44 &plusmn; 8 years), the prevalence of ER was 5.8 percent (3.5 percent in inferior leads and 2.4 percent in the lateral leads, and in both in 0.1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a population based case-cohort study of individuals of central-European descent (n = 6213, age range 35 to 74 years), the prevalence of ER was 13.1 percent (4.4 percent in the antero-lateral leads and 7.6 percent in the inferior leads, 1 percent in both) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4191980\">",
"       'Prognosis of ER pattern'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In the CARDIA (Coronary Artery Risk Development in Young Adults) study, 5069 participants (mean age 25 years, 45 percent male, 52 percent black), 941 persons (18.6 percent) had ER on baseline ECG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/17\">",
"       17",
"      </a>",
"      ]. After 20 years, there was marked (50 percent) loss to follow-up; however, only 119 of 2505 persons (4.8 percent) of the remaining participants still had evidence of ER.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21544732\">",
"    <span class=\"h2\">",
"     Inheritance of ER pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ER pattern may be sporadic or inherited, although first-degree relatives of a person with the ER pattern appear to have a two to threefold higher likelihood of also having the ER pattern on ECG. While the vast majority of ER is likely sporadic, familial ER appears to be transmitted in an autosomal dominant fashion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study that evaluated participants in the Framingham Heart Study (n = 3995) and the Health 2000 Survey (n = 5489), siblings of individuals with ER pattern had increased unadjusted odds of having ER pattern on their ECG (odds ratio [OR] 2.22, 95% CI 1.01-4.85), suggesting heritability of the ER pattern in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 505 families, individuals for whom at least one parent had the ER pattern had a 2.5-fold risk for ER pattern [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/19\">",
"       19",
"      </a>",
"      ]. Familial transmission appeared more frequent when the mother was affected (3.8-fold versus 1.8-fold). Heritability was also higher when ER was in the inferior leads or had a notched morphology. (See",
"      <a class=\"local\" href=\"#H4192139\">",
"       'Family history'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In a study of four families affected by ER syndrome with a combined 22 sudden cardiac deaths, the ER pattern was present in 36 percent of screened family members (61 out of 171), with transmission in a fashion consistent with autosomal dominant inheritance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21543852\">",
"    <span class=\"h2\">",
"     Arrhythmic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perception that ER was a benign finding devoid of clinical significance changed as case reports, case&ndash;control studies, and population studies established a link between the presence of ER and an increased risk for arrhythmic death and in particular idiopathic ventricular fibrillation (VF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/4-11,21-24\">",
"     4-11,21-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Large population studies have shown the presence of ER in the inferior leads on surface ECG is associated with an increased risk for death from cardiac causes as well as all-cause mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/5,8,9\">",
"       5,8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one case-control study which compared 206 subjects with idiopathic VF with 412 healthy control subjects, ER was more prevalent in subjects with idiopathic VF (31 versus 5 percent), and ER was greater in magnitude in case subjects than in control subjects (J-point elevation, 2.0 versus 1.2 mm) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/4\">",
"       4",
"      </a>",
"      ]. Patients with idiopathic VF who had ER were also more likely to experience syncope or cardiac arrest during sleep than were those without ER. During a mean follow-up of 61 &plusmn; 50 months, ICD monitoring showed a higher incidence of recurrent VF in case subjects with ER than in those without (hazard ratio, 2.1; 95% confidence interval, 1.2 to 3.5).",
"      <strong>",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even though ER is fairly common in the general population, idiopathic VF is rare. In one report, which estimated the incidence of idiopathic VF, the estimated risk of developing idiopathic VF in an individual younger than 45 years is 3 in 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/6,25\">",
"     6,25",
"    </a>",
"    ]. The risk increased to 11 in 100,000 when J waves (",
"    <a class=\"graphic graphic_waveform graphicRef56369 \" href=\"mobipreview.htm?29/22/30051\">",
"     waveform 2",
"    </a>",
"    ) were present. Although ER increased the relative risk of sudden cardiac death (SCD), the absolute risk was very low. Therefore the incidental identification of ER should not be interpreted as a high-risk marker for arrhythmic death due to the relatively low odds of SCD based on ER alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21543859\">",
"    <span class=\"h2\">",
"     Athletes with early repolarization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether athletes with ER have an increased prevalence of ER and an increased risk for arrhythmic death is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of J-point elevation among 121 young athletes was reported at 22 percent, a prevalence rate higher than seen in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/6\">",
"       6",
"      </a>",
"      ]. However, an ER prevalence rate of up to 44 percent has also been reported in athletes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/30\">",
"       30",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The reported higher prevalence of ER in athletes likely is related to the physiological balance in autonomic tone favoring the parasympathetic tone and its regulation of the action potential [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another case control study reported that ER was four times more prevalent among athletes with a history of cardiac arrest (n = 21) than among healthy athletes (n = 365) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/29\">",
"       29",
"      </a>",
"      ]. However, in this study, the prevalence of ER in the control group of athletes was substantially lower (7.9 percent) in comparison with other studies. The presence of ER increased the probability of arrhythmic death from approximately 2 per million to 3.5 per million in this population of competitive athletes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In young healthy athletes from Finland (n = 62) and the United States (n = 503), an ascending ST segment was the common form of ER, which has not been associated with an increased arrhythmic risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/30\">",
"       30",
"      </a>",
"      ]. Amongst athletes with ER, all but one of the Finnish (96 percent) and 85 percent of US athletes had an ascending ST variant after ER. (See",
"      <a class=\"local\" href=\"#H4191980\">",
"       'Prognosis of ER pattern'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Notably, the association of ER with arrhythmic risk is typically at rest or during sleep and not during physical activity when J-point elevation is typically markedly reduced or eliminated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4191980\">",
"    <span class=\"h1\">",
"     PROGNOSIS OF ER PATTERN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain ECG characteristics may distinguish the benign ER pattern from patterns associated with a higher arrhythmic risk. Additionally, ER pattern may be modified by physiological variables with subsequent effect on prognosis. The coexistence of ER with other cardiac pathologies also likely influences",
"    <span class=\"nowrap\">",
"     prognosis/arrhythmic",
"    </span>",
"    risk. Reports suggest that ER should be viewed as an adjunctive prognostic variable in the presence of other cardiac pathologies (ie, ER may incrementally worsen the prognosis of other more common conditions such as ischemic heart disease).",
"   </p>",
"   <p>",
"    The presence of the ER pattern has been associated with adverse outcomes in numerous cohort and case-control studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/3-9,32\">",
"     3-9,32",
"    </a>",
"    ]. In a 2013 metaanalysis of nine studies involving 141,095 subjects with a collective 3.6 million person-years of follow-up, persons with the ER pattern had a significantly greater risk of arrhythmic death (relative risk 1.70, 95% CI 1.19-2.42) compared to those without the ER pattern, with no significant difference seen in risk of all-cause or cardiac death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the ER pattern is associated with an increased relative risk of adverse events, the prognostic implications described in this section should be viewed in the context of the",
"    <strong>",
"     overall very low risk of SCD",
"    </strong>",
"    in those with this asymptomatic ECG finding. Thus, even with a twofold increase in relative risk of SCD, the absolute risk remains exceedingly low. Additionally, in spite of the data discussed in this section, there is no current risk stratification strategy for asymptomatic patients with ER pattern in the general population and within families with ER pattern that would allow for the identification of higher risk individuals with the ER pattern who might be candidates for treatment. (See",
"    <a class=\"local\" href=\"#H21543845\">",
"     'Prevalence'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H21543852\">",
"     'Arrhythmic risk'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H595931\">",
"     'Treatment of ER pattern'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4192086\">",
"    <span class=\"h2\">",
"     Prognostic variables",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variables thought to affect prognosis that have been investigated include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Distribution and amplitude of ER",
"     </li>",
"     <li>",
"      Morphology of the ST segment",
"     </li>",
"     <li>",
"      Gender",
"     </li>",
"     <li>",
"      Family history",
"     </li>",
"     <li>",
"      Slurring versus notching",
"     </li>",
"     <li>",
"      Ethnicity",
"     </li>",
"     <li>",
"      Association with other cardiac pathology",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4192118\">",
"    <span class=\"h3\">",
"     Distribution and amplitude of early repolarization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inferior location of ER, in addition to higher J-point amplitude, have been described as variables associated with increased arrhythmic risk in both the general population and in patients with idiopathic VF.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      J-point elevation greater than 0.1 mV in the inferior leads in the large Finnish cohort study of 10,864 persons was weakly associated with an increased risk for death from cardiac causes (adjusted relative risk [RR] 1.28, 95% CI 1.04-1.59) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/5\">",
"       5",
"      </a>",
"      ]. While observed in only 0.3 percent of the cohort, J-point elevation greater than 0.2 mV in inferior leads (",
"      <a class=\"graphic graphic_waveform graphicRef83891 \" href=\"mobipreview.htm?42/15/43256\">",
"       waveform 3",
"      </a>",
"      ) was associated with a three times greater risk of death from cardiac causes (adjusted RR 2.98, 95% CI 1.85-4.92) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/5\">",
"       5",
"      </a>",
"      ]. Similar findings have been reported in a series of 40 patients with idiopathic VF, in whom the J-point was nearly two times higher above the baseline than the height seen in controls without VF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another population-based case-cohort study of 6213 persons (1945 persons with ECGs) with a mean follow-up of 19 years, ER was associated with higher cardiac mortality (hazard ratio 1.96, 95% CI 1.05&ndash;3.68) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/7\">",
"       7",
"      </a>",
"      ]. An inferior localization of ER further increased ER-attributable cardiac mortality (hazard ratio of 3.15, 95% CI 1.58&ndash;6.28.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4192125\">",
"    <span class=\"h3\">",
"     Morphology of ST segment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The morphology of the ST segment may also determine the risk associated with ER, with a horizontal or downsloping ST segment following ER portending a higher risk in both the general population and in patients with idiopathic VF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/25,30,32\">",
"     25,30,32",
"    </a>",
"    ]. However, despite the increased risk of arrhythmia associated with the",
"    <span class=\"nowrap\">",
"     horizontal/downsloping",
"    </span>",
"    ER pattern, the prevalence of this pattern in controls (approximately 3 percent) compared with the exceedingly low incidence of idiopathic VF renders this variable alone devoid of meaningful test accuracy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/25,30\">",
"     25,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4192132\">",
"    <span class=\"h3\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with ER in the inferior leads may be at greater risk of cardiac mortality than men without ER or women with or without ER [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4192139\">",
"    <span class=\"h3\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conflicting data exist regarding the prognostic significance of a family history of sudden cardiac death (SCD) in persons with ER, such that no clear recommendations regarding risk assessment or treatment can be made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/4,35\">",
"     4,35",
"    </a>",
"    ]. Further studies are required to define the risk contribution of a family history of SCD to the prognosis of a patient with ER.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4192170\">",
"    <span class=\"h3\">",
"     Slurring versus notching",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although both slurring and notching type ER are observed and may exist in the same patient, the prognostic value of one compared with the other has not been clearly established (",
"    <a class=\"graphic graphic_waveform graphicRef83883 \" href=\"mobipreview.htm?30/7/30840\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef83884 \" href=\"mobipreview.htm?22/10/22702\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/8,16,25,32,36\">",
"     8,16,25,32,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4192178\">",
"    <span class=\"h3\">",
"     Ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although ER is more common in African Americans, there is no clear attributable risk associated with ethnicity, and African Americans are not specifically over represented in idiopathic VF cohorts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/37\">",
"     37",
"    </a>",
"    ]. The ER pattern itself, however, does appear to be more commonly associated with African American ancestry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4192185\">",
"    <span class=\"h3\">",
"     ER modifying risk of underlying cardiac pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the context of structural heart disease and primary electrical disorders, the ER pattern may be a modifier of the underlying arrhythmic risk associated with these heterogeneous cardiac conditions, in addition to the rare association with idiopathic VF (ie, in the absence of other cardiac conditions). As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with ECG findings of the ER pattern appear to be at an increased risk of VF in the event of a myocardial",
"      <span class=\"nowrap\">",
"       infarction/ischemia",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. Abbreviation of the epicardial action potential occurs during acute myocardial ischemia, with the decrease in the action potential contributing to ST-segment elevation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30890?source=see_link&amp;anchor=H26#H26\">",
"       \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\", section on 'VF Predictors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The ER pattern in the inferior leads has also been demonstrated to be associated with an increased risk of life-threatening ventricular arrhythmias in patients with chronic coronary artery disease, after adjustment for left ventricular ejection fraction, especially in the inferior leads [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=see_link\">",
"       \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A high prevalence of the ER pattern in patients with short QT syndrome has been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/42\">",
"       42",
"      </a>",
"      ]. In multivariate models, ER was associated with arrhythmic events in the short QT syndrome cohort. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/61/19417?source=see_link\">",
"       \"Short QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The ER pattern has also been demonstrated to be prevalent in patients with arrhythmogenic right ventricular cardiomyopathy (31 percent), though this retrospective analysis identified no correlation between ER and clinical findings with regard to cardiac arrest, syncope, or arrhythmic events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/22/32106?source=see_link&amp;anchor=H1492612#H1492612\">",
"       \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Ventricular arrhythmias'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the ER pattern is potentially a marker for increased arrhythmic mortality due to a vulnerable repolarization substrate when combined across a number of heterogeneous clinical conditions (eg, short QT syndrome, Brugada syndrome, or ischemic heart disease) in the general population, in addition to rarely being a primary arrhythmogenic disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24315026\">",
"    <span class=\"h1\">",
"     GENETIC BASIS AND INHERITANCE OF ER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic basis of ER syndrome continues to be elucidated, with the evidence restricted to either case reports or preliminary studies that fall short of clearly identifying the genetic basis of ER [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. The reported implicated gene mutations involve the KCNJ8 gene (responsible for the ATP sensitive potassium channel Kir6.1 - I",
"    <sub>",
"     KATP",
"    </sub>",
"    current), CACNA1C, CACNB2, CACNA2D1 genes (responsible for the cardiac L-type calcium channel - I",
"    <sub>",
"     Ca.L",
"    </sub>",
"    current), and the SCN5A gene (responsible for the sodium channel - I",
"    <sub>",
"     Na",
"    </sub>",
"    current) (",
"    <a class=\"graphic graphic_figure graphicRef70771 \" href=\"mobipreview.htm?19/59/20401\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/44-48\">",
"     44-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23509702\">",
"    <span class=\"h2\">",
"     Gain of function mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consistent with the reports that I",
"    <sub>",
"     KATP",
"    </sub>",
"    activation can generate an ER pattern on the surface ECG, several investigators have detected a rare missense mutation, S422L in KCNJ8, to be associated with ER and idiopathic VF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/44,46,47\">",
"     44,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first report on this variant was a case report of a 14-year-old female who experienced numerous episodes of recurrent idiopathic VF unresponsive to beta-blockers, multiple anti-arrhythmic medications and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/44\">",
"       44",
"      </a>",
"      ]. Recurrences of VF were associated with a marked accentuation of ER.",
"     </li>",
"     <li>",
"      In a study of 87 patients with Brugada syndrome and 14 patients with ER syndrome, one Brugada syndrome case and one ER syndrome case hosted the identical missense mutation S422L. Investigators demonstrated that I",
"      <sub>",
"       KATP",
"      </sub>",
"      was increased significantly in the S422L variant compared with Kir6.1 wild type channels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A separate study of 204 patients and family members with Brugada syndrome or ER syndrome also demonstrated a similar gain of function of the Kir6.1 channel (identified in three Brugada syndrome and one ER syndrome proband) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/47\">",
"       47",
"      </a>",
"      ].",
"      <strong>",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    KCNJ8-S422L is highly conserved across species and was absent in the reference alleles in these three studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/44,46,47\">",
"     44,46,47",
"    </a>",
"    ]. This gain of function variant appears to be pathogenic in ER and idiopathic VF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23509793\">",
"    <span class=\"h2\">",
"     Loss of function mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of function mutations of the inward sodium channel gene and cardiac L-type calcium channel gene have also been implicated in patients with ER (CACNA1C, CACNB2, and CACNA2D1 genes). Two small studies (three and four patients with ER, respectively) have reported that mutations in these highly conserved residues were associated with ER, suggesting linkage of these genes with ER [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/45,48\">",
"     45,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24316804\">",
"    <span class=\"h1\">",
"     MECHANISM OF ER AND IDIOPATHIC VENTRICULAR FIBRILLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;ER mechanistically demonstrates some similarities to Brugada Syndrome and short QT syndrome (SQTS). Although the exact mechanism for ER is still unknown and the precise mechanism for ER-related idiopathic ventricular fibrillation (VF) is also unknown, fundamentally, the purported mechanisms all reflect an imbalance in the ion channel currents (",
"    <a class=\"graphic graphic_figure graphicRef70771 \" href=\"mobipreview.htm?19/59/20401\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef83884 \" href=\"mobipreview.htm?22/10/22702\">",
"     figure 1",
"    </a>",
"    ) responsible for the terminal portion of depolarization and the early portion of repolarization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/61/19417?source=see_link\">",
"     \"Short QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is controversy regarding whether the ER pattern represents repolarization or depolarization.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 206 persons with idiopathic VF and the ER pattern, only a minority of cases (11 percent) had late potentials, with a prevalence similar to the control group who did not have the ER pattern (13 percent), suggesting that ER is not a depolarization phenomenon (",
"      <a class=\"graphic graphic_figure graphicRef83890 \" href=\"mobipreview.htm?16/3/16438\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, in a smaller study of 22 patients with apparently idiopathic VF who were monitored using a signal-averaging system to record depolarization markers, repolarization markers, and autonomic modulation, the incidence of late potentials in persons with VF was significantly higher in those with the ER pattern (86 percent versus 27 percent in those without ER pattern) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/10\">",
"       10",
"      </a>",
"      ]. In contrast, repolarization markers did not differ between the two groups. These investigators concluded that ER might be more closely associated with a depolarization abnormality and autonomic modulation than with repolarization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Efforts are ongoing to more clearly elucidate the mechanism of ER and to determine if it is fundamentally related to depolarization or repolarization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24316862\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H594480\">",
"    <span class=\"h2\">",
"     ER pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the relatively high prevalence of the ER pattern in the general population (5 to 13 percent) in comparison to the incidence of idiopathic VF (approximately 10 cases per 100,000 population), the ER pattern is nearly always a benign incidental ECG finding. There are no specific signs or symptoms attributed to the ER pattern, which is identified through the use of a standard ECG. In the absence of syncope or sudden cardiac arrest, no additional testing is required in persons with the ER pattern.",
"   </p>",
"   <p>",
"    Asking patients to perform the Valsalva maneuver may unmask or accentuate the ER pattern. While performing this maneuver has been shown to aid in the identification of the ER pattern in high-risk familial ER, its applicability to broad populations of asymptomatic persons has not been evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/20\">",
"     20",
"    </a>",
"    ]. The Valsalva maneuver is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21224?source=see_link\">",
"     \"Vagal maneuvers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24316877\">",
"    <span class=\"h2\">",
"     ER syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;While patients with ER syndrome may rarely present with syncope, this appears to be unusual, and syncope has not been shown to be more common in patients with ER pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/18,49\">",
"     18,49",
"    </a>",
"    ]. Such patients who do present with syncope are likely to display high-risk features of ER and may have a vagal prodrome. However, most persons with the ER pattern identified on ECG who experience an isolated episode of syncope, especially syncope which appears non-cardiac in origin, will",
"    <strong>",
"     not",
"    </strong>",
"    be diagnosed with the ER syndrome in the absence of additional data showing ventricular fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of ER syndrome is most commonly considered in a survivor of sudden cardiac death (SCD) with ECG evidence of ventricular fibrillation (VF) and an apparently structurally normal heart following extensive testing. A systematic assessment of the survivors of sudden cardiac death without evidence of infarction or left ventricular dysfunction is reported to establish a causative diagnosis in the majority of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/16,50\">",
"     16,50",
"    </a>",
"    ]. Systematic evaluation includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiac monitoring",
"     </li>",
"     <li>",
"      Signal-averaged ECG",
"     </li>",
"     <li>",
"      Exercise testing",
"     </li>",
"     <li>",
"      Echocardiogram",
"     </li>",
"     <li>",
"      Cardiac magnetic resonance imaging",
"     </li>",
"     <li>",
"      Evaluation of coronary arteries, typically with invasive angiography",
"     </li>",
"     <li>",
"      Intravenous adrenaline and sodium channel blocker challenge",
"     </li>",
"     <li>",
"      Targeted genetic testing should also be considered when a phenotype is suggested by the above evaluation (eg, long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33897?source=see_link\">",
"       \"Diagnosis of congenital long QT syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37641?source=see_link\">",
"       \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=see_link\">",
"       \"Brugada syndrome\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients whose evaluation revealed no identifiable cardiac pathology, idiopathic VF and the ER syndrome should be considered. A careful review of all available ECGs for evidence of ER is warranted, particularly around the time of the cardiac arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ER syndrome causing VF",
"    <strong>",
"     may be diagnosed",
"    </strong>",
"    when:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Other etiologies have been systematically excluded",
"     </li>",
"     <li>",
"      When J-point elevation is augmented immediately preceding VF",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ER syndrome causing VF",
"    <strong>",
"     is probable",
"    </strong>",
"    when:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Other etiologies have been systematically excluded",
"     </li>",
"     <li>",
"      ER pattern exists or increased parasympathetic tone provokes ER",
"     </li>",
"     <li>",
"      Cardiac arrest occurs at rest or during sleep",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These patients may also display a high-risk ER pattern (J-point elevation &gt;2 mm in the inferior or inferolateral leads or globally",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    horizontal or down sloping ST segment. (See",
"    <a class=\"local\" href=\"#H4191980\">",
"     'Prognosis of ER pattern'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The ER pattern is not always identified on routine ECG due to the intermittent nature of ER. Bradycardia dependent and vagally dependent augmentation of ER has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/51\">",
"     51",
"    </a>",
"    ]. However, no provocative test, such as pharmacologic augmentation of parasympathetic tone, is currently available and validated in this setting. Although the utility has not been studied systematically, tilt table testing may be of assistance to establish if vagal stimulation is associated with",
"    <span class=\"nowrap\">",
"     VF/syncope",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if high-risk ER features are provoked. However, the diagnostic accuracy of this approach is unknown, and vasovagal syncope is far more common in comparison with VF due to ER syndrome. (See",
"    <a class=\"local\" href=\"#H4192086\">",
"     'Prognostic variables'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27399?source=see_link\">",
"     \"Upright tilt table testing in the evaluation of syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3161175\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3161269\">",
"    <span class=\"h2\">",
"     ER versus Brugada syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some individuals with Brugada syndrome also have ER (approximately 12 percent) as variants in genes encoding the L-type calcium channel, ATP-sensitive potassium channel, and sodium channels have been associated with both of these conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/45,46,48,52-55\">",
"     45,46,48,52-55",
"    </a>",
"    ]. Additionally, some ECG characteristics of ER resemble features of the Brugada ECG, including J waves, pause and bradycardia dependent accentuation, the dynamic nature of the ECG manifestations, short-coupled extra-systole-induced polymorphic ventricular",
"    <span class=\"nowrap\">",
"     tachycardia/VF,",
"    </span>",
"    and suppression of the ECG features and arrhythmia with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/11,56\">",
"     11,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the Brugada ECG feature of provocation by sodium channel blocker is not observed in ER [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/57\">",
"     57",
"    </a>",
"    ]. In fact, sodium channel blockers in most patients with ER attenuate the J-point, whereas the J-point is augmented by sodium-channel blockers in the right precordial leads in patients with a Brugada ECG. Furthermore, a positive signal-averaged ECG and structural abnormalities in the right ventricular outflow tract are not consistently observed and have not been reported in patients with ER, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21544950\">",
"    <span class=\"h2\">",
"     ER versus acute pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As is seen in ER, there is J-point elevation with resultant ST segment elevation in patients with acute pericarditis. Symptom presentation is markedly different in the two conditions. Unlike ER, most patients with acute pericarditis have ST elevations diffusely in most or all limb and precordial leads. Additionally, patients with acute pericarditis often have deviation of the PR segment, which is not present in ER. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37625?source=see_link&amp;anchor=H2297355#H2297355\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\", section on 'Electrocardiogram'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21544966\">",
"    <span class=\"h2\">",
"     ER versus acute myocardial injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;While patients with acute myocardial injury due to ST elevation myocardial infarction (STEMI) can initially have elevation of the J-point with concave ST segment elevation, the ST segment elevation typically becomes more pronounced and convex (rounded upward) as the infarction persists. However, the primary distinguishing factor between ER and acute myocardial injury is the presence of clinical symptoms such as chest pain or dyspnea. The distinction between the ECG findings of ER and acute MI are discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11658?source=see_link&amp;anchor=H31#H31\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\", section on 'Distinction from early repolarization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H595923\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H595931\">",
"    <span class=\"h2\">",
"     Treatment of ER pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the ER pattern is nearly always a benign incidental ECG finding, with no specific signs or symptoms attributed to it. In addition, there is no current risk stratification strategy for asymptomatic patients with ER pattern in the general population and within families with ER pattern that would allow for the identification of higher risk individuals with the ER pattern who might be candidates for treatment.",
"   </p>",
"   <p>",
"    As such, for patients with the incidental finding of the ER pattern on their ECG, we recommend observation without therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24316898\">",
"    <span class=\"h2\">",
"     Treatment of ER syndrome with idiopathic VF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among survivors of SCD due to idiopathic VF, the reported rate of recurrent VF ranges between 22 and 37 percent at two to four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Because these patients have no structural heart disease, they have an excellent prognosis for long-term survival if VF is treated (",
"    <a class=\"graphic graphic_algorithm graphicRef83895 \" href=\"mobipreview.htm?11/29/11733\">",
"     algorithm 1",
"    </a>",
"    ). As a result, such patients are best treated with an implantable cardioverter-defibrillator (ICD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/61-65\">",
"     61-65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H595044\">",
"    <span class=\"h3\">",
"     Acute treatment of ER syndrome with VF storm",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with ER syndrome and ongoing acute VF requiring frequent defibrillation, we suggest intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    . In a multicenter observational cohort study of 122 patients (90 males, mean age 37 &plusmn; 12 years) with ER in the inferolateral leads and more than three episodes of idiopathic VF (including those with electrical storm), isoproterenol was effective for the acute suppression of VF, immediately suppressing electrical storms in seven of seven patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H595085\">",
"    <span class=\"h3\">",
"     Chronic treatment of ER syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic treatment of the ER syndrome should include an implantable cardioverter-defibrillator (ICD) for rapid treatment of any recurrent VF. Patients with frequent recurrent episodes of VF resulting in ICD shocks may require suppressive therapy with an antiarrhythmic drug and, rarely, ablation of a stereotypic initiating PVC.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with ER syndrome with prior resuscitated sudden cardiac death (SCD) due to VF, we recommend implantation of an implantable cardioverter-defibrillator (ICD) for secondary prevention of SCD. ICD therapy is highly effective in terminating ventricular arrhythmias in nearly all cases. The potential benefit of the ICD in patients with idiopathic VF was illustrated in a report of 28 survivors of VF with minimal or no structural heart abnormalities, in whom there were 36 ICD shocks in 16 patients but no cardiac deaths over an average follow-up of 30 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/65\">",
"       65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link\">",
"       \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antiarrhythmic drug therapy is a therapeutic option for patients with recurrent VF following ICD implantation. For patients with ER syndrome and recurrent VF, we suggest the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      , a class IA antiarrhythmic drug, for chronic suppressive therapy. Class IA antiarrhythmic drugs have been shown to prevent reinduction of polymorphic ventricular arrhythmias both during electrophysiologic (EP) study and in long-term follow-up in patients with idiopathic VF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/61,67\">",
"       61,67",
"      </a>",
"      ]. Twenty-three patients with idiopathic VF and inducible arrhythmia at EP study were treated with the class IA drug that was effective during EP study (usually quinidine); during a mean follow-up of 9.1 years, no patient died or had a sustained ventricular arrhythmia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/38/38505/abstract/67\">",
"       67",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3448?source=see_link\">",
"       \"Pharmacologic therapy in survivors of sudden cardiac arrest\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with ER syndrome and prior idiopathic VF but no documented recurrent arrhythmias, we do not suggest chronic suppressive treatment with an antiarrhythmic drug as the frequency of recurrent VF attributed to ER syndrome is highly variable and not readily predicted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24316993\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early repolarization (ER) is defined as either a sharp well-defined positive deflection or notch immediately following a positive QRS complex at the onset of the ST segment, or the presence of slurring at the terminal part of the QRS complex (since the J-wave or J-point elevation may be hidden in the terminal part of the QRS complex, resulting in the slurring of the terminal QRS complex) (",
"      <a class=\"graphic graphic_waveform graphicRef83883 \" href=\"mobipreview.htm?30/7/30840\">",
"       waveform 1",
"      </a>",
"      ). Most literature defines ER as being present on the electrocardiogram (ECG) when there is J-point elevation of &ge;0.1 mV in two adjacent leads with either a slurred or notched morphology. (See",
"      <a class=\"local\" href=\"#H21543526\">",
"       'ECG findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ER is an ECG finding. Two terms, distinguished by the presence or absence of symptomatic arrhythmias, have been used to describe patients with this ECG finding (see",
"      <a class=\"local\" href=\"#H21543506\">",
"       'ER pattern versus ER syndrome'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The",
"      <strong>",
"       ER pattern",
"      </strong>",
"      describes the patient with appropriate ECG findings in the absence of symptomatic arrhythmias.",
"     </li>",
"     <li>",
"      The",
"      <strong>",
"       ER syndrome",
"      </strong>",
"      applies to the patient with both appropriate ECG findings and symptomatic arrhythmias.",
"      <br/>",
"      <br/>",
"      Persons with either the ER pattern or ER syndrome can have identical findings on surface ECG. However, the mere presence of ER pattern on ECG should not lead to a classification of ER syndrome in the absence of symptoms or documented ventricular fibrillation (VF).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several population studies have estimated that the prevalence of ER ranges from 5 to 13 percent of persons. The perception that ER was a benign finding devoid of clinical significance has changed, with numerous studies suggesting a two- to threefold increased risk of death in those with ER versus those without ER. While ER appears to increase one's risk of sudden cardiac death (SCD), the absolute risk of SCD remains exceedingly low in otherwise healthy people. Therefore the incidental identification of ER should not be interpreted as a high-risk marker for arrhythmic death due to the relatively low odds of SCD based on ER alone. (See",
"      <a class=\"local\" href=\"#H21543845\">",
"       'Prevalence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21543852\">",
"       'Arrhythmic risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The genetic basis of ER continues to be elucidated, with the evidence restricted to either case reports or preliminary studies that fall short of clearly identifying the genetic basis of ER. Both gain of function and loss of function mutations in various ion channels have been reported in persons with ER. (See",
"      <a class=\"local\" href=\"#H24315026\">",
"       'Genetic basis and inheritance of ER'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The exact mechanism for ER is still unknown, and the precise mechanism for ER related idiopathic VF is also unknown. However, fundamentally, the purported mechanisms of ER and idiopathic VF all reflect an imbalance in the ion channel currents responsible for the terminal portion of depolarization and the early portion of repolarization. (See",
"      <a class=\"local\" href=\"#H24316804\">",
"       'Mechanism of ER and idiopathic ventricular fibrillation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given its relatively high prevalence in the general population in comparison to the incidence of idiopathic VF, the ER pattern is almost always an incidental ECG finding. The diagnosis of ER syndrome, however, should be considered in a survivor of sudden cardiac death (SCD) with ECG evidence of ER and VF and an apparently structurally normal heart following extensive testing. (See",
"      <a class=\"local\" href=\"#H594480\">",
"       'ER pattern'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24316877\">",
"       'ER syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with the incidental finding of the ER pattern on their ECG, we recommend observation without therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H595931\">",
"       'Treatment of ER pattern'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with ER and ongoing acute VF (VF storm) requiring frequent defibrillation, we suggest intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H595044\">",
"       'Acute treatment of ER syndrome with VF storm'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with ER syndrome with prior resuscitated SCD due to VF, we recommend implantation of an implantable cardioverter-defibrillator (ICD) for secondary prevention of SCD (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H595085\">",
"       'Chronic treatment of ER syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with ER syndrome and recurrent VF, we suggest the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      , a class IA antiarrhythmic drug, for chronic suppressive therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H595085\">",
"       'Chronic treatment of ER syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with ER syndrome who have had an ICD placed but who have had no documented recurrent arrhythmias do not require chronic antiarrhythmic drug treatment. This is based on the frequency of potential side effects from antiarrhythmic drugs as well as the variable frequency of recurrent VF attributed to ER syndrome. (See",
"      <a class=\"local\" href=\"#H595085\">",
"       'Chronic treatment of ER syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/1\">",
"      Rautaharju PM, Surawicz B, Gettes LS, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Circulation 2009; 119:e241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/2\">",
"      WASSERBURGER RH, ALT WJ. The normal RS-T segment elevation variant. Am J Cardiol 1961; 8:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/3\">",
"      Klatsky AL, Oehm R, Cooper RA, et al. The early repolarization normal variant electrocardiogram: correlates and consequences. Am J Med 2003; 115:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/4\">",
"      Ha&iuml;ssaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med 2008; 358:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/5\">",
"      Tikkanen JT, Anttonen O, Junttila MJ, et al. Long-term outcome associated with early repolarization on electrocardiography. N Engl J Med 2009; 361:2529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/6\">",
"      Rosso R, Kogan E, Belhassen B, et al. J-point elevation in survivors of primary ventricular fibrillation and matched control subjects: incidence and clinical significance. J Am Coll Cardiol 2008; 52:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/7\">",
"      Sinner MF, Reinhard W, M&uuml;ller M, et al. Association of early repolarization pattern on ECG with risk of cardiac and all-cause mortality: a population-based prospective cohort study (MONICA/KORA). PLoS Med 2010; 7:e1000314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/8\">",
"      Haruta D, Matsuo K, Tsuneto A, et al. Incidence and prognostic value of early repolarization pattern in the 12-lead electrocardiogram. Circulation 2011; 123:2931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/9\">",
"      Olson KA, Viera AJ, Soliman EZ, et al. Long-term prognosis associated with J-point elevation in a large middle-aged biracial cohort: the ARIC study. Eur Heart J 2011; 32:3098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/10\">",
"      Abe A, Ikeda T, Tsukada T, et al. Circadian variation of late potentials in idiopathic ventricular fibrillation associated with J waves: insights into alternative pathophysiology and risk stratification. Heart Rhythm 2010; 7:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/11\">",
"      Nam GB, Ko KH, Kim J, et al. Mode of onset of ventricular fibrillation in patients with early repolarization pattern vs. Brugada syndrome. Eur Heart J 2010; 31:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/12\">",
"      Antzelevitch C, Yan GX. J wave syndromes. Heart Rhythm 2010; 7:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/13\">",
"      Antzelevitch C, Yan GX, Viskin S. Rationale for the use of the terms J-wave syndromes and early repolarization. J Am Coll Cardiol 2011; 57:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/14\">",
"      Surawicz B, Macfarlane PW. Inappropriate and confusing electrocardiographic terms: J-wave syndromes and early repolarization. J Am Coll Cardiol 2011; 57:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/15\">",
"      Wilde AA. \"J-wave syndromes\" bring the ATP-sensitive potassium channel back in the spotlight. Heart Rhythm 2012; 9:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/16\">",
"      Derval N, Simpson CS, Birnie DH, et al. Prevalence and characteristics of early repolarization in the CASPER registry: cardiac arrest survivors with preserved ejection fraction registry. J Am Coll Cardiol 2011; 58:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/17\">",
"      Walsh JA 3rd, Ilkhanoff L, Soliman EZ, et al. Natural history of the early repolarization pattern in a biracial cohort: CARDIA (Coronary Artery Risk Development in Young Adults) Study. J Am Coll Cardiol 2013; 61:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/18\">",
"      Noseworthy PA, Tikkanen JT, Porthan K, et al. The early repolarization pattern in the general population: clinical correlates and heritability. J Am Coll Cardiol 2011; 57:2284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/19\">",
"      Reinhard W, Kaess BM, Debiec R, et al. Heritability of early repolarization: a population-based study. Circ Cardiovasc Genet 2011; 4:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/20\">",
"      Gourraud JB, Le Scouarnec S, Sacher F, et al. Identification of large families in early repolarization syndrome. J Am Coll Cardiol 2013; 61:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/21\">",
"      Sugao M, Fujiki A, Nishida K, et al. Repolarization dynamics in patients with idiopathic ventricular fibrillation: pharmacological therapy with bepridil and disopyramide. J Cardiovasc Pharmacol 2005; 45:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/22\">",
"      Sahara M, Sagara K, Yamashita T, et al. J wave and ST segment elevation in the inferior leads: a latent type of variant Brugada syndrome? Jpn Heart J 2002; 43:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/23\">",
"      Kalla H, Yan GX, Marinchak R. Ventricular fibrillation in a patient with prominent J (Osborn) waves and ST segment elevation in the inferior electrocardiographic leads: a Brugada syndrome variant? J Cardiovasc Electrophysiol 2000; 11:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/24\">",
"      Aizawa Y, Tamura M, Chinushi M, et al. Idiopathic ventricular fibrillation and bradycardia-dependent intraventricular block. Am Heart J 1993; 126:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/25\">",
"      Rosso R, Glikson E, Belhassen B, et al. Distinguishing \"benign\" from \"malignant early repolarization\": the value of the ST-segment morphology. Heart Rhythm 2012; 9:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/26\">",
"      Balady GJ, Cadigan JB, Ryan TJ. Electrocardiogram of the athlete: an analysis of 289 professional football players. Am J Cardiol 1984; 53:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/27\">",
"      Hanne-Paparo N, Drory Y, Schoenfeld Y, et al. Common ECG changes in athletes. Cardiology 1976; 61:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/28\">",
"      Zehender M, Meinertz T, Keul J, Just H. ECG variants and cardiac arrhythmias in athletes: clinical relevance and prognostic importance. Am Heart J 1990; 119:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/29\">",
"      Cappato R, Furlanello F, Giovinazzo V, et al. J wave, QRS slurring, and ST elevation in athletes with cardiac arrest in the absence of heart disease: marker of risk or innocent bystander? Circ Arrhythm Electrophysiol 2010; 3:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/30\">",
"      Tikkanen JT, Junttila MJ, Anttonen O, et al. Early repolarization: electrocardiographic phenotypes associated with favorable long-term outcome. Circulation 2011; 123:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/31\">",
"      Barbosa EC, Bomfim Ade S, Benchimol-Barbosa PR, Ginefra P. Ionic mechanisms and vectorial model of early repolarization pattern in the surface electrocardiogram of the athlete. Ann Noninvasive Electrocardiol 2008; 13:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/32\">",
"      Rollin A, Maury P, Bongard V, et al. Prevalence, prognosis, and identification of the malignant form of early repolarization pattern in a population-based study. Am J Cardiol 2012; 110:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/33\">",
"      Wu SH, Lin XX, Cheng YJ, et al. Early repolarization pattern and risk for arrhythmia death: a meta-analysis. J Am Coll Cardiol 2013; 61:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/34\">",
"      Aizawa Y, Sato A, Watanabe H, et al. Dynamicity of the J-wave in idiopathic ventricular fibrillation with a special reference to pause-dependent augmentation of the J-wave. J Am Coll Cardiol 2012; 59:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/35\">",
"      Nunn LM, Bhar-Amato J, Lowe MD, et al. Prevalence of J-point elevation in sudden arrhythmic death syndrome families. J Am Coll Cardiol 2011; 58:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/36\">",
"      Merchant FM, Noseworthy PA, Weiner RB, et al. Ability of terminal QRS notching to distinguish benign from malignant electrocardiographic forms of early repolarization. Am J Cardiol 2009; 104:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/37\">",
"      Perez MV, Uberoi A, Jain NA, et al. The prognostic value of early repolarization with ST-segment elevation in African Americans. Heart Rhythm 2012; 9:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/38\">",
"      Rosso R, Adler A, Halkin A, Viskin S. Risk of sudden death among young individuals with J waves and early repolarization: putting the evidence into perspective. Heart Rhythm 2011; 8:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/39\">",
"      Patel RB, Ilkhanoff L, Ng J, et al. Clinical characteristics and prevalence of early repolarization associated with ventricular arrhythmias following acute ST-elevation myocardial infarction. Am J Cardiol 2012; 110:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/40\">",
"      Wilde AA, Janse MJ. Electrophysiological effects of ATP sensitive potassium channel modulation: implications for arrhythmogenesis. Cardiovasc Res 1994; 28:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/41\">",
"      Patel RB, Ng J, Reddy V, et al. Early repolarization associated with ventricular arrhythmias in patients with chronic coronary artery disease. Circ Arrhythm Electrophysiol 2010; 3:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/42\">",
"      Watanabe H, Makiyama T, Koyama T, et al. High prevalence of early repolarization in short QT syndrome. Heart Rhythm 2010; 7:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/43\">",
"      Peters S, Selbig D. Early repolarization phenomenon in arrhythmogenic right ventricular dysplasia-cardiomyopathy and sudden cardiac arrest due to ventricular fibrillation. Europace 2008; 10:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/44\">",
"      Ha&iuml;ssaguerre M, Chatel S, Sacher F, et al. Ventricular fibrillation with prominent early repolarization associated with a rare variant of KCNJ8/KATP channel. J Cardiovasc Electrophysiol 2009; 20:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/45\">",
"      Watanabe H, Nogami A, Ohkubo K, et al. Electrocardiographic characteristics and SCN5A mutations in idiopathic ventricular fibrillation associated with early repolarization. Circ Arrhythm Electrophysiol 2011; 4:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/46\">",
"      Medeiros-Domingo A, Tan BH, Crotti L, et al. Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes. Heart Rhythm 2010; 7:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/47\">",
"      Barajas-Mart&iacute;nez H, Hu D, Ferrer T, et al. Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8. Heart Rhythm 2012; 9:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/48\">",
"      Burashnikov E, Pfeiffer R, Barajas-Martinez H, et al. Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm 2010; 7:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/49\">",
"      Maury P, Sacher F, Rollin A, et al. Ventricular fibrillation in loop recorder memories in a patient with early repolarization syndrome. Europace 2012; 14:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/50\">",
"      Krahn AD, Healey JS, Chauhan V, et al. Systematic assessment of patients with unexplained cardiac arrest: Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER). Circulation 2009; 120:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/51\">",
"      Mizumaki K, Nishida K, Iwamoto J, et al. Vagal activity modulates spontaneous augmentation of J-wave elevation in patients with idiopathic ventricular fibrillation. Heart Rhythm 2012; 9:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/52\">",
"      Letsas KP, Sacher F, Probst V, et al. Prevalence of early repolarization pattern in inferolateral leads in patients with Brugada syndrome. Heart Rhythm 2008; 5:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/53\">",
"      Sarkozy A, Chierchia GB, Paparella G, et al. Inferior and lateral electrocardiographic repolarization abnormalities in Brugada syndrome. Circ Arrhythm Electrophysiol 2009; 2:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/54\">",
"      Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/55\">",
"      Hong K, Berruezo-Sanchez A, Poungvarin N, et al. Phenotypic characterization of a large European family with Brugada syndrome displaying a sudden unexpected death syndrome mutation in SCN5A:. J Cardiovasc Electrophysiol 2004; 15:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/56\">",
"      Roten L, Derval N, Sacher F, et al. Heterogeneous response of J-wave syndromes to beta-adrenergic stimulation. Heart Rhythm 2012; 9:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/57\">",
"      Kawata H, Noda T, Yamada Y, et al. Effect of sodium-channel blockade on early repolarization in inferior/lateral leads in patients with idiopathic ventricular fibrillation and Brugada syndrome. Heart Rhythm 2012; 9:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/58\">",
"      Nam GB, Kim YH, Antzelevitch C. Augmentation of J waves and electrical storms in patients with early repolarization. N Engl J Med 2008; 358:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/59\">",
"      Roten L, Derval N, Sacher F, et al. Ajmaline attenuates electrocardiogram characteristics of inferolateral early repolarization. Heart Rhythm 2012; 9:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/60\">",
"      Nademanee K, Veerakul G, Chandanamattha P, et al. Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 2011; 123:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/61\">",
"      Viskin S, Belhassen B. Idiopathic ventricular fibrillation. Am Heart J 1990; 120:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/62\">",
"      Wever EF, Hauer RN, Oomen A, et al. Unfavorable outcome in patients with primary electrical disease who survived an episode of ventricular fibrillation. Circulation 1993; 88:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/63\">",
"      Marcus FI. Idiopathic ventricular fibrillation. J Cardiovasc Electrophysiol 1997; 8:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/64\">",
"      Survivors of out-of-hospital cardiac arrest with apparently normal heart. Need for definition and standardized clinical evaluation. Consensus Statement of the Joint Steering Committees of the Unexplained Cardiac Arrest Registry of Europe and of the Idiopathic Ventricular Fibrillation Registry of the United States. Circulation 1997; 95:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/65\">",
"      Meissner MD, Lehmann MH, Steinman RT, et al. Ventricular fibrillation in patients without significant structural heart disease: a multicenter experience with implantable cardioverter-defibrillator therapy. J Am Coll Cardiol 1993; 21:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/66\">",
"      Ha&iuml;ssaguerre M, Sacher F, Nogami A, et al. Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy. J Am Coll Cardiol 2009; 53:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/38/38505/abstract/67\">",
"      Belhassen B, Viskin S, Fish R, et al. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 1999; 10:1301.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83199 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-15E18CE5C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_38_38505=[""].join("\n");
var outline_f37_38_38505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24316993\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24315018\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21542558\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21543526\">",
"      ECG findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21543262\">",
"      ECG classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21543378\">",
"      Concealed ER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21543506\">",
"      ER pattern versus ER syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21543802\">",
"      PREVALENCE OF ER AND INCIDENCE OF IDIOPATHIC VF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21543845\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21544732\">",
"      Inheritance of ER pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21543852\">",
"      Arrhythmic risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21543859\">",
"      Athletes with early repolarization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4191980\">",
"      PROGNOSIS OF ER PATTERN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4192086\">",
"      Prognostic variables",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4192118\">",
"      - Distribution and amplitude of early repolarization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4192125\">",
"      - Morphology of ST segment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4192132\">",
"      - Gender",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4192139\">",
"      - Family history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4192170\">",
"      - Slurring versus notching",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4192178\">",
"      - Ethnicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4192185\">",
"      - ER modifying risk of underlying cardiac pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24315026\">",
"      GENETIC BASIS AND INHERITANCE OF ER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23509702\">",
"      Gain of function mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23509793\">",
"      Loss of function mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24316804\">",
"      MECHANISM OF ER AND IDIOPATHIC VENTRICULAR FIBRILLATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24316862\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H594480\">",
"      ER pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24316877\">",
"      ER syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3161175\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3161269\">",
"      ER versus Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21544950\">",
"      ER versus acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21544966\">",
"      ER versus acute myocardial injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H595923\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H595931\">",
"      Treatment of ER pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24316898\">",
"      Treatment of ER syndrome with idiopathic VF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H595044\">",
"      - Acute treatment of ER syndrome with VF storm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H595085\">",
"      - Chronic treatment of ER syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24316993\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/83199\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/83199|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?11/29/11733\" title=\"algorithm 1\">",
"      Approach for the acute management of ventricular arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/83199|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/10/22702\" title=\"figure 1\">",
"      Action potentials in early repolarization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/59/20401\" title=\"figure 2\">",
"      Action potential currents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/3/16438\" title=\"figure 3\">",
"      Signal averaged ECG in early repolarization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/83199|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?30/7/30840\" title=\"waveform 1\">",
"      Early repolarization 12 lead ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?29/22/30051\" title=\"waveform 2\">",
"      J wave",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?42/15/43256\" title=\"waveform 3\">",
"      Early repol 12 lead ECG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/6/33897?source=related_link\">",
"      Diagnosis of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/61/19417?source=related_link\">",
"      Short QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/48/27399?source=related_link\">",
"      Upright tilt table testing in the evaluation of syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/46/21224?source=related_link\">",
"      Vagal maneuvers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_38_38506="Seborrheic keratosis";
var content_f37_38_38506=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59020%7EDERM%2F81260%7EDERM%2F58923%7EDERM%2F70644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59020%7EDERM%2F81260%7EDERM%2F58923%7EDERM%2F70644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Several scaly, well-circumscribed lesions that have a \"stuck on\" appearance are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 362px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFqAZADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1ayufMmLE5I+fJrRuMm2nMgCpx05yfSuc3G3cRBWwByex+ladtfPHbNna6ghsN2OMU436m8o63I4bhkd49yrHINrEjIq1YPLZs+xyjD7hxkGq0UTX0iqGihWOMsXfgcdqZHOI5FhldU4zk/oKdkHL0RdNwjSs1xIGb7xB/iPerVk4aG4uDEFiQbQPUms3TBCJWkuCxZgfLReO3XmmJNuVUHQdc9z60N2G1YttC8duJWCBWfaADzmoI5vKd2wSTjHt61pXcyXkCiMRlkAyFGCAKxF86NishKE5yjdfrS3Q1qaDT5jLucxu3zJnr71PfyFbOBIGXY8flsCnPXOfxrIkIeZUhkBGPmz2q3JO5kYlRtAwe4/ClzWKtYW4b7LGINuZUwc8HB/xqjqO/eFnaOSRsHepHA9qu2SrcuXiCjDZYSDjae9Qa9iQrFGsflh/9YoyW981T1NIv3hkhkiZXl+WQ9B2xjpVqe8ns7YG7TaQAd4bjaakS2R4ohIJLi12bkI6pjsRWXqMbS6c1uxeSAsSqMPuj2PpRFWdy4pNq5saPfWtvG9pOHxOgdZCMYJ9D/Wq1ifs91I4OPmKnYc5/wDrVBpKwR6U8U6HzkOYmznC+mO3NX0ZQoUDEY+Z2Hp9KF5inZNpGnaSyXLtPdgmFRsVSOB/9eo9QuZIblo5uFYbi/8Az0Ho1Ubh8gyQK4aMbsk9Vp89yNUTC8Iq5Qseh9CfSqW5io9SN5cRoI1UsPmCqeqnp+VMnuf3UcLo6OpJZemahVcXLTAbWjQEDdlffNFqZL67zI5ll25Y47dl/KlJ3LkkaqyPdRQxxFzgYIC4wPTNSy2zXlpC0KSSXSElgXycDv7f1rMWV7a4MkbOIDjKgkkD0P8A9etiS722UN5bTATuCkgJ5ZexxWabM3psYl3cMs8TkDyoE+8B8xJ9feobW7IuYQ7k7jwW6qKtNJ9ouipYyRg5+YYLEdBj0qK6gQKZIcli21pAMDPtVv3jS6a1N+O5nlt1ggmDeWcLIq9Paq1yXZ28/wC+q/f6j6n3pRcS6ZFFECjJLHlSoBbB7H8ap3v2mzZpLmEZkBA5yOenHrQrGaXYTTLj7HfR3DZliH3ivOAfWrGpXiGQpb4QuMyFTlTnnp2rOvLRrK1iuD95zj73X3FRIF8gPMSU6Ii9T7/SotZl2TdzaF8IU8iPO4EAsp+YcdvzrHvLh5rzfAyvcDC/KOHPp/8AXqJnkkKqGZ5GGxUxyR71PZ2r2r8KhZiAVHzcDnFW46GiSirk8aAxTw6iZbSWNSxOMjd1wfrVOxSVQvmvglsRlzx781euNRW8vZVvAuwn5WAOM9ifXA6ComjtJR5FvFLJsJ+YKW+TrnHr70rdENOxQu7sxSlY8koduemec5rQtri1uL3F8xRerOF/iPt6VmQp5+pyC3RwkqsyZ6lQOefWrzWcSwRuiSvKvKFv1HHUZoceqHJInhhQ30sthLHHAshSPzcnc2PvDHTmq1210WkjnZZJGJypGTux61o6dKmnoQ0c6Xh+VSFAUk+56U8fZ2nBtPMmmRt8zu3y1NzPn1KVvDLaypLHO8LEfu3PJA75FMne4hZZb2EyKG3AdMn1PrV7Mk0ssyPG9w2CsTjBK+o9KIrmK8QQtbqt2WOUYk4x160l5jUuokFwLyGRBHIkC/M6KvOM+p6Cst5dl2Uw4jxlPM4Kp/iau39wkEDJcuxliUKkSNtDc5GcVk6fFc/bHExSRs+cxIOS3YGm1pctJbmzaJMts9wqxtsAzGeoycD/APVSXWoQpaoIXjaR0MbROnQ+v/16qvcSpAySrKik7ioXv2bPeqtuzXqyXYASKP5VLEbs/T096m9iTVijWKJd0koO35flwG9Tn0p5iSWCKRrhlUtsVscL9aet1M7RvexvLCBuHHBHTcRTIU8nY8QDokm5kkPysfUUkZ6lG9gNrOUkcvGV+aWA5XB7VW08F1Z3GYowcbzjd6AVcurlriTy7ePy4p5dzEDAIHcDsPWiKOJLyP7RHMLZmLKE4yexGabLvZDljbyVLr16DHWtiznvJI2ks7WMRxDaCZPuevFP0TET3MZXFwcY3csFPYVS1aYRTTCJPKeb5eDjamMYI9+tBm30KIR7qaRgxCZLOzNx9c+lbVu8o04y3Fv5luFIUJ1TP8VUdL043ac4+zKdv3/vMOfyFachnjC5uFaQNtCgYznt6YqVvcbdzhnwspVTvVeDz3NOVgLdtzY254I5z71G1zGYj8uyWPpxgvUzWzPYxyzoEWQkg9Ceev0rdq+wuXqLaTK1vKgUlyRtbd0X6fWny2xJV3hCE4GGOTUcFqi6gsH2iMgrvBHGa0dUKrHAqht2Ms5OS1CvawPQkt2tpLRo5o92zO0b8FPoe4rJYywMZ1BPOAMfpipJJFMQTHXnIpLGeVotqhzH0JIyFHvQlfQmMS9aGG5ikXd5MhBx2BqtdOsjo7uAzfKCWznFOureERB1KyL3aM42n0wazriKUXCyxlTDCFZVb1Pai3QqMSSEukcxUAIGyB3JNa1hYyXGn3GJlQphlDD7x9M9qpkrcyeckPlI/JCnIU98Vp6W3kW0yupZGBCyZ6f41MbMTZTWJnxIsZijk42dRkdafMkazIiAsm3J3Dqals7poJ5GYElgcYPQ1Wvry3Zo4gh83qSCSSc9Kq3YFeT0CBfIn3qzgY+fB6j/AAqe7kW6vUG4SRp8qcYwD14qlHIo8yRyykHAXHWui32wt4bRY4EyBIJQvzEH1PrSVtim7GcsFuFaMBXjB4JGGJ9M0y0tULrHfmRIAxIdFz+dW5FjyVUZiHQnrmrEPn/ZZMKJLeJixBxleO4pPchyZBcaPBhnsZmuFx+8B4KrnjFUbOSOGbzNmYgcPHnA9OP8K1IJJImY2oyCMyRZP3fb2qlqTWYlE0IYCX/XREfdOeoPfNF9BKTe5PJFBtVVk3Qp8xG3DO3p9Peq1krQR3N0hWIKw3ruIO3296bYh55j5cZZcZ46gVsW5hgtbk4ZlYBdjKO9Ck2PmsZs4uIwJhsNs5IUfeDD0J74prWuDIJQiSEgpsY4APatG0kt4NKuYJxuMh/djkkEdKqx27lhtD+WqmRlY+nele+4r3M6SzmZy6/J6A8bh6irFzOssSK5CrGNqqBwuOvHrWjFP5f/AB9rv2gqEZeQO2Kz5rjy5liUqsqZyGXh/c+9VYpXZbtHjupJZDIgCKHVT+QFS6tExt1uFw2TtZcjBHqPSsnTWjNw/wBsAVJeQwGNvrWqqwzQYWNooEyA4GWkPbk9qS0G1ysxzIZIkE8zhEUhV6lQPQH3pkWYmJiYqzqCR1CL7mk1SMgPI0blEA2sGxtPqf8ACoYczhVuCYVCja2Pv+h96aiaRjpc1LVPKhe4kDplcRO2PmOeTz7VYlkeSIMvzgIBuXHSobiwdEhgEryzFNxWVvlQeuKW4NxDH5cs1uPJAUoRtJ+nrV2E7dDIuEVb2NCC8Qba2ONxqa9lurG3ngEU0DXAIKAYUDsVxz7VdhvIIrRY7yHzkZ2d4duAzZwPm7DvWTHPJbX4mnw3lklY2YkJ3GPXHGKl6FJ9wsZF/tRopXYRJBt+XgjHLYFbGg635c7S3C75NmI+MLt/pzWXamGeGSS5MjXcj7myAFYH1J5HNQfYrhJbdmbMUmcKjBmIHTj+tVo0VK0rpnQ6i0+qKbmRQmc4A5OB2A71nPNdYe1sgJIlxveJfv8AtSzXjNawwNDLBJB8oIbkn6HpTNBvo7G+Mc0jRqFLAjIO4+nY496zdrGfLoM/0hroSybopAMoG5Ge3NXz5E/mS306QyscskaYkzjjHbBp+q6va3DqztkhSpUIQWc9M/8A1qzYhHLI8l0DF8o27Ocfh3qLdUK2lwtQizrNdYZY84z/ABN2B71atw6TGUMEkJ3b8chj39wKqNvlC/KNqnGdgVvbOOtOkSchVZwzJ3Vuh9Pr7UMHqWr+ITqqvMqsx2szZ+Ueg9sZNUl82FRIsSNAj8RkcAfz96SwnlMpVIhLMcpGGHJz3A/rWpcwCzJbU2Z7ny/ljYgJj0461na7DVENldzz3M7jm5ZCuTwNvpjpTwyRIn2jzJZFO5FYEAj19xWdkeUY1IW4U/uwM5Jp9xcyJ5iuzvcORveQfNt/un0q1tqFi1aCS5vJbm4DGHBZwvB29lHoOlVhKHeQM2xTyVBJH/1qWISXEbsmyBS+S3J2gdhVjbCtrM7FImKBVSUEs3qVPp70WE0XdK1AwSNBqQKNs/cyyZyM+p9D2rOup5Jm8yUff+4M888VBIjyuonLDERZOeoHrnoKgsmZHS4mjaSLBGSe9IpROptnt4xFCRgxLt4+63vnvT9RcyNEZZgcNtZhj8Dj+lZEX2lo8mGQp97G7Hb1qwjrKkcUu6NYwWXjG8nuT0ouQ+5hx2s+0xRKZN53FSNx/wDrVSlSUF9jYaPggt1xXS6Pd+QJZLeTZPsOA3R19vRhXLToftWcscn0/Ot0r6ihq9RiShHju433PkgxuMjHrWo80dxITJKAFAIy3tyOetc/eyMrZjVmVvugDpV3RljuPLN5HHHEM5Kg5kPvWjilqdEorluySSVppNkYwgOMvxmrunS3On3RcSqY5VCkjBC9uR60j2627FlJmi4A4xgVZsAwt5ogiTwPkgNwVb1GO9Q+yMXJJWRZuNIiWEyO+HX51RThGHqD3NUNUkSN2REKSnAZQMDGKuTXD3GiR2JLPJE+EXb1z3B9az4IjHcCG4XJz82/7xP1olJqOoXbV2TW1tNabTOACQJFjfOGBq3LcxS3IlhtjGmBlA24Vdvp1viPIVhsjAweSB9aqfu44QR/rRxwcDFLS2hm5XLV7GktoJfK2K5wnr/+qseK1LzGWEHzM4QE1pajIotYcPukc5wP4R0A+tV4hN9lAcgKpyyL3+vemrsqF0gRZZgZDErJGct82Djpz6VNallfYIssW5jZtpJPSs+eFpImG7azHqf5VYjY3MQt5IkNzHz5jHDH296yd7jauWb2UpP9nNrKjE42N1/OpkmCDDwyIjkHae4Ao0wJH9pt795FfblFb7xb056VYjtURXlW5aaVfl2SJkFfY9qq9yXbYrvcKZ0ljkcyHrlcA/l29qllhtJUHBDMMZL42n6elWpJYi6mONYlAwBjGfc1Y1URgwqiIrPCJGIXBY/0pohGbp0TWE4LTPCrLlXVch6LzybLUwmDNEQGCxvxn2p8cTmNR1kVsbCeBnoQarApA7faHdLhXzyuVqbDW92ad1NbwWyhYwZXUMzHnyx6D396s6TIPsbSRx5V3CuO4X0561jiRpxJO8TFSOGA6/8A1qdbzyR+Q0JaNHk+cn7uP6cU7DULjtSfcm3eXcHaH/2c8D8KpXfNxOk0bfaGAyxP3QBxz7028nN3dySQqqWok2q+DlueW+lTLDtcJJKVJBzjliB3NOV0apWQy2lTYIeFWMdepPqPYVflysRjRmWM/Mq5zge1Zb3EcObcRx+bywcLywPrQuvPBbJAYQY0bKnGdp9AaluwOLb0JJ0IIjnO6R84VhjNV9FaKzvyt4R9nAJj3rkZ9KZLNLMPLK+YGIwD95fQewqvbXys4huwPs8bscL1De570+ZGiWjR0NvYmXyjMjySSjdtUkMi9sH6U3VNOdJILe6l/eK7MjMuFKgZGT1JzgVUstRmgbbZXTiIncEJxVi7ubm4vRLcqW/dgFB3/L86qLuZq9zGUMTOskYlkZS4UnhT1Jx64qPyywQiHezJsVe5b1/CprqJhMGVQgDEYbqPenNdNbglXjZ5BtD4wUHfFD3L6kS27uFRgWd8bP8AarViitZ7eGK6iW0kGX+0dSTjgGmWN2qgNcRyzARhYwh4C91q6LmTUJDELDy4ymFQAnp3PrSRN2Zjb5bmMnFxMTsXcchjj7xzT2t7i1uIjF+8kxnyxhyPfNIllczRSSKrZh/h3YK1bsZJovK+y7/OnOMOe/qT7Ur2Yua2xFFZhrtobuVZbmRsySMCVXIyePUdKkWzS2R2ikaWZW/dqMEEep9hTfPSO5kdMs5fK7u5HUk/Xmqd9qL3TlFZsv8A6yTGC/8AsjHQUN2FdssRLJIvmvINhYkuSM7j3/wqaCCS4uUEp+zxgbR8v3s9Tz3NV1vIbeKFo1YyA/xLnyz0G31NaUMkmoPExckISzRseVx3PuevtUt6A7og1LT7YyEWomIiADEndg+xFZdwWkRlnmklc/LGwbh/r34q1fXJaTKt5fmMF3KSMH1461Umts2o3RhZQSPmJ3SEngj0x6UrBHYfazGzjW4Gx3YFVVx39aqTl41LziR5LgblyfvD/PSrdvCLkvO8Lra2kYVwp+8e35mm6ZLFHfrd348wLl1QkAkjpn29qOlyvMktFlCRxzNHbwgmRd4yWY44q8lvLePHuO4HcIgxxux2HpSW+m3WpFr2UbI5SzJGTztFOlljjRoZozFEBuRQ25kPoM9OaCW7sgvt9hp81pdRNHPKwIyRjZ/+ul0yaKF2huY2NrJgSRyDlf8AaFVUtWupDJO5I3AlpDn6CtS+m0++Coo+yXCKR5jHKtjsf05pMGtCOO2ljuAAk0lqDlot3zMueMe3rW3qG62iFwjxeXjbHGV+VQB6evtXLWF5Otwnl8spzhzg/T6e1bGoSSXpjupR+4B2KueN3fAoCS7nOSEzadEF42cAkcjPWoJNwsXiZ0w2dpK/MB9a2dAaOK6xKUIYEFHHDCqd1aJJcPJGQrY37M9B/ntXQmrGcZHNwKDNtQkKF5BNbOmW/wBoyQyiQYCqe49ves69DbvOQArHlTjqc1e04x7I5Xdl7grSavaxtNtq5dnMsCncmztsPNT6aQwfyIzK5Qny8dPcH2ov53/s2KUlGR5SqtnLHA6H2qrb7nOInO8HJZD0H4fyoZha6GX0bi1iCzEEnIRQQQarwGZZVchmIPytjJBFWtUdioRWL7Ocn1qssrrslkDg/fyR/nIolroaLVF/TL57e781nG9T0I+8KW6njlIdFbbnEgBzlj6VUlumE0kjRr5c3O9cceuKsx2sJf8Adb4yBuD55b2xUicVe7H3DSXdygt1wI0GB9KlRRHGXfIk4Cr/AHj/AJ5rOWXyZtwfy2Vsg45+lWftBc+awZlPrx+NDk1sFtC5c2qLLGHYGMgncDxmqYjQOQhKdwHPb608obn5VO4Y9etMuLJgVjV9sw6hm/TNJq412bNW1ktr6IrfSGO6ChInxwR2JP8AWptOluoGmedTNGAVyTz/APXFYCrJZALcRn5iRHETn8u9adpcTLbSPcpIzKAwUHjFEYhydiJ7ne7ZHyjndjrUtsonkHngsuPkXOMn61nzfvV86EgLIxOz0FSQNKFCqrk9do6Z9vShp3FY13vXSXMEm1SoQD+8B2NVdVu2nKr5YjUdic/WpbKJbsOAFDxpnLPgBup6+pqtcvHcgRFfnY5JUZ2Y9BV2vqCV5Fmy86SxEcESv8xO9ieD6elTw25KSJLhAuQ4c8fgRVWzUXVkbRpyZY5CsfyYG09SfpVW5H2C88oTLMAcB1b5SfT8KfK1r1L5enUmt1EcRSAKjbCI97dAO/17VRu74RABPmlIG3/Zq067LaS6kfCjKpgZyelYlmiuzySZ2R/O0hPQd8is5aFxSSuxw23Uo83cAD8zdx9a0NTghtrKBUY7HBclhkM2eKwGu2kuPNWPCq+WJYDf9F74FaMt+dXtw1nB5cCcN5jAc+voCKwcrierK0lwI2L27sruNo3dAMepq1pd2sVlb2kkUU8Zkfzgxztzg5B9aqmOO4s5YAMzNkLIGzjA5/P2rMtpTBFCY0VckDaDzx7Vm52sPdHY6nZwW8UEkMq7COPU+1Rt9pht2nJIVvlVh0J9KppP9pEAiRlTYxyegHc/4VDYXrM8cc0wCrIoXd91VJ5OO9bqdndkxTRZusK0LKyybyN20cAntSoXklSFCBg7guAQMdTj+VWbyMG6nUFH3SZXyx8p+np9KTS5hFe8RK5Lcgj7x7D2rVtNFJpq5Ldw7GRfLNvMFDJ5ZJJHuO1bOk6nJbXSRXr7vlGXUcge/vUN5Jdpm5cRAgfKrYY5+veoYkiisxczSJJdTHON2GU9qTfQyburMuakWW9lu1VE3/KYyeXFZ9zLC8ctxEWFwzbQo4ES/wC16+2KkeIyXcBLBpJ84RW6Y9z3rMZjJOUcY2sQWPGcetS2JKxD5jx2ytGgEjMQWIyMdiPeiyQqHuJ/mQqV6Zwx7mm3chDFVYeWB0B4x35qzf3Ed48TW0Pk4QKxIwrY6HimjREtpYsY4714xLbIQ3l+ZhseoHWtS2NtKY7e3jInY7jO7Y4PJJ9eKxglrbxKfM+0TnJYnhVPt7VPbzRxvGyRB9o3FCD83+FK4pajbiKFtSk8wS+WR+7II5wcZ9qhdhLIYbf5o41JLN0z3JPfiprsuizeYigsN2WP3SeRt/wptspjAUNmSYgYxgH0oejFqQw3aLYmz+8xkDuQcNt9AOn41JbIt/5sn7uOWP5Y4T0Pv71ehtY/tZAIkKDMrDv6KKLi2kuGkmggD55AAwOPTHQ1Kug5izYpd3LSRLv+1Ip3o5wMdsenpis66SW/vhE0kjzgYYsuCG/ugVE97CyhzLcwyLkEeYWJ9s1FZqqIsklwYyzYzklievbn8au1xpPcmuZ57Xb5sGbeNdrNEO5/vH1qGO70qYszwyYAztDY59CasvNGsKpFczrwWfA4PoAD1NU49IzbGeRlSFhxnGCfRT3NXGKZrG1tSoksaOxJkdFXch+6f161fgvpLgxB23QxKQqg/dFJdfab1EC7JYrePy428opkHqPc0uk2k0cMzqif6OAH8wZBz2x3PtUSjroOVieGzMtq0q/wnk4/r2qvcwuNrNGzfNtUjgH3zVnTpFknVZdwi3fP7fStXxA0TaeZI5VMW4BVA5BFUnc4Vozk7iIs5R12SBunSqaxpayOrE4B5jbpz1xXQzhrm0819rBOjEfeJ96pzWqNbKHUuM8Hjg+lWjaM7aMpzLE8EQUfKuSMHp7VZs54reOUqVLPndgc/his5rbZkqxz6A5qvFMtvdNDdNsST5lkPAJHb2NS5NFcvNszQlkZkPA3OeTnOK144hLZwR3HloMfI+PnA/wNYyyxiVTF88anLOO+fQe1aErsIIvKVZFUnLj7wz6/T2oV29RNMijh8iQpJHvV8lCe49R7VoRwgKssMwWQEYQ9QfX6UQYu9OOW/eREbDj+H0qMNtThfnY9PSpZnJsg1u3jN49wB+9Jy67shj6g+9Msbk/Z1xb+aE+8p4YfSpBD++wASw4XApNphldGAOeVIHUetC1KTTVixcIbuM3doI7aYHElu3G0DuKoK955pVXUSnkyDnH4Gt5sS28cKAKyqWaWL5ix7A1FFpy3EciNKsF0TmNs/LJ/s+xqrJApWM29tDEqXcfmyF1AYvyQenBqaK5ea3EcZaPavzF2xk+gqzbXEp2RGQqANrcdBVTUtPjgl8y1ZpYn5GTkqaYc19GVdUd7by3RWdjjzAfTtWlBcZtzcReVOi8uinJxTNOZo7Q3Cgh8kMGGQwHUc022hjGoGTTiLcumGjf7pHf/AOtVLU0TTVmOTEqBiBtLZJUYOfT8Ksi3iG0QA7hy7dDmo4fmm8tkK9kTrV61txJO0bnJIBQ9A59K0TIbaKaOWuZVaRzKYwd4PJOaSWzAspZpEDuxG2RvXvgVYtSbS4u0m2I2cMOpI9Aap3F9LPLHBCqqqnIBPGe9Q3YabWxR1KdAkW3LqgyVJ4B9hXP6vttLGFD5jyXc2DGmD8oGc/SpvEN6IrhDDCvloSME5JPcj2qhr0UMs+mzLDI9o6K0zsdn3jyAe3HFcU6vNe3Q1T2bDRbJNbjvL11eCOyjLhVfC7gOm7rz3qXSYra6tPJjuIhayDAEhwCx+8T6gGmzahFrGtPPb2iWltF+6jiU5BA6dPXqT3rSt7G1trKYzo7DaZHZSNpHU/hXPKpFPl3JbdtShqVxfrf+XarbuyoFUW53KQON2TV+TTby1itXcO823ex28Kx6EY7dqi0mZryye9trZDE6qY4lUjIHWqcmr3sWsNp1scXk3zL5jZCY74PTAqb2dktBJtqyL1zdkOsnkusTqU2o+FYf057Vd02K2S0v5Lln2KMiANuJfPygn6mo9HVljlW8aKRQSAhOfMbOST9aoW86JNKjxy2wbK5KhhjPXitozuwTv7tjokRVsHDqyzsQVK8DPU/zqOVZAok8qQx5IYA4y3rRbIk8wHmiONBgytnaT2yParF00lxOyxsGUYTKggYxyea6Y7ArDIJJrgwTTOxiRfkTqD7VpQsj3DSXUkcUhTKZXqewqJYJAqqjIe20Hke5HrSvp6mNXWRmYEl1I6flTaZEndiXt0kFzE6gI4YHgZA+n86q7Su+4LfvAzMD1BHfP51ZOnxtOGRd5JA2McCqmpJEMRCF4nD5IDcKPYe9Fu442Ks0StEzEnzchlUDHHc1dg1JWUR3EoQbtxyPvn3Pr+lBhigIBtxLgFuXPA/xpkVjHPZyzTLtCj5VHYdMmqXvaI0jaWhZluoLaeUS2wOWVvMHzEcZ2kf4VM1887NJ80UasPkVQCQB1Pt7VgjdBJDHM7cnG3GSAO/0qQsWYRBh87bnbv7Lmpem47dyxhdQuxMEUbz8qkkAe/0FTrsku5XZy+FI80nO4jof6VEIOHLTCJRGeF5Gc8JU2mxqzxK7lQDlsLnge1S9SJPTQu6XMYYmtlTZdTsMF+9X7gTbfs1n+9uCpO5G+ZAD1J96pSWUQvPKQyyu5GZD8hU/Q9K02SPToUS7lhUqucFsb85AOR6Uk9bGbOUv7dvtMkYK+bGBuYHILe2KjVRNcrGE8qeQYYqBsRcdvrSEGRWjKnP3yw7evPpS2hYSJavGis2CJSck56YrRWepvFXQXkYWNg8oUqNm1Orj2qK0micqBHKrDhhP8+B2K9hUl3Gk129q2Dbb8Ty8nHsMdBWjp+nRahG5MuI4FLBj1wPT+9Ta5dC5NKJPp/m2tu2pyMGRMmKNx8uccH60yAB9KLvOyF5DJIM/6w9uP61l6hdTSb4pW3qp3BV4T2OKuI8FnaQGV3kvXXIiC4VAe5PcntUuXYyeupUs36EOQQc5HXNatwjz2zEooYnaexYmmWtpGsbeYSWPcDgVaibyZ1MpDBDz3zVW00OaT10KlopQzRHKxKMFOcZqaeBrfSi7gea5wvzAkD3HaprtVtL2JoJiyS/Phv4T25qHXgscu1kEcmAXUDAzilZiW5lbFEO0oN+c7s9h61TltXupVzg85bIz0q/HvEflkgq3O0dfzqWSHADgcqM+xp7milZlfTbUMZCw3NGcYI6fhUtwnzhlVQ3XAPFGhyPHdSOEDZGQpPJp+ojfIGP8RyMdKvpoNy1Cy2G5URqRIepU8CrCwrJfMM5UA7mBOD6UlhdPah2i2bnXaSVzge1SzXAQEIhySOSent9Kz3ZL12KkjNBBsYo2ckMD8wPvUAnMqorgZAKq3Q/StX7NI6lVCBpFIYScbT2BPashIWLxoI/MYHB2mjZaAi1YXjW4diGDj7p/hPsannuoZ5RPhQSMOnbPt6VJZ2q3e+NZtkozhCBj2HNUZ4fLlUYBJHzcY+b6VUUOybL6M9tcxltvmlcESD5Sv/6qg1FrYReXFAA2eTvzyaY8UhIMo2jbwu7PH9KrHIcqoXjAB9BQm1qEe5KpZ0wV+6vIJxn0q/a2scMUQQlGds/Nz+NUoPlcFiBgZIatBGZfmmQYkG/HbHampO423sJIi2821kMrc5QjGPrS3twix2jwyHy1RdyjsaqR3NxBFJtlCpJwwxksM96pXFyyxOYgoiBwSD3PQVtuh8uo/Upd12w4jLYICnI+lVru6W3edUjCMqBRk9+pJNY1xeNGjSlnchxux1BqP+12ZNhjUufmSMHLOprgq1Oa/KMhFxLNPvQuXlJVlb7qg8gkn+Vat/oyw6QUaaTa4DCInIf8PUflVFVkuWZBCz5Tg7gRGRz8wHSrdzq39mmAPsfziIhcsDtiz7d65abncJPsZ2pQ2unaMp8x/NUiYCFdxc44X2JFcxrvih7e2hs00+6K3YZZEA+YKefX6Vc8TQtaSxvZXd6k00hhR4ThYieMyA8daNL8IzWiNd393Hc3zHIlnlLndjv0AB+lOnBSeqJ5lHVsytM1zXLO3htbzS5YEjQgzRy7QRn5SQT8vUflVy1bbqV4sE63N6sP2qS7/hZs/dBPXjrV2KI3+mtFPbywIHAKvNuEmTncx6kfSufjvYDeXLW1q0MrgQSNGpYK6scFR7jHWtY04KPumkXe/c7vTILP7NaGebaJ48qkBIBbPPJ6471rappq29vaugKiRtmxm4APp/MiuOt0urtrZ1S7Nzb7isly6wrEhGWxjrmuseWe6ns3e6S6CKSFicHjGcex9axinzkvR7ktsJoosSyLIHYqsY43c/e+laViyBpTIzbAOccZPbJrJdrk7LmWELgndIDkIOgXFacDSR2fmRCIsrLywHOOckd66+aw3tcns2XZJKYmUA7QwbofWtPULeSG2E9tNGpjA8xQTnB6Z9fpWXcPDIsU8R3r1wv3CSe/0q3PIuGMrEuxwoB46feNSm3uZPULSaWZgyKoLHaR61WuMz3kvnfLGRkvjlQOBU8LyW2Yy4CSLycbh7VD9nMsc8qyHbnDdyB6Gto6ouLtqQRrKsqR208bI/O7HX8+lR3kkpzHMgjRQFYKOuKV4ZIzujxk5Ax1p01zKbeOJ4AGVtwfrj/63tTWhcSO4uPPWL+EwghX7kGpNOi3KzoY1cAndKQAPcepNRXCrtVFUEgZJ/oKpEElRhlb7ux+GUe/tSerKs2tDVuDbQwpHbF5rt2+aRzhVHsKUzGK2LuCQxGCvUD/AOvVG3gncAl1dsYwP5Vp2V79gdlmhdrlPlVWHC8dcetT5EsdNJdMouZpMebGXWUjPToOOlZ32wzhVndvLhywB+Ysx7H2qS7uYkLMoYx53eU5+XJ65x2qm9wHhaJ9qh8t8q4+gHtU8t2EY3Ld5K8FuYhIhN3hpWA52jnb9KivpfKhhZF3Iyk7cYMbn0/DB5qrpDj7XFJeFdhOMt09MVdnjtFkniYieRuI3RvlH/1x0q4uxorIhsmLMFt2KEjBHUHjnNdObyG0s7eGWBU2DKSxncPUgHufb3rmSkdtIgYRXCyxHzACcoc8fQ/pV2KKB7WSY3Q3xrkQgZxxzj86a1ZMuhTJMss85AX5jux0GeamL+ZHCiEDooyOQO/PpVzTESHTJZJZxG0qlPKC7i/+H1o0+0xtllXIZcDPb2pN9RcxYYPHNhZFeLqrL3+vvUQbzQOMMe+c5HrUekXm6EwqoO7nkc5FOZtjsVI5wMA9BWj8jBqzsaENtDJYXnmk+Y20A/wg9qp28hmkkaRTM6pht4zgAcVPbXSxrkNkEEYI4Jqm2BPNIC6S5wyg4WojclXIoklZ5JUQ7QPm/Gr0ttHJZo6YWU9V54x3/Grfhn979oSSVVyvKP0ceme1V54WicqoZRnhWPOKtasG/eKNtC0NxscbWYZ4PatC/sXeISW5jki4wAOQfSqkWx5Dj/gQNXBcgzCEbFjj5y46/lR5A27mVCVVpPODhh90DGCfer0MSOD5j/NjI9vrTpTDPcMG2KR3TODUvkSC4WJZNwKjaWwMj+hpJWYMhu7kwkHez/LsO4ZOPQ+tVYoPPUzwqWw2TGvG0eoNSXseIigTkHB9QaS2aLzI97DeBx6A+hp2KWi0JB5T7W8t9+fvHqKT7N54zM5IU54POPrVqW4SZfJnXyp1BKyr0b/ZIqvbSKAEkOBjnjnFO/Qm73ImVkYqiqikYBPJ+pqA2uW4P7wngk0+7cO22PdsU9Ce/rUVw7Mm6PGU6c4NK3MaLUZf3sjmNJiqyDjdjBI96iguJdqqAcDoM5rPuLl5b1kUYfo5I7d6t27W/lJGWYOoJDdiff2oSdzTlsi/5sj7VducYw3auX8TvLEHSMlgi+Y20H5ufat5HFzcqirmWToR7d6LxoNOinnk+TzPkUzHcRg8YHfNViKypxt1I5+V2RyOlyGa0CXiyHLZ3gDknovvgVjrfWQ1Fm2GDMxCP5hU4xx9B3rpEtpNTvJ1slNikfyl22gZI9emayta8OfZtPmn1JDHdGPbGNw2sQflxjp9a8+lOE17pLdnqUPEGsJHZRy6bdHT7U58y5Rd+5h0GPUkd65BNavmsJNRjvLWOaNyP37lUlyRsbb2PXJ6VpWl5a6JqttD4ithDMEMrRTgFRkZ6ehIGayo9Uv9bmW3sLe1uvJiHnW7QhQquxCqCeMEkc+gqpctrsuCa6HUH4kaLF4Ya4NncRzCTE0JUkO/Izvz0J6GqEEzeIbqHWdSvH06MTxiHS2cnzIh96QoOeTxz2rl7/4Ya8mgnUJbixWG1ZpBaRb5GyDyOeoz3rX8BabZ6VBb3em6Vb3eq36N5s9xMzLBg8gj+8emBzQqcJQ5I6Ih8sfejuemX1irWdwLKAfvozuMQyVYD5cd8etVZPDtlBYWtsZxBNPEzqiAnzJSOx9R71zL6jrOmPpEulRCwtZJma780b44wDl1LeucY9Old0/l3sFktzdQi6Vy8MpGwc/w7ugPNcilKg1Bsd+bVHKfb7PSohpoSS7RMhwsTIFPQ5zwMfWul0fyX1aVELbIFUHMewEMMk/XPese7u47ayea5AksLCds+WTudu6/7XOK1dFiludGXUr+eaW7uGEjwL0ij/uADqQOue9Zyq6tLQ1UdLs0jen7ZDZSZaG6yI1/uge/1q1p93BFcTKwfawIIAyT2x+PrVe0vIG2yx28htoXIVweCM8VbFrd21oZFaN7SeTczlMFW6hTmumlVT91/IhaIt3OqyFhCIUtoUySqKACcdPyq3CjTWaXW5Rbyn5VXt68dqyJ900wVVDdyRgsD70+aEwQTMGkKiRU3luHJ9AK6EJouPIf3m1SFyPLPdvfFWrWWCIXMkquUC70THLnoR+dZ0YYXLLFHJG6rkB+ufb0p1nILl3SRjiNgVGeWOece9awd1dFKOlzcEkFvYhCQ10OXDrwuazb5fKZPszqxYDLhsirM8StAXT5MnBDnJPvVRFVpW4b/Z2+vbNNkIhS3UxMGyZEGcqcHJPpUE6KzOWbfKRhjjt71cWORZmk5boCRwVPpVhxb+ViNGWXkSGX72fWmXzWJNK0tNSSUJII5FwF3HAb1qhdyXdk7LLtkVCflLbtp9QaktE+0ARr1HzNlsY9KoXOHZ7eJwCCQccfnSTCN76ki6oL2633dqpVV2oijG7Pc1I1lEYwyzKHAwQ3UfUe3qKsLHZixhCXkS3iDDIefzNE13cSWzxwJgvhJXCgq3PGO4o9Rt2Mq2VAspm24XhTtypPvVmysmlaOWZFiicjYy8qQTjJ7ipJbTyggxhVHUjhj3pILwp5giChB8655IP9KjUrm00JtRFlZ30NsivOsvyh1OCD7j+lMO2C3eJsIWbGQoJK9zVWZmZ1mYrGSTuJ6kew7U353w8hITGVBH3h7e1NXI1NC3HnH5TxngnsK13xbpFGm9kyWc54JHvWUN1mp3A7sZbaOBnoPrirI2pbhxu3Mdiow6e/1ppkPyM/TN0DF8kjPKjsKvX0calSMAYyW/xqppk7ZQthmyOAeT/9erGqF7m63ELGB99UHTH9a1jqrk7vUz0lbJCB8YOfQVfQ4tz5ajI+96VGcpHtG3B6VNJiNY4mJwRztFGwmx+kSpDOWmIYEchuhPatgtBeWc6zukcx5Rj/AJ4rmMmOV43OBnr/AE9qsmaNt4Y5YgDg/dpRu2Ty3dyMuYlMYVQ4OSe5q3FdmKEBUQSN/GRn+dUzA7qZEkRynXsfy70sALPFuPyqckHtVtWLaLaqCAGQK/cinS4ijkWRhuxwSeDUwj3SjySTg556is+/Q5O9iUJ5AOKpIlasZZztJ5kMz4zzH3BPanIiNnzF8sjksOmfSqMkiI6hTjGME1fmlie2RmkyS3KAdD9ahq2ho0+gkykYQ8dCCPSojKRtBOAvBA64960NPlDO8J8ny3H3peQPp6GoZLKKV2MXIQ5bceg9qLdCL23GXNsCUMLPhxk/T+tDWSMm2KQsxIJPHGKpLM8U3JYgDBYmtKK5jYAxkeYegFWrbMV2tjHv4poGZpo0yZAd4GP8io2XzpGYPwqk4J2gD6Vv3KSXVpHCqs8jHgEcHHcmuQu7xr3X4NPtbWX7Nbruu5lUfuzj5QfXnn8qqc1BXL9q7HRabbrYeVOIwjSIRtc8g964zxlrUFtcwySQl9ylgF52YO3I9Sa6G01q0v2ntvNV7yzgLzl1wcMevpzXBWlwJdbufPLS3EShY0+8kaHkE+9eDiJS5rvqxU9XdnS6Vc6LdOs13tjeI+bFGZBgqP4mHrkYq7qF9c67p8k5VfIVgq+WMMgz1A+lecJBbXdrqcEgVvNmMRjjbMnLZBT09T2rsND06Wy1OEvfmOzaAyNFjdhscEY/lWElJNKPzKtFK7foObR9Gv7+KGfRlu7qCIuWky4wB8pY9z7VmaB4IjbxTqOq2E7PbkxFVb7oCLkrjuNx6V1finxRZeDPBt7qGoyGYMvkwCNR5kkjDhSPX+Vef+E7S48N6NDqXihr2Jp2+2F4mIS2lbBEbr/dxjt1zmm4uMPUcJt3szr5bUO8uqmW4lkYqQkIYKTnayhSeR/hXn83hO7gur2JUW0O9poprZi7TKCG2yp/CT6j0rvk1KG6vrOazvJZ0dQ5jhbKoGydwz0PH4ZouXtrq9aSKW4juZf3MrAblwDwPQDqMjmtaVfe73IaaMzWnFvY6egjkk+1uskixHcemcMP7oxmrf2eK90hdOvtqQSMWWReVX/az7+laA8PCy026eylngMieXGyMWLKerc8gVh6pPcW+izXOrJcWltCPOaUD5DGg5+pJ9PWoT1vJ39BprRRMyS8il1zQbRYyhEkokV0/wBZKo+U4Hbv+Fdg+sJIhjtLq3NwwOYinluFA5Cj1z3rN0XwveajZ/2lcWC6bazQRy2lo7fvkPUySN/CzDGAOgPNYuu6pZW+s2lpqFzaxySv5chJ3yMykDaDjgc1pSo1J22KnUjey6HS+C5nvdQvLTy2g062AjLvwJCOu38T1+tdNrGvWcEjaYCv7tS2zdzk9K8mW81aXxh/ZVihj0qKTZJNE/72Tj/VKx4X3PWur0SOW7v7jRJrMaXKqGbznkDtIgOD8x6nml7L95ZFvRKUjr9R0lbjSIby2LJcLHiTB6cd8Vlajf3l3FBII1NpbIrRpHjDHAGc9qw49RvdD1OC3uE8uxmVkebzNwQ5wrOAe9b13ZQ3EbrHdorAAmNRtJHXP0rqgpK8WSnb0J/LeFHCGWS7uAFJP8Kk9F9/etQ2ZtI40RVkc8Fh/Ae9Zs8ubm1ELyRGJNpYDkHr+NRxX/yIsju2FyVHy4JODWsfd2H71tC9HdtvkDSMIQ2GB5apg+UBhOwg4Xjmse4vgkcSNtLMcED7y/3d3tWxZM8cSrNCZYwwEoXgj3BraMuZhvqWIILVgfOndLn7ytnr9aoTXImlkIYyNkbi3f61pyW1oFMsbTTRjruABJJ6ZpdNs4bhnjGAAM5A9OuapoV0ZsYt4FaTyDOCOMyFdp9cCnWWn2g0sSXcqm4mc7EV+cere1XXsV8yRbaQPHEMscgH/wCvVVrWNLtWuEMan5gAOanlHEbIgjkkNiqoiL8zIuFP51ZtBNfOJppVCptBzhR+HvUdzLFJIyQx7IF6+o9xTrZktpVM0YeMjJUc7PTI9aliexNrMz3aH7NCiLCuGZTgMvv61lm2aCJW3qC6h9qc7l9fatK6dLyHyrZOWbALHGP8KgtLS4mLu8avFC20rH1Pf8elVYI6IrFbaWXdMhSKMbtrNlpT6Vfgjkv7nzHGw8AA/dReyjPQVAxe+u0xGFjQce/1960LiNY4/JG4uxwdvXP0qXsKTtoSWglNpLHI0PlecSPMHDEdsjpVVQZLokDhSduDnH0rSFk0MA+2lliUF/JBGfqapxxs0nmyPsQ8cDAx7fypNkGJZZSctJ8rAkkAYAP0rWt4Ult/Mm3BC2N2M5NZtxMsmTLtEynG9ejCtRZUFuqQ72QDnceD7AfWtr6ibZWlO2VlkQSIrBQyjGaZOAZX3fKFHHPf0pGJbJDZYcqCefoKgMqrcnzC2OjAjnNPcErjEQmXDMV9eO1SSxjeSB19KtlAQfMXdkff6Ux0GwdB2yau1tguQbCV39VHJ7EVcijD4kGN+R8xPb6d6rEgKFxtHfPPFXooEurdleWOGSNflBGDJ7Ur20BssPOsV4JBAkZUYYryucdfao0iEspnkDbSOC1ULl7iCARSAqkh65+9imQXsm0xqx2LzgngH2pNtMm1tQvY8hg0abT93jORUIK/ZYQgGSTn1FSylpHyGLDjINRuPlcICT94n/Ck5X1NEy1HGEjyWLO3OPSrdqwNq6rNEkrpyjDlgP5Gsbz/AC+MkMRwKkjuozOjMm4DrtOCKL6ku/UYoGHVgRt9s/jVa6cwYO7dnpgYrS+R1Y4znk46VnXhjaLdtBI5x1PJ61ajoQ5FW91q6s1l8ppPIRDl9pID/QVgeEryJGvbSxlurzV7rMk4liYdfule20f0rWkv/wCypZRazRT3UrYhtywaRkA+b5eo5q1J4lg0PT5Zr8x28LxiWeVsBlPox/TFefXr2fp/X3iWuhxmoeF/E+nX02s6c+m6wkqCKaznUx+ci/3WH3SMda5O78XQeLvFum6dBp8mjaiZhHPbXREfmxAEkBxjJyMAcZrtLr4iTy6vappsTXVpJCHEcMAYysT8qg5wBjmq/iDwLpXxMtrS5nL6ZqMbEHYVB68jOMdfrXNzRndTT1NG5Rs2NtfCkWqw3ws1uba6llZZW8pkaFARyvr7Cuf8Z69qvw8vtP8AttxAtk7ZSIgm4mVeN/cDPHJ7113w/mi+Fd7rPh/xD4gkfTNn2u0W4Us2RxIFcdSRghR7+9cVZ6JZ3moy+L/GF4Lm4vXMkEDqJRbwlsRpzxkAjgev1rVQhC6W5knJvXYc3iSL4j+JvDVnYWV3PotvdreXjsmRFIFJCE9CM4Jr2vVbmN4pFVmYCby2IjyTuOOVPb3rx0eJbWLUtPj8OQIsfntbq9vhGll7Db0AbBAPc1f1PxFdWUdxN4pTEMsx8u2MoWZAq5IJz/k1zVoSb21S0NoxvYu6rpWqeGr5p9DvUXQ7abzr6zmiDsgIJO1uqqc/QdaxLG38XeJ7ea50e7OmaX5vmWNtHbb3lA5BcsORk03wbpE3jXWF1rXbG6Wyuws0dr9r/dT26/KisPbGcd812l5deIofFltpek61FarCjK7SQ+akncJkcjjAyKmWi217jXa5zMfiH4lGWFdd0a01GC3YYawcQu5B6EH730wBT9Z8TeMdY0qez1HwWkenTMAFS8UvHg7gWB4JGM4GBXpemX9xffabfULQf2hCp2xDvj0buDnNSRT2GsTXOj2wMV5bov2hVQlYVxkAseNx/lzWkeWT5kvzRnz8uljzPUfijaXEa22mW1zrWsP8qW0BZGYY5LDGFx61zt9d+Lr2yu/7W8MiyS6KKJPNBaDP8e3BYkAduc4r2zT9P0Lwo1xf6XbQDUJkzdTuN0suOwJ/hHoKqJqc9xdXd9FfR3YVflQL8o44GTTdSnTaVmzSn7zukcZ4KTRxplnBpUc7WkEv724APzkZOA3ck1W+ICyhojfyGGCUGNpFmLShT0VMehwTj61P49KaNoEus6FBNaIkyjUrYnaihzguq9iCe3vUz3+laja6PfX+pwQsqNCWLfMIz3H1FQqig7x1TuaNXlzFODQLzVrWyeSS4VQSJIICNqxjjLMfvE9T6Zrr7i9swmnGNtuMxM65Jwn8JBqt4ZsNStbKe6t5bFdMEgNvtB3Sr3LZ6E1NqaTTajEty0KtIu6BYwQAT1GfTH610Q1npsTfUuXMAs44zbuxSSPdMwzkA+vv1pGEEc5hjZyzMPmcYUYGee/pQ16Z7Ro402tI4gt1J5685+nrV3XrI2kypa3Ek7SgCZnTPPqvfj2roBPZM5SWfUZdQ2TANmcOZAepHQY/u8V2VjdskgLbSTgn0BPY1g28Xnt9otm3FGZfPkXb8oxlsevOBVqJ9jRpCriJTudnXGW/w6CqgrM0stjo5LuF9rQx+SeSQOQT647VaSJ0tI7dVPmytxzgnNYcFwkl1kAsqjaeOlb9n+7kE7bsKuQGPSttbmclbYtE21vGBFGYbhAAcjJz3IFUi6mIRtIrs/KqeWHt7VDqF40zhMhhnr3B+tU5oJY5I5osFAcFhyM+lNp7IcVpZlt4EgnS3kkBKfO8hGecZx+HSq0Eclw0kiSqSWywzjj1p8QRlk8+ZUbbkNjIPt9ajESOWZlVto4C8Cs7dB2J/s8mWwCuACVPBIpszrvQqXUgbf3fyk/41LYNPPu8mViwfa5RgdpH8J/wq4LeSSRwzoSgyWI4znoPWi1iXoZOnl4bswiPeWPQnr7Vpw3Ys5A1sgkfZ8zuPutntTrqxVxCDlZwOSDjPtmqotWJRFlT5ichjhhjsaLD0lqTz3LzbTIwYnJY45qSCVPklb/VrnapPG71xVb7O4RzlVwnGT1qq9wZNkEMZeR+OOAPcntS5b6go8xDZSCRnjmGYSdxx3qxpFxagzQzCU7jmIofu89xVYhRAAItpIxyf6VStWMN55uzIAOPUVvyu6ItzGjdbYmLHIUnKk/WktmtpGmivHCsxLRzBcsT6Z9DUCw3F+xKn5U+dkBxx7UNCsDLnoTlWYdRSatqDXKXUMsK7M7wo49cVDcPhOMZb3waW1k8y2cR/wCsDc46j0NQSzFbhDIQ0h6Gqv1FbUdFE4kDeYuF5IH8XtVyN1dw84ZO5Mff8KrvG62rzjlATkLyQf8ACordzLGwc9R6+tQ3qJ66lmVTNG2TubGTn0qSCxhuLJldjHcLyG6qw9yOn41NEiTFo9yxzqAVQ8BwOoz60XWmzwMkkUmCxAGxs59sU3rqTzFa0t5lkCHBzzxxSPGwkm2hiR7dKuxzK8qtOvK5Dr93P+FOSRDJhpPLXGFwM5Bp3WzFzamFfQtIQ1qmHVd0iscBfp61HZgROGmUvnn5eSTV6RhA6sNshB2tjoRTFiIjMxVvL3YDf0qopX0KcuhUur0xzfu8xh/4SOh96wri+MupWojmEaqxbaQdrdQASOcZ/lVnxrqUWkaFe38kO5Y0yMN87k8AD0rynwp4jk1vXrW7t5rpdMgia3LyIOXUjAOO5ycGscXWdKNorcFDmR6HJo1t4f1B9WgW1j1meIiabeXCr0IjLdOoNeUeKdOkuPDt3p0V2EtVnLX10xWR5XJLLtXOduccj+VO8UahG3ji/tNdluhGFURMhyETrtOOAT0JrB8ftC+opcwPFaGOeOJ0UeXJt2Zxz/CR3rzIylz6luGi13M0eNr+xEOnaNDbKLPbJK5iMbTsAAcDtxge+K9H8CfEyW0k8nUtGke9t8xPFbocIpOcnPB45z1ryTw7Zavd6pNBpktrDqcKmESvIPMlDcqFHc8dewPNelfCzXJNZ1MaC1sIr+eU29+65wB0LjH8RPHYD9K3rJWvFGd9HzHolzf2XjEC91awMFjazboBKwLSv2PHp0x61zvxJ0X/AITJGsdLcW01sd8sJYRoCFLJ7cnj2pPizYSaDo9vo+gwS2xsBmKOMHai8neGPU5zk1yvhu5zaQ3Xia8uYQ9q+xJW5YjgKAOpJIPvWD5lJXexdOKcbowLKzvorS3to7K0t9b1O9VLeGV2WSCSEZEox2zx7mvSJ/h34cmvbS/8aapcavrd3tkneWQQRkEdkUA4yCM57VSGsWQ8XfDuSWDF3l1WMkKY5GGN5PfnGBXLfFTxTc3F9q0aLp1vcBhbSpKSJpIlbKgdhznOK6HeSiodSHrJ8x6604+wLBo8yCxEKmFB8rREHAUf7PHHqKs6DLc6hPqOrXas0wfZCVGwhFGC23sevrXh3gm413XvCtpa6RNvmsb0y3IWQiUQ4Gxc+hO4cmvUv+EhSysobXWEgjur+TKN5hBVM8oGHAwBXPV5UnGO/wDl/VwUXoyz8UbzUNJ8M6ffWN9NaXs11BbIIn3SqGb5lXI+ZsV3NpHBpumPpGm3C+ZN++mkbmTce755LH3/AArz2LR57j4o6GZ9VF8bG1ku4YpB9x3O0YB6kDJH0rp/Es0M9xPo2n6m0OrXjBpp/KEhCpjG7HTvzWShdJdv1/qw7i6VpZtvku7y3nCKzKLj5yi9wWPpnpXP6ldTWkFs0dmryTPtVLebaJW6ZI9f6VYg0a/1PxFd+aRJYRRL5JVztZu5K98nmq1vaWuopFpU0iT3FlOFjkjODGwz82Rz14xUuKT1RSnbW5U0e4fX11PRtbMCxIglmnkbcnB+6V74OBz6Gszw74b1yzIn8NWNvd6fcP8Au5JXCJExPzLnkhcfdGOKTxtpi2EunaN9plm1PUrkXV5gkNJDH97PoDgDHf3r1i4u49D08yNIYkCifyQgzHxzx1JrV6Ll5dHr6dhxqOOqe557b6b4gm1Jbm/t9T020glK+SbhMK3dlC5yv1rpLrVW+zxq0DO5kWKNM/d54OPU02y8Vw3Onpd2cJlVnKqu0AspHcdz61v6XpdrqBl1SZxHdRny0KjcqkYyAOnXvSpTSk7LU0lLrLoZl8zW5i86ExztkCPPUH+VRW94PMjEZd380FyZCTjuoHpW1LAtzdSz3oRGtx5YMpwS454H071zurwlNQE8Nn9hhkOEkccknuT712Sn71khQaejNS6LTai1zDiOKI5JOCF4wDVn7T/oixbS/mE72bgsuc4H1rCW4aYGNEMYx+8G4AHHX8K3UMTP5cBWRVwFkH8K+p963j3K2toamlWwuJAT8m8nvjnsCauyOFSQOXQHgjHII7Z9Kjt4WhhRAOSM9ePrUkkaXEyxwSGVxyzZ447D1roVkrkN6kWnxi6uRvwoLbVCjnHc+5xU91aJHblrJ1eJ5Ni7idw9/en2iNAGnUBQGwexU/0zTInlM8Zt1AkU5RMZU+vFTzBzXeg+2iibMjLGyoeYnOCff3oVZpmebywsSkDaowFFXWudpAkhjWfuuzIb3/8A1U6GRY7dkxu81sOR/d9Ki/QnndyrDLFbxyRW8UarI29tqhSWPU8dT71ZtJUZTIseI4eeuSc9yO9Z92sSNGts7YbO5GHzL9D6U5Ysxq4YI2cYbpxUvcGT3Li4RyQSN+dx4zVWW2knYCNjvGSxUZIAp7rMIy7KQj8Bj0JqSCURQygEhnXG4HqO4p3KTshbS4eW0a0UqBJkhyeMd81BFjyxFGPlIxI/972HtT7y4tpIILeziKzn77dMGmxyfZtPeMn7z4IPU49KproMymnG3MnGM1XilSWbCkbT156mkub1LuLYUUg9HAwR60ght4o0eKYMAfuYwy+/0q3pqQtEa08fluqxMY3QfTiq+pM8gUyRCPC9uje49KGvVngRpC7yA4z3wPeoZ7iSXYN29B2Y9PpSV+pKuty5bWcv2D7dbRsUU7XVeoPqfaqd1GZZPPAKscZAHAqe1v8A7GzG1Z4y3HYgjuCKZqFwbhjtxA7DkRng/hS5lawXaC3mmhD7GYE/eX1qJ7Zo4Xni+aNDtcA8oartMy/eJPG0e4pS289SF4wSMZ9aV7hc1YPM1Yr5SbrmNc8fxgd/rT7W7mtHLlVYY6OPu/SqlneGB4/KOHHOV4P51YM7ys7sOD0OOv1qou5DGyysZzMgySdxU1aukP2dZ42ALjIQdh2FVJblnbdFAq4HQdqmtSJRt3AA8DjoaLa6k7FXDCJRJ8pB9MVUvGktJMOsiITwTnH1Fbeqvm0SNVXg5LDufr6Vj3l8V050l+dFHCMf4vatY6BFnm/xjhv9c02PQtFhFzdyyB5pedsa+/bmuf8ADljqfhDS7ixcW8EibZ5WncbEb/pnH/ETx+Ndpds9teteQyDyTCrNGZMZbOSx+lcR4wf+1ryyvSGvYbzhV2k7m3fMAR6dc+grycRWdSbXRG0fwKl14nsr7w9eXUMFmF814bw3E37xnA+Rh6fNmsXXbKDxb4UW5CRW+uxbVgiJ3rcRBfmO7pkYrkta8PXGteLnGlWx+yXTYjVztK7flOSepyCfevSPCXhA6bZ6ha3cqz6MsoCzwPu4BwXcdRg5yBxWfIoWcHd6A5K2qsc5aeANY03Thq63VnZQ3ISNbxEdptzHP7sD7ucYycE17p8Lbez0bX9V0C3it1+z2VnLujQZ3Mpy0jdWYsCea5K4+IOmpJcaFC4vrXy0MMtt/wAsXDABX4wDjJzVDwPeXV5q3i/xfPutnnlW1jkZiEiRAMPz97NbdPM553ludTq8B1XxRrFz4heQRwb1sF3lFdiuQCP4uQOK8zsL7Qte1B9Su7O8N1aRbbiB38tYDnqinjtk16hql602l36XsSy21soLOMM4Y4+bA5HY5rL1jwxJcfDPxDILiK9eW1LbpUUO0gPy/vOMADt3rm9opVfZyW/5GsfdhzX8jx7xdfwa1ptzrF+/2GFn3aZBBjzmIBCu+eQpx26Vj2uo2/jbU7C28Val9guVAiF95HmCQ9B5gHJPQZ71JH4a1jSvAt1q+oaXcmC7K28Mske5Y4/74IzjnimX+jwGSGzsbW70lpp40M19GdjHH3lkxleT07163s1yWvsSrM774W+HvEaR38EdvF9nEhhRB+580ZxvzjJXrjPrXudj4RVNKG2wsZpY1wwLcxjvjIwP/rV494O+IkOkvHa+LdPvrjxNYy+UmyBizxDowx1x15HPUGux1LxRefEm4trfTbfXdBsSSj3Yl+zNdxYI2KvOck5JPTHvXC4RU25qxEnN6IrweINEjlgu/Fd3plnqUTgedbOwXykb92FPU/ey2O9d3qmkrq6vLpclnbXSxGaO8tWWQMCR849c9PxrAm+Dvg/S/CrJPaJqV3uVFnuZW3HP8Klfu49q85Hwxk0i+lvvB3iG602KF2W5MjbgncIQMfrmp9in7ydh8yeiZ20+parYeVo3hyw/tHxXcxSNmRsRWsWcF5CMcnsB3rI8HfAvVbL7WdW1KOS6YEo++QLGzcluCDnNO+Henaxolzc+KvEl1IdTuVHkWEHzu6Y43N/IDgda6W6+IU720sksLpLKN7Rgl/L5xsbHpyc1mqjgnGK2NeSW8RnhfwNHomo6hPeaxLqV1FsRpJ1B2tgt97r6VZ1GwtTcW+o3E8j3cCko5ByQ+cnb/j0rL8V6idK8S6DqFvqTi1vInguY42BikIXdFkdmzkZ9K0NMubq5eMXMcjsqk7kf5F7nJ7gfzrNNOX9fiJ3tdlO+0qaCKxgk8u2vbglvPhJLRx/xNjGAcYrd8M6hbw6esX20wWG3Ymfvk54P49zTm0u71e1jb7TfW9rMoiiUYDkc/Ox/u46CuM1C0fwzNLHLqct/YmcQiRgEaLPZR0x70QV5JvobRXNHl6nayXlpq2vOs8kdvZRZCvIcM7AcZHcelUb5ILi9mtI559QV/lG08KRg559KofZxM5eCMyWdv+7F0ynJPUgepwevAq1YXmk6Xo812JsTYYxbwWctnBruablzdyFotC0LM20MlvDa/bGV9znftGDz+lX9KEa3CCVyIycH8O2e+Ko6Zq0sWinZbsLqZ2M0zDC5PQD/ADxWtpyIsp8pQY7ZACfc8k4/Gt6T5ldlqT2Ztyy/6OIwVfI6r1bmnLaGO2E0Uio3IbJ4+lUVlaWcukax454B61aRxIuWVm9gMAn1Na7kEE8zSyKzHcMBQR39Kuyq8coW3BLY+4w5HtVKV3eY7wN+c4UYFXUmhsV8xvMedhyAeMfXtUuJTIVaRVAKybycbmHA+lXLcnyw0Lbnzg47VHAz3j+a7BVXgbeFAqZlhN4I7ONlVxhl3cZ9anrchuwxod4knlyOSFx3PrUBnCvt2h3AwOM4+lW7mT5tqqyrHxhjzTfJhNmGZ2+0gkqFHUD1p2uwTuQyKGiHmPl34UE8VWldCVjjA4BIyOnt70XUqSRNJJtjYY2oAc/iaht5tznzAAgwPrQ0+hso9S5p0CqxedwjP/q1fjcfr2FV7wI1wWCsqA8nPf0FDzeYxTyg+BhST0NOa1fzIEcmST7wRB/F2z60PbQG9bmBZhbiLe0iqOoDcc9xUUztGd2PzqrYwstwWaQAdhn9au3kqTRqB/rcYLDv6cV0TiKS1HW7kQO5546ZzUsDLMrAkIcdz1qDY3lM20yMR90nGKnSMRqA0KPvHDDjb7GputmQ7FG/la1YAgiQNjaTjj1qOO9aRRsyzucMQegq9NDHcI6vA5kBADk9B9O9NGnG2ETAqI5ARtQ88dyO1ZySvoHNGxPbDao3ZJI6n+lWYQZGQKAdpzhulVUXbtEfrk57Vs2jRzR+W4TGOnT8c+tQYtjE8hmYyQYOPm2HGDTptmE8vlSeAeOKrTu28qy5A4HFFrJvJy4BHQVd2tCbF5LcrHkg5bqR/Kqxnispcuflz90jmrzzL5QzuVgMhScEk1Q864gcMwR8fwuoIFWldCXmT3CtPaOMjplWz2rndXgngt3jZlOBlSCCOnWtyOUrw21dxyIwP5VzfiIhQrFcEZGDWqV1qVHVnms93fWVpraeYzw2kDSrK4Gxiev1HOcVyfhi/OoadbTS6gLKwiLSpICUYXCj+DsDjjHOSa6Tx1dDQ/D14048y6mDtDF2YYxn04zmvIPPs10DRV0e4nsr2S4K3PnSZhZ1wVkwemM9a8yrSU9Eaqdjptd8avpF7bQ2ckN3CQZA06h3hYnksBjJ68Z5rs9H12w1i2kuYtfjihdkt5GlTygjEcYUe5/OvGNR8Ptp146anc7knj82zuYBviuMnlt3oOc9+OlSaVoupXepRaXpF3Bdy5a42wykKCnfPHPAxVU6NKDvbXuZuTlueqR+DdR8PW0FnBFZTXt5IZjqcm6SO6+bARUHcZyScd6wdcu7nRvE0/h/xrqDwG1f7QJ7f95FO/DQl1H8IBxj8/Wu+8Iwaj4Q8PzQXF39svJt0ha4J/0acKCQOTkE8g/jXT+BPAHhnUWvdV1Wzt9Vku4lR570li0rAs5UexOM9sVzPEU3NxitxuLjHmbPG9V+JkkGoC+0HybrWLtSk5EDCLPRSIzwWx9RXYaL8LfFXiqFZPG3iRdJ0yVPPext+o9AyDCKfzrqtStPAXw/tIdTht7WOfzvJBRCfnBxz15GfpR4X8fz3/i248PxWqXsRSSX7cwI2DHyqw6fjmpc1CSUVp36/wBegayi2jB1HwI+nau/hq08SXT6bPEstjEiciPjere44IPYVu+F9D0bTZNOtry2W4k84HZLN5jvg8Oc+/esdtSc/FGwis4i8egWM8995ZB3NIvCjJ5PQ1mWXhy5vPEkWpxTSJK0bTQbpy6J3VSB25OfelVqSbSV0v8AMcI3WrPafE9n/ZSf23bzS/bIx5Imt0wZIzyF9yPSuG+H2uR6lqF7q00ks5+fZCBjy8HGRnp7itjT9cu7+20+ymlu55NzByVCCMKCCfc14R4t8Salovi+/wBMt7UxQvOszCBDuLDO7aOOHz8w/KuinaqlYyUbXT3Pa/FPi2Ox1GKziKPc3gBCHPy89T2BrY8UW2l2/wAL7+4lQt9oDySqpO9nPA3d68u8LobPQNLu/E8YurobpLVYZxuUL90MT16jua6ixuJNU0PV4fEDfZjdB/Ltw25kUrjFZe7Fp9Hp/wAE0cbrToa93pGuWXh7S55GC6lFYpFI8ZwigL8rBe7YrL26PosUwWzdphEryXbL5h+b+FfU5PNangTVLnU/h6dI1DU4jrGlStaXU7vlgiEeUxGP4lwOfT1qLxjI8TxSLbQGOJd0MEAIZ5P727uPQVNN06Tk6j2/4YOaU7QRBomnx3rTrqsNiYmYRJE4AiIPTPv1qbwt4Rg0/U9XtrXUJl0u2m82O1SYiAZGSOeSOOlQW89rpPh24v714EXynmSGdh8zKOFXPV8jj3rR8PW0sUMOp67bW8N5fxRTRI8uGEZAO0juw6VjFe0j7qepV3G5oeLNft59MuDaXgSefbbuIn5QccD+tYeqX8UpuNOisvtsaoT58o+RAq/M5PYD86n17SdLh1uW+1X/AEVbqP8AduhIy2ckkdv61geH9LQeJ7qOy3XMb4mVjISscIOCrDvn0qruLTa2f3/1oVDl6Gzdb7vTbO5hlV7EKislvJu3dj7YI9ahjNiuos9jabSG2sScqhA6c9DxzirGsWP2yQ2uiNHFGSQYE+Xy2POR2I/lVe3hvLC0ZblbZnhUQhx3x1JHc+9d9Npq3Yat3LVjcXEN7JAlvFJGUefc52Bj7V0Hh+J7mOQyuSzt5kjAfoK5+2t5XSAT5BOcDPAI9B1rvtBtNtur+XmONdzHpuY1tBXYSdkSwbV3xzoTmP5ccYOOM+tS28sUojg08sS4+cSDAUDqc+lQzwbrhh0bGSwPQVWHlKCkAKpnls8t7fStWRuXNkSS5jZnUZ3N03n1qFITc3GSxC9cHrikXGz7/T+HH6VPEPLgLq+T0Kkc49ql66Bctlvsh2Kyup9B0qGTb5byFWJBATacEUkVx5sbRKWILAqpH8VOH+jCSMPvmYYYgcJnt7mp0GkQxOqoXkGWPTnkeua0GniaFIEYRcHzHP8AEPY1QWXNxuwoRRtUAcD1+tXHigMDSxHZIR80bj7x/wBn/ChKzG0kzNvgs8ixwb2UfdB5xULWhXaucwkZOByK0WtxbIG+dZefl6HGO/tVMysVADsIUztUnoD1FX0NebSyLcU8EUSxJCkSqPn7mQ+/tTftEogMbLsVzvyOCPTHtUunxSTKXeFWDLtRmO0D3oaG1kywl2AL1mBwcdhUWM2cIbvy5N8YA2nI3LwfwrVt0S6HmyJiQ/NlDgflSPFbXixDKQXCpj5hwxq3o9nLcXQsywguP4AwOG465ra6tqEpJrQbHGqRyFDkHuadb25k+UHHsKrzRzWsm2XKjnkjOfep4JyoyrDOKJWvYyYGExPjOfXNMuUIdWPDdwPSnzXGeXHHoOlMifzE+bOex9qyv2FcHsY3jWWOcM5wSgyCtTiFiQkh8v0Y0yBTzk4znHvUvmqFAlwRjGDV8quS3YgNwY3MdyQeeGznippbUEtNENsTY5z1NQxQLJJtA3KwyFP8I9qTc0DlPvqOcHjHvRYZZnnkMaLdK20cI+3n8+4p/lvHaJI0gZOuPf2otJhcIiHzJI1+9G54x3xUstyYLWaBButXPyhuq+mDVJ2F5Ip30IltMoxUjlW9+vWuQ8U3LNpyRyuVdHwZCD3Pf1FdPPI9zYIMttVvlA6E981wvjWfz8RK2N8iqMHHeic7K5cVqjh/ict9OLjToVjURW5eAk/M524ZV+vJxXjsNk0+h3ME09qstmROsbybHCsBuIyMN24HNevePtZS0RorWR4r6SNmgkJHlEjgqSe5GcV45cPLFdLDfiBoZ0jSSZQGIHB3BuzDvXHGXvtDktEyzDqzWeiQabehbrTzObqBopNssR+62Cc7QwGcY9DXWaXf6B4I1i01W3sNQvPNj863kkcAgEcgjHBUnBPOayPAumadP4h+1iCe4061DylZyoDY4UHI5Pc46V3b6VFHqH9vauFvtLk2kx7dirI6n5CD1CjJNZ1qsYvkeoowvqaVl8R73xJOn9h+C7i4tY1YSTST5YDvhtoUHrxyeles68W0uC0g0G0mOmxQAxzRchi2CTn29a8z8NfFjTdVe+8P7bfTICgi0xUURRFugVm/hHvXbadpmtaB4e8y3nTVNLKsZrJrjCxzMvDRSdlyeVPB68VlKj7Tf3WzNy5dD50+IGv30PiPU7J79b+18x18p48LHk5xj19SK7D4MNqOoapaXN7OtpYeW6CKI4a8IOBkdwOnvijV9J0iLU7a51mztrLU7uJjcQXI8yGJ16MsoO07hzj2roPAnh99PaLXEa1GmyjyllDrLLFknlFHQH0pVZezjyOL6amtk1dMo+H/ABLaWdx42kuxBFq9xqB3iKJsLCB8qhueM8YpnhHU/F3ifVbmLStIsgzMpkuLZ8DgHIYMfmBB6DGMV0ttotrrfxkvbTRdPvEtPsCR6nKriMRzqdytkZySMZX3r0TTtOt3NtcNqyW8tmWESW0arl/SQDqSBjmtZxgpcz3/AK+4x52lZHmt5d+J7VBDp0Jv7wg21vZqojMYHDuO+a4L4i+P9eV7vw1qekCzYRLCVlG2UHpkN/dIr0b4meFNSumij0/7XaMC9+1/aFmbBHKlQcgk4wQccV4V4g8O301zO8U95qEiIJA0xLPswd27J4INOnywlyy36ehS95XRKYNWtdK0ueJpL/TVYva2jqzKjHlu3OMc1638KZJNS0/+2L2SK3UTGWS2B+afHVizHAAxwvfFc/4J8J6nceC7ddSS5lkW48y3sHuCjJwGUlDjEbd/qKfrdhHq+iCK+lTT4GbfGbD5oiQSpi9ODUVo+9FVF8zSDumkdZ4o0C8GrHXvBWpxw3UtsZJ7e4Hy3CDkBx045waseB76TxBY6PdS3t3Jf3+UeBIR5dsUYhhubpnHQc1a8GWBstHLxyfbJCqRJGBuKAdQx6fWjwbf2ln448T6Vqsc5uZrsX9kwO7ZuGMKPr6VyynGrFprVW/r7wty7FvxbpEMviTQNPvQqQfahKGdRI22PJ4HQc45+tdYuo6TYxyx3vlXFwrsIGZeeecc984rk9OtPtuoa1qN9IzwoTp9v5ecvzlx6jB449KrajoCR3drPqOuQxQQECK1UZmfHICgnLH3NSvdTklt/X9ehSs7RbKPi/UrS502/uZ5ZzIrRhlVsshXsP8AZycGmeELe8tkN7cWNzbLcxhoJt+OGyNjA9R3rqbCBLmS2W2svsMCuXnjnYTSTOBlWcrwBz0rkvEniS81Ga+0W500i0cZjkMhDR7RxwO5ODiumlSU0nN/8OClvFL/AIY6fTJrLw5ctPf6pNds0RWIrHkKo52qPUnv3rHudR0/UtQGoQPPsZ8mAqQVPoR9as6HqqaXpFrp97ZJOgQu91cMd6gDgD8fzp2kiKeN47G3cXFy7PK0g5UZ4Fb0qCi79WNO71N/w/CrS7BnZ953P3sY6D0rrreR7WFvJ+XzABg88euK5jTI3todixsVzzJ156VuQZQL85OTgn2rs5XFCki+syqOFDHuzHge5qNnNw252GfugjipDCyIWURyLgkMTjH1qqBkFmGMYC4pvUlJMUph8oTtB6E0TXTM4WMHaO2ORVmAGUiGLcu7hmIqzcS2thvRoRcMcZEvY98GpXYr1KmRH/rPlYjjaakMyoRDExaQjLsRnHvVVQtzIJWtkWMgjYCQB71VkBjYBZOBnLHg/Sp63KSLgl2MGTB4xwMVJ86Kk+8cNjcOqntTIjG9pEiR5fkls/lUn2S4uFKWgMqIMtjjH+NFrjHi4mupmVSZXc456sKbs+zu/nbQwyoPUZqC3ZrSXBUohGC2Oar3Teawi39RkgU+hSXToaYvWuYtskpKHqBwKjvbjzSFX7g4GfT1qrFGUUKCAU6kHrRHGrSM2SFHQdajUlqxkT26CR1AbAPGe1WrG5d3SC7nZ2VT5Tqcso9PpSmaS5VWucF8ctjBJ96zpbYG43AkEHjB6n3rpTITvubcV55qPb3QBwMAnoKrTWckU26EF4m6M361HJGREBHhXPG7vSxySwsUYgr0xnPNKZLsiz9nkCswJIIzgDgVRjlCyEFgDnIya0yZJIURCwwOFFUbibzCqXEY+QYD7QDilFdSFqXYZRs4Ib0Hoain+aRVIBUnGOmaqW0m0KwkHXoe1WGPmyK527BwMdaG9bIVtR6uElznAHQe3pVlhDdqWRSrY+Ylun+NUNQkWN4mDFgTg4prB2i32zhmXkr0OPSnuyuXqWUkMDsIgdw6+49MUySR5F5YrGx5Y9qo+dN58ZlQo2MgVctkW5LsXJTIbbjqaVry0FbUxYZX0/UcFz9ncH5W6Z9a4fxxOiRx7ZVE6yb1HPIz2r0HXtNAl821kK46IRwwrzvxPcfbLkLKsSeRCzA57+me5pV42WnU0j3OG8RWEWpvam3SW6lMjFVf/VyR4yeD6EV51bypa6na3NpEbSFNqXMjIsy5LcuEb+Hpge1esfa1v9PRHlS1jtYW8mb++erKPQn1ryuO08vWzp2sWtx5TSB/kdI3KYJABJ24x71z8ummo5o7Xwfo+tQ3l9qkOsW8GnRPIytNas1vIrclvL/gzwQP6db1qdd1jwd4ivZPPvL2acSxxCLEUQC43DsDszx6e9Lo11ZFLw+HdRvryS5sWgEFzEY4zLjaAT0ZlBAGO1N8Jah4n0hbi3vJpb1Y5ltZYYXBdSoAAYnAIwe/pWWJjeCm16/1+ZMdL2PKEmM2pWtzJawygbWNvGpAkCnBBA7nBzX0l4N13xfqVnPcHS7G30dkUf2aQS0gwBuJPRe/4Vyng+PTLLxNOYNID30YeVTdCNFR3HKKikgjGMV1PiHxTceE/D9ml3Gk8ouiXSNSvmxsMmHPQEZ/ECspTdSzS9CJK2jO70nR9G1e1vxLaad9o+WSZXQMjhR8oUHO3HP5muE1fRfCVjaz6vB4dvbM20UrQTRb4cSL0dwONvTBNYVj49k8SSRHwlpa2WqTSiAZZgoPUNgcOQuSQa9l1vVLbw38K3tdcv5NYvLpPsUSKoR7qaXKhF46ZPp0Fb05SSSk797mEtHp1PGYtVn8E/BtJdOuJI9dvnae/wDNBWcSMeGOe2Mc9+tY/wAKPE1xqmpsn2G4jkX97dXFvPtikJOC8ob+LnqDXoU/wo8KWFpp0vjbUb+f7LaLDJ5cpWJj2LNjIxkgfSrN38L/AIemOzbSrbUvs4UTzH7RIsM+D8qHcMMSfTtWH7tpqb31NlLsXtO8W6bb3euaU3iazi1CQK7RSzBIoRjaiq54Y9CceteUfEvxhNdT2tjYanpV1p0REl3cQwEp5in7hYLzkA4A6+te0eINP0LUwkknh7Qbx4o9qRywKWTjO3IH865Dx34v0/S9Pi0HUtDW2tLwq0Mf2ZVjJQjAGOO4AP51vSqxcrQIUWndow7nxRrPiLxMdc8P6FqerE2ph2opjtVA4LRZwWBxjBzjmiXTodb8Padq+qWklrp0W90ihAUCRQSyOvbBznNdj4Z8eRxWVhY2ulzWcjoqrHLIE8lOeM/Tp61d8R2dl4lgnstGaxbV7seZHvlKRqOjSyICd2Ppzms6q9q2paW/IqMnTtY82t/HTJK9p4cWF3jHkncSiDOTxxlse3WpPEGoTza94NuvCsj23iq5Us00yECOFgULOp7E9PpW5L4C8X6Pd2uo6RaaJdXFtFuaPPNw3RtgP3CQOPSt34Z6D51he65qYdL69ud05d/MaBI/uxL7A5Fc8EoQ9ovT7zWTjfQtXOg6zpeieXJ42lhuQSssrWUQLHqSuePx61z3hGOy06CfUbzVn1W9MhQ3kqAnbzlQP4RkYz3rmvGd/rXie2n8JadpMotzcM73TNnGGyAF9OgzXKaZ4K8TQato9uZBBDECd8YwUOckPjrz0JrX2MZ07LcItp6nrDJqcNrqNzp+oQwym5ExaPLtGAOp7Yxjg+lZGl62t9dmOXMzuhRrlx5W7nkgfjx3roIzp/hTQpvtzm4uLlGimZRglm5JfPT2rl/B8umQpdNdQXDRb/3LMxJYnJOPTA71pCn7NJLcd+a7ZtalbRxR2dn9va4ZiSWV8gL2yB6V0nhvRyyhPNJRMElerDtzXM+Ho4Rd3Zt7fMb4EZkGCpPJ4r0fTbabTpXiYqWMahvQHriuqEXe427aI0hbRSeXGswhDHaSRwuO5qII1u+JSGIbAC9D709XTDK6gBhz3BoljCRq8chlXjPy4x/jWzWhKFeUsVjQNyDgVbjtZIo1Dng9fTNVrYyMMhNjZyW7/SrF9cYiySS/oe1ZsduhHf3floUhHyr0K8E1RVRJMPOZjkZB/wAaDulIOQTnAXP60yR1idQucbec+tS3c0US+JBgktjpx1zUMjCRgDjrzxVWOY+WWwCvUhqv6dGJT50inZkBR6mlu7CehJBGRt2rnaOh6n/69PjumjdwpxFu+5ngfSmXbNGp6jk5xUVojPGXmYBc5G7ufU1e2wlqaK3KZYSLGxdAv7wfd98+tVbLT/7RuZDBMsCRru3OflFQyASZWIFgvO4npT4LcQxnzGIiXkhTzUbjWg+7idrpoHI2jDEoQy9OxFMuImhj/cPtZcHI6g+gpA5ZlEaLBBjdubgH3qYyx3BfyCoCgbSfUc5p2uGu5m+WIwoHzHHP+NVTGEMkhHJPr0rRiMMs6rNIvHG8nK1HqdpKgYiMeUejKcj8K1i20zK5FBOJQEIIx3FWbu0iRImTeXbnDf0rOs5lgcg9cgYPf6VqTyCaASeapHTaOCv4VK7MlvUrW11Na3CTRJhozkN1H41MsstxNNLb2yziQHfEVztz3FU4LgBXTIwW5z1xT7mVScwM8TYwwDEBquLsNMiFnHOpVZNkmPunt+NRsLi1RVliJTHEg6VGzlXwx4b86SS6kVHRiSeoXGaLJlRVxJLxHlT9wrhBy56rnrioYkma5EiZHzZ4ODir0H2e5RNy+U7cM0Y4/EVceykhyYiJ1HO5B2+lO3KgbtsVpbqT7lxBG5GPYj8agRh5oa23LjgoTnNSXEhdQrAM2MHsapvBKkYkjJYZ52nkH3oWuqJRq3TXFo6GfB8wbWRhyPQflXm3xO0u2glikt3DeZhyg4GccjP6V3N5cNdL85JIweTkg/41ja5bz3AafZCdowEIx26gUTTkuUcXZnh1zMNRuIbW7ij06NGbDopIUY43eoNcnrukLc6hBFp12l1FnZ5uwqFbPTB616HrVmDqSLM/+jrjKlec+nuK5i4sLMalGVlubazMgEiqc+Vz1HvmvPjNp2aOlpNG/wCH/D3h6zTRYoNV1C/1Q/votPLfuVlx83A5B/nisK88Q6zp3jLUbW0tFtZpWMl5DcOv7/YM5yfukgdKntvD4TxLPNfSLBFbOskDQym2llz3Q8/N3Jre1K78O6TJLb3mm2oj1QshubrNxJaE/dlLchgecgUTfNJxlr5GElZaD9B8SXE9raXkVjZafaXUhZYRy1zIp3MykjIHy4x3NedeP9b/AOEo8a3UkiHTbZ32rHI5IQgfebtk+1dpfaHpWuGXQdH1Qy31hF52nTxyFbbnBZFJ5Oc5GOhz9K8wlMUN1PDfWE8l9saJleUrtl6BsYyfpnminTjGWm5m2dt8Krm20LUjfT+JLOzeOVRsYGRJgfvBs4AGB971Ar0vwfqF14w8RWuueMrtbLQ9I3/2OJYisU7jgOWPGMcg+v0rjvC3hLw7oQ0yTxBqNlHqdw6ERXcXmKrZ5XHTAyOTxXumq67ZXujajpEV3Z6lFFbFxHFtwmAQRt6YPQYpe1UlZbMiUX2OO8a3fh/xNdPZ6TrLanJawvNOYlZo2IP3Vbozgcgdqx9f+Kqjwnp2m6a8puZ2+yxPejZ5KjA81j6jPSuOuNenuvh+GtGmsr2KNw0Mabfl428Dtgda5HXtUbX9Gt7iaaRUs0O+TAwZX/gC9ycZ3Z6ZrCmuaW2mxu4qMUn6noehePtbs5L/AE+0Vr2aIg+dBAGjC/73ViTwD3rhrJ9R8f8Aih4tZnS3kiMs0kpBH2cAZI29OuBjrXJaZez2DOySTxbgVyhIww5Ujkcg811/gNZLi/1TT7hrbz722DuZZcySvkOAp6bj0x7mu+jSjSVomTbbudL4T0f/AISvUdTk1m9MWjxRi1CM7M0rjHzIp6Ngfqa9o+H+n6BYR319pOm8xRC2maPqVRgAqtngDv0zXkfh7Tb/AMF61Nc+Ib+wsr26Ura2JbzVzkF3cjO0genJJrpPO83Sb3+x2uJreePcJVm8vF4SXLHOB5ePWlUipL3iXrsel6vrun6ZaXV+l/hJ2W3jjYbjC54zjvXPeHvHWnaO0eiWERunWWSO5M6mNySC/mYP8LdciuD8Hywa7rUFtda1NbGJllhvZh8suGywUEYIbpWp8WNYi8K+LrbxHpVrbXH26NYblJI2+eNOGYD0xgZ9cVxU6PPBq3n8/wDhi9FKxsX2rWmo3cTWl01hJKoeQwqGVoeuM9c1f02a20xb2GORt10FEUsoxtU9hmuI1qe1huo9duINOtLCaIxWDCTeRkZX5VOc9eccdKo6dqbag8k99dTiONQUhdeAcfeA9zzWmHpe+m9bGnLzLTY9E1ee6vbc29jao8ci+U85YMJHHdQeeDjrXDXOnahaasBq18ksoG4yK4Oxeh6duD0pkviSa6t47e4SQw+YXOxeVJ64Nafg7QG1K7nvBFuhjxw74yPT39TXZGPPLlSNKcHHfY7TwdpSvGLm6l2I2WRivJ9CfqK6uKGV2yZPLQjJB6kVBpZSOCUMm8j7pcYC/T1rRMgEcKLuD4zu/pXQ0uhlJ3Y+b7NHFwGfI6sarI7TAHkRg49gKs3UUVrB5k775WPCHPHHU1RF1C1s0puVLK4RYR1I7mk7pFRi2i3HcRwjL5Zj15xmlYSMnnTYP90e9ZAuYQzPICRz3pYb/wA6386OQeWT8objFS1c19k9yea4KT5l/wBe3BHTj2p+zzslweOvtVBT5twvzk7eSwHf0p885SQrC5ErHkA8Coa7luP3liYozqFZhngqR0rTlnY29vaxqNiZfOeuaz4ACEj2b2+85PerkaxoVLlmB6kdqlLqZtJEiHe4MhLMBwo5zUxHnuPtMixNnjtn61LFMsKq8EeVPHPG71B71TvbmJSPJUru5YdcH29qpK6JjqWGmt2zHbp5aIPmYnlj7+1BJKDzFGw8rg8Gqtm4Em/BbByBjgGtG2itd7z3ysAo/g/vH2qWEkkZ955jKBN8o4wO9NX/AEdlMbEMB8uQKsCVHuvOiICKcJGec++OwpHCFDuT92xBJ75FJId+hQ2WavuaIohbhIz2+taTTWwKxQXDCBhkK+cJ7VkxzBnwEDexqSSJJF8wZRweVxit9jD1JLnSHws8RVmzjCnd+NVmtJoiWb5gTjI9fpWhbtJFh4yUYe9PuXjmtwY/klXO7B4Y+uPWjlT1JuZk/wA8heRP33cgYx+FRGWJoxHKVUg43gdKt7iyne2W4BJqG8t4iMoqIcY+XvSSe40MMUXlsxfJx1xTre03yBWdQCMq2cg+3FVrpJYIw0i7VI+VuxqJ4WMIYTLGVG4Z4z+VRG/UtEt7aXWlkXDmPyn+bCuCSM9wKSzv5HDFJByOgqlJ5kq/Pnaej4OPoKdPbJJCm8tHOMYcHAx7itXK+xTtbU0pGlcCOPr0y3ai0j8hQAxUE8luRTbKK5QBYgZk74HIHrirSOsiSr5kJdDhUYFWIq4pW1MyOPyAjRzRB5WBKSZ5FUdRvhKFS5jyyHJYcE/0qeQs4OADg/wnP41cWxhvIkW6hYxtkZTq3/1qdrt3E9Hqeb+KdDF2RdWWHAbzGjZcMB9e9chHpqapqaHUkMNrET5jqoUYAPJr2zVtEn062a5t5hNbONucfdPoc1wl/ao1lcAxsAEOCvPJrKtTjutzVVNDyvxbAJfENlc6bNNcW9uFfA/ebApzjHdf512+vT2Pi7wtcTXFraWkNmjI9zLE0MR5HAGcg579K5++e2ttEa6tbz99bDbIqHC5HTnrnnpWR4319de8H2y6VeF5VUfbbUptcAc8HuAR/KuT2alJNhLyN34da9o+lX81jqFxbwjTIS8Eqx+arxn5id+eOW9M81y3xPu0s9fgkZNNuoJNkhkXYbgruDAMByhA+X3FUPA3hvw7qelXFxrN9LBdBwIY8hUI75J6/wBK9Q+Gvh/wja6PLd6nplld3RuGQwMwl2AHCjJJz68Vz1K1Og3LUXI3qYvjfwp/wlmjW/ibwpbMbuBAzrj/AF8Z5UgHjcvT3/Cur8AeBV0HwxJqv9oJc6vcws1xtkBjTAyY+Odw71v2WknS9Rmm8PapbRArJI+nT5WErj5FHdMHuKwLGfxGNI8zVfA81qJ5JGN7p86uGLHI/c53EZ75rFzlOC5Ve39fgQ5W0ucq3gq2uPhkur6QJLrU7yMyzb3KPISx4X3XHTv+NeNDTr9rQgRzOiO2YVyWjYAZLJ1HHf2r3fwr4taPxMnhiPS7u7S/l8y1S5zA8EnVwQRhlOCRg5HSs34g6cPL1TVNRZ7C/EJWDynMciIrBTG4HDk54/8ArV1wlLS+5PdHkWk6PLqMDMsxVCRtjzl3PGWC9wM9asRWE8usT+QJbeS1wdzArIwHGcepruPBtzqej6ck1za6WNMYlWhmKpLEuMhg3Xk9fwqDS5pPHbxaPb6UlvMZSi353OUYnIOeDmtW99dBG746160s7KO902WKS6eNdxvIBuhc8lUUnIYjq3pTl1TWbnwjcHVrQ3ljbMJWWGALbyxqATGWzu9ecVry23gz4eX/APZ/ifTLTVbSJ45Yb+CHdLKx5IO49iCT2q5qviXxH8S4p/8AhErW00fwzEyoWukAecg8lcDnp0odtFbQnmM3Vtah8X2WkrFYtGtlGDaxW86wBePuOeoA6cVR1rW9MvFtbSHRftJsSX3zO0kUPqFcnnkjgcV1OneCEh1pHkgY2MyGORLrYFB7s2OVB6gZ5zV+Xwz4etN5ea5t/nJNxEpMUaqe46AHirklRs5f0jWLSOU8KNptprlte3mjPHbOBHFOWyu3dlzz2zkg+grc8WDSLTxW5gjin0qPaPLSQHfk8kAdcCrmvW2lXNrfW2qarao6YW1KSD88dB/jXLNpkN3qdjY6IpjNuSZJjzg1cvedzSLU3c20tYPFGuqulxPb6HZkn/V7CxPrivR9Hs7a1EKPEGVeSucLj0qp4f0ey06wWEKxfqzZxvPqa1Y1iSU5jLDoMnqe1bwjyq73FzdF0JjCBE/lmPZv3DjLJ/s57inoTGjNuBOP4vSorm5HkrDkhE5OCDzVeS4XeqYUnvk8c1PNdiSbIbu5kVy0WZnCkMpJPHpXJFruW6uYFdIJkIPlH7xY/XoBXVmcRmTdGroRtZxkFfQg1h3tm8txcag+XuJ2C72OOKmVSysd9GUYqzMpb3ULm6ddT2zbD5W3IBVv7xI6109oVcLIhDImBGpHGR1zVC80g2csZljIZwX4OevuOtaOkbI7dUEaswGcscgf/XqeZ2saVKiavEvCb5NxA4OSRxUdmgEhnIBY/d3U6eOS5QM8WIlO3KjqauWoiUiQg4HQdqyktTkbCKRuecY5NXZZTLaRYiRIEzjaOWY1RnPnSKqMAvVmHpVmFcBQSTj5R6U1oQ+5LEyMg5KuPfr+FRmMEMVIOTjgc0/yi7BVGM9MnHNT2shspknzuKnHNUmgT6lOFzC4zjr+VSXFy8mUD4Xv70XgF5cOyr5TkdF6H3xR9jMEQOd6k5Pc596lq70HdPVkdnPmXag5H3QakkkeR/Lz++bPyDnmqM7xqicYbOPzqazYRP5nzc/dNHoVa+pl2V0ZFIDgN1K46VpCYiEHcCMcGqTaZLbTSS7W2ZxkDIH1qW3mEMqOVDop5Qjg+1ayTOaW+hoJOWjUMpA6ZqteYh4fcCD0PWpJQkrF4lCK5+Vc8LVS5WZ3zKNwU4PPP51WxKQ4zBolaPnB5GME1JJfFYT5kQb+HJHT3qtGNkYkbJ9s9KkWeK5JikLxsejf40bFWJrSSNhsuEaS3zkpnsaS4ht45MIwaNjkew9D704WskakE5xyMdPwqu8Zy/mKwXqDWbk0RcWDzGcwByUzkJ2Bqf8As52aSVvmx2PPSqMjC2QHG1W5BqS31KVYxt+U5zknrSuMsxI8wYwhjIvOF7CmzW00aZk2c985JqOGdJpJCzGJiMBh/FVy0eGHi5Uuyj1yBWvN3E9DOEgWICPdG+PnOeo9MVZg1CW0k3QuQRjaMZxU01mkzubcgNjcAT2psKrHGsN5GyOfun1X1FHXUT1H6rfXdwYkupUbzMMobhFPv2rjbtkXzYySckgj1rrbq0uJlcQr5kBGQD1x6+1cbqFlJHM0bAg9QxPGfrRUV1YIo8I+IzNa67MsKmK3J+ZF5UehPvUeqWGkSrpq6NazXCFDHNMPuySY5K+ld54p8IXF68siR+b5hyB1B/Gs+2tQllHbxremGFSxtUX5Y36Eg9xxXK4yTtY61smYmq6NqXiHREjfy4YNPOI7aKP5skck/XFcleeH9Y0vRoNXt4LtLQNte4XgK3uM5Hpk161YWskEovdMnkt5o0y/2w5WTvsx1Ncvrni/WbHTNc0+XTLVobsEyXEZIZFc9cdPaplTqQtfWJEk7XRwlt4m1GGJ3OoX5vV2rFIZsqFByQQRyc+9d1p3xE8RX2k3GntqyzJOoM19cx7RaKTg9P4+OP8AOPMrOyuJiJI0kWJfmM207VxznNNuZLld6TTORMRK678hieQT7896fso/Z0MG31PeYfE3gHXdAv59fvLye+to1it55l8uSEno0CKeORk/rXluqDU9N1C7/sLWLrUorqMwSyR7mdlbB2N19ulcnLPJKkayOWWMYUHsM5rW8O+IbnQZ4ZbOKAvHMJSWXLPgfdJz0+lXCPKIp3jX8MqpqK3KEKF2SgrlR0GDXaW/iLVJLG6trLQ5rGYRxmZtMiaF1gUcHPJ5zye9Y914wv8AU/Eia/qsyXF3abTbQyRho+DwuOmBkmu78OfGK9uNfU6nbWVsbrEDXcY2+Sh4Jx0Ix60pTcXdK40jL+Guj6drum3l3f6aNUuINwk868YMg6hgo7djnNdZpWvXPhuyC20kTPuMYgs0JFum7pkjhueorm7cXN5qmp3mmauh0K0gea4NuPLZk6CMgdc4zgcd6snQtQksTPHqKrE0aSZhyRFv5+YnrxxUxld3ZSSOjuvEup6uL20uriWGymmyzOmJZMY6Eeg6etSW8Gq6jCw0rVL6e4mDGWO4YeT5a8LvX19e9VzolxaWyX7ahJcQAA+YSCQCPemaRNqVzrDw+HZp4Yiu+V22h2Hfjt9Otbz/AHis+paWnunOafp17q19g20U8kcjfNArNGvY5NetaJpSaakcUKR7iNzt33e5/pV/w/FJpVj5dvMdjPvYKAuW9/Wt0JG0e+/VsOCyyqMkEnq2O1bUqMaY3LoT2c628StNgn+FRzml1Jg6IysfmySh5A+lZs8pUbRhucZHQ+hotQ80v7yUKJCF3EdPrQ5MhLqSoTwY+M/eJp6TtCwQxhh1BIxyaPJdJJPKkBwSMBevv9KWSNkTc0pweSBzS0NE1cy72Vza3CMzqxz904waz7K5klto4pGVi3RQc4FdQum6fJCst0buRGBDLBhQD2wx6+9ZSaZbwEujSeUeBvGWB9celZS1OiNSNrDochUDbgFGCCM4+lTWVoZZwiPsB6g9/ersFiEdT5wDYBAYfeq6+noGRWJWX7zFegqYpmftNTTsUYRmBJMQDl/U+uDWdcwN5zDIHZSB0FaEVvCLd9z84yGB4I+lVreTbIGjPIPVuauW1jNMS1sLiOAztGXj3bSw6D60pTy4ty52Zzz1H0q6Ln7MjEEvuHK54qu16l3PGJUEWPlZh/hWaFdvUjR9vPykHt6ioLm7O8mF8Fxg5GcA1YvIISrTQMWiZtoPp9aqCGFF2fM2SCcjmjVFpIt22wxHP+t68nqPaonuAJTzzg47VburhYoliSGCQH7smCCPr61VEtufkmQgpwSOuaPISVxl1aRLHG3mrJIwDblByD/dxVaX7V5jjymUKMEkcLn1q0BMkiPbTbG7MR92rtw88VmtnLEMMd7Sg5L57k01oXzWRFZazdw2j2x8poGzncOv41jeYkys1uG2k4IP8JpL+5hktw7QmGYjDKOhPrUOn3cKRBcDBPzCulw7GCjZXL0AkiRtyBh9OtTR3UqWnyKrA5+oqGSTyWXa+8HkYPT61BcmRsuc+9Z35SEjU8PyWl1ePFdOsKFSAzLwTVxdOgMM73AyCfl24zXFxbo7jdkkZ4rRTUpgNoYlu1TzXepUk76G7EEiVljuSHQcJIualOoiMATJFIqjAU8c1m28qmFmkx5rYxnvTpZhcqsMwCFchXA6j0NUktzK2pX1Ga1mUgIqcfdDdD61nMjiMHcvJABbt9amNlHIWZuQ3oajuk8naMEr/F7VOjNF5EkkWxFKzCSQ8kqpGKu2qwTQus0LRyqvDqc7z71WgvgtmyFI3T+FX+8vuKd5+3+8Md/WqSTJaexPZzi3uQWDhApwRyC3vVuVkug0crfPgCKQdBzWNG5aZv3mB1IPQmtBLOS8+W1DByMlaadtOgNaklvO9uskRGSDjGev/wBas2/tjc+X55aJN3LdgfpQn2i2udsxYt05HatK6kieKHyST8uWzz81Ve6sLZmPf+G7lLWSeNBdWcXLSR8g/UdaxYXjiYARrsHBArqVv54TI8TbMjDKOFYehrPMVrOjOYlVuSWQ9P8AGtLu1kUpN6FebQ7e+tg00kKqQfL6Er/hXlPjDwk81tcPDA14lucSKHKsD1wcckV6jPptxHMs+nXLOF5+5gk+hzWXcRML9fOilgldv3nmHO716VTtNWkaQfc+a9QF1oWo2V48atYyv5iWjysylVbmNh1HpzWDfzJdXc9yiRwiWQsIVz8gPOB7V9KeJfCmh+II5P7QtsXcalIWhfYAfU+vrXkWrfDHUtKvViu7q3MToJEeL5tyk8fSsJ4eUXeOqFKm2/dPPqcSXbLHk967m98BNZxQym8a5Vv9ZHFEVdDj3yDzXGS2s8blXikByRyp5xWc6coO0kRKnKO6LF5eR3NvHH9nghaFQFeJOX7fMSfxqra2813cxW9tG8s8rBEjQZLMeAAKtadpF/qF0lvZ2s0kjnA+UgD6ntXcWnw91W0u7YWszLeBg3nqdiKP9k9fxpRpykvdQ405SOJWfUtFupbcST2k8blZIjxhhwcivSPAl3fakbh9fvJHhuI8xQF9oJ7NtA6cVqaZ4GvrS5ae6SB5JDty581z+fr1zXpfhrwwtgyXMLQm7H+sDIMgf7Pt7VoqEmtdEXycqu2ctBa3OpRJHudY4lIQuny49h/U121r4e06PTbZbUCC7ChiWXl29d1aEVnPcyyIkaBl6qoxketSyQ3CKke4kKOFJyB9MVtThGOu7FzLoTWtlF5byTqSyjAZgSGb0FPiYgCN0Cr3wvP0qzHM6xCG4DOqr8q5IA9xioJp3cDLA7DgHPNTczT1JY7HzkK7tsa/NsB/zzUlvBFZIqNGMHlyec+3tURuVQDdndj+E9TUK3LTfK2D82ee1ZXe5V20WH/czRF1YblzhT2/rV9fs6xF1kImB4R0yG9jWb9rWOJY7oqo5CFkJ21M9x9ljBt54ZXZccr1B+tTJPdDsTKoeOMxJsUn5lDfIx9cdqfe3DW5azvoUKpkKoxhSecgiqUVwYU+c4kPUHtn0ptzdq6nGHbPJJ5qE7ajWg+zVPOcRsGULnnqv4Va87bkwIdoPPfFUInwQ42gEYAPBzV9pIoyrxI0Zxhlfofoa0SsrmjsiWSRAhZTz0KjvUflE7XfMZcZGBQkiK7ZjCAknBPT2pLm6VpAuMqAMY61KSRJYdwYtpjzISMPntUDwMkjIjk7uPl5H1qSFmC7udq5OfSnrKhwIN67hh8/xVF+oJ2KiK1qC8ZyhXDRnnd7/WjzW+z/ALxG2HgAjnNWoojcyhYvmYdQKS62WsQLshmfgRkHI96cVctSuMjRV2idSZByzbvlA7AVNDZtdyZUgoAeegIFUeQMdulXPMkGFYbcCk1qErobcgRxjygWVeTiprUYHmNkkjGD0FMUEOJN5Ykc4qCeVmCYZhg/d7Cne4lroZaMdS8pJk3soIBHBJ96pDS5raR5svs7AjGasabMyyHjAI6+tbNzrkz2wgdEMeMbttbRd3dkObWiMaWWKOI/MylRnHUZ+tR+bMYzxmNhkmrDBY5VmIRwnRCKUb7qZVMZUEYC9BWbethJkCQCRHKuQM5psVp5c+9txUAHPrWk1mYlLIXQ46NyPzFV/InVt5b92ecZ61pFJagmX7SVoMMI1KnjbjipmitJxuimlW4J5jdeB75qCKcCNTtzg8EDrUT8yB93JHQGpcuhkyVo1RfmxsVvvD1qjOy3EZVJVyOMMcVNIDuILsM9VI61FHY2zfIvmsSc59KSVnccbIpIUA2sT15Iq22ZIgYiNg+UZPWpG0pkc+W0j2xHzHH6UkYjR9iLwBjFWVIXytpBUFiMYA6ipIbt4zvDFXHykHgipxE87+auEkPG6s/UbeeKSN7hSu4nac/epPYVrmgLo3Mex1jyp+93qMsFAYw4HTg4zVaCLkt56h1G4Ke4p0l1LMEDnKg4GfSkk1HUlxLcqwKgD7wG9BWQbpIbooYFlhBzk8H8K0/NLqBJhgo29MVlahHCxLRjZ04Jz+ta6sIGlNNctZJLDcgwzcvEvGzHQGsTU4hLhZI2IByjZ5U+9W9LkT/VzkBM4OO1aV1bWnlrJEzq3TPYCrjPSyKT5TkpLPDRIq5Z/wCIjgVT1Tw4NuDLuXIyV5K/T2r0CxSyFuRezuA4KyAAH8awwghuULqWjUkbSf8AWLnjFXGVlY0hUZycWmRrpskSrK8RcGTBGMAenWqf9nQZjjs0bYo/dllG5fUfQ16K2lWlxJLLaS+SxGdnY+x96ii0SGdJJHk+zXAX92T91z35rSNe2lrlRxFjBsbOO1TzLhEmlmXJYLgJ/ia09SvxfLGk5RljxghAGHtmq11E9umx2DLwcg5/Cq9nbLcguXO1T0P8/pWcpvW5L1fMy/Y6ZLKoukTziCdoI5xVu5k24BVVYDGcc1OlpIbYLHeiI9osHrVd7Sa2lAvdpZm45zketRKoQ3cm0ySQsRC+12U/ODj6jNaEVkkEQkk+dz0OelQwgLH+7EaoOmeaV76OFxGcyyHjAHAqOayuZu72CW8kLLGT8mOF9KhFnvBZXEfzbmbGQBU6zbkyFQlj3HT2olVkG0H7/Qg8VMn3HsULiwHmkQziQKchguA1TSQGJCejsecDtVu33RAM6qzgghSODUrlJg4CeWxPAz8oqH3KuzM2iYeWZAyg8Ky8U28gW02okyszqOXXABPb2rQlhS2gVvkYtyVX+Gqjytdw+TLtaPHy56r+NNO+pUZGM1y73uy4VmVOCN3XPYH9adLI7OTbr+79D1H+NTG0KEKE+Y+tXPsqxhTkZx1qU9TVSVyC2d/MUsu9cZGOgrRhlTJLru6j5uRmo4LaSTLoreSvDlR90VatglupLlmcfdOOtNvmZMpXGCCediyncAuSP4setSRNHEgBj3yk5Z2P3fTAFSFzFmQZ3HuOPwqqZw5Z7Y4bkFTxzUW1uw1ZYaWQcAAL3Pb8qYjqxIBPPGRVd5DHuWfcCSMqRSMyJC0i5Ld8dfwpPXYErl8ztaKWgkIkb7zDr/8ArquoabE9wWZs5G480ywbz2LOCUYjgcYpZ0KsED/KfWnFWXkXHQljUvkoSQo4zU8O/wAvazlxnIDVArMI8LgKvXFS2z7zlgSy8ZzyaGDLEgEcRAIOeuahW3a+uY7dNquQT1IzgZ/CrEcR6yfOx5AB6fWnxyRxxboifMJ5I4NTa7JWhz7W6w3eYgwQ8Dd1/GrRhkufljXJHY1cW+06501o7hWS/B+Vh0Io06UeVJAcLLnO/pgV0RephzdTJCKwI3hWzjaaS6aRUUAkFDzg1a1S2sziSzkk39GB6Z9aZFNNCEKAMFXALc/WplJRGmghkDIDHI2/kFOvFXS/noH2hNihWKLkfiKScWoKSWzlW2/MretZ7zywklcgHrt71aknqDd9h7IxfG/KDsOlREMXUg5HXjsKleYuoDcMf4jUU8ewbg3Tpmo3ZKEe+uo7jaQsi7do3jPFTQ3KkhSB83GR2NU3y7FnOB7VDK0kbEcEEdVNN33RVjUu9Sa1RUtpigzkqTxmsyS8L3KvI2WPBIpkdyPmSSAMO59BSywRzRHycI4GQD0IqknaxSVjUtb8LEQH5z/DSXiySzB0kEpA4Gc4NctBcTRXAjUbTnJLf56VrR3EyfPkFj3B60kn1K5Lalt3QlSECyDqc801HeWVcjlTggdKpPdF3LuoBx94cZPvVqK7hNv8jgs3XA6H60uXuTZlmRx5JDMeO39DVG5g8wqzBhkZCqe1X7Cwe8JJPyYz97BqGSORGKlcKDjeB2qoNpELQx5C0CcgsScdKswvKYcsWCqPzNSR7/tPDHgYxirCRq4CqNrdFApJaltkkV/HLAkM0aAgffC80RwvdO8kC7kiAIjzk49qakCws8UiDcSM56g06aH7GySwSls5wBwVq4xJVugfaIzONv7oE5PqPatCfUS9utuY1kgTOABzzWIw3Pg7GJHc4/WpbITWtyY5kYkgMuT1HrQnZ6iaHXliBbiaLy5lPGN3zJ7EVmrBJblQ4VS/zZzkYNb7j939oDCN8kD1/KqbeSU8thuYkkjOcn1FHmy4t9RLTnESKGbqT6etaUbC8YxrbGRlGCCcnHqKox2/lGJoJSJAD8nT9ajjuGTc6/LLn7ynHSotbUl+RevpIkjSOB2zyNrL0+lRWFqoWT7Ym0sP3cgbhT70Wtt5pMrnd7Gn3brGgV2wpwQooveQLshs4S1kAWdXQEfLjmrEVyp8sDHzc4PP41A4smh/0djE4GXD85PsaLOFRbGTgluuRzU1FZoGkXJVaRg0KkueMCoGnkX7373vjHerkEP2Zg5JEuMimMHurjauxXc4wOAaTRJkTNcsgaXhS3B9PrT4sKR5jDkfKcVpZuNOmaO6t1KsvKuuQw7Ef4isG/cGUCDcqE8rnOKNEjVanS6WLZ8tcjdGRgcc0+8tIdokjymBgnORWRauzRryQqjgf41eklCxod+cn8qmK7k7F61kms4Q6eW8TjB5yD9RUDbGJdFKqegPr7e1Z0jlQSNyoepFaNk4lizGwwPX+lO66i8yBoZZHJf7gqUQG2gd47J3bOS+enFJfXCwDnbuBOcdKyRM/nO4lfy8cEfxfSi66Fx1Ld88l2il4j5oT7zHkYqnHFJEFjbJdgDTkd4l8y5JYOQQT+VadjF5k3mOyoWICBsjj60NXNG7Kw5bWWOIFIiF/vCmoXDESwFlU7SuM1fF3tiGDjacY7fWmXN5K8IigHlseHk9fT6UrqLsRF6maYJZrxotzJGF6PxjHarUcaRLh1YSK2OR2xTC5jmjjhyWHc85NPeVZItrRndnLNuzRo3uXJ3B5MMQcgjt7dqhdTyzBgegJ7mmNO9sjuV3gnADDOf/AK9VIjczo3yHI/ic4C0W0HGJn21pNqEzxwkGRRn5uPwq/DcK8KxOPLmQ7SPWq+0RFmiZt7cDacE0thbtcXJjQqJvvc8bqck1qc8tS08DNAxAVVUjJ96ps8i4Abgd/WrMdxsJWQnduxg1NqCqpzbA7TyykdKPiJXYpMQWVvzzVqPLwyKeF6hV7VErLtIGOB+VSAlWVyh45x0rphHQerIkjKTjeRgDge9WLgQzQKYWKuDgow/XNU55CzlmAPUgHsafFMERdqqc8bs85+lS1YbRBHDcCaRbiS3EZbMRjBBVcdGz1Oe4oFrcoPtSQ+bEDgkHINTu0CJunywzz7VnzSIspewu5Gj7gHH4EU4rS5cUWZfJn2eRtiLnkMelUruCUAAlSoOOtRFvLkRo4y2SSS1WLeeKWR0udyuQPLZT8oJ7ml6FJdUQxxvJH5RGVXLhu4/+tUUsZjGRKAewboas31lLHc/u2M8anAdD8ppIrd5fM8wgc4xncc+lZe/fQd+pTdw7iM7gehNaVlaLgIp689ec1WkX50jj4yfve9Kwns59lxlGPT/9dW7oTb6FiOaS0ZjMCdv61JZaoWEiSkojkZLDoP8ACobq4e4ZQxGFGCQOKqXKA7ckEdeKjm1J33Op0+GCVwxmjXB4OPlNLMsMLNINqnPy7Tjn1rmPOe3j3R5wB1U5pg1SSXcJG+Xp81Wm29hKm2bF5MGczSk+Z0OB94+tVXuN8mVBIA5FU0vw6JH96PrkjkVbQWryRm3R1JGWJP8AKrtbcrltuR7SxMjHgHgVPHIyruBDSKMgnPyil2LAzM5LJ1Aqta3VtKsu4ETA8AfdYUPa5VtLl57yOaNQfl38E570kUBSR5U2zqo3kKeRWJdy5m2LlduT7VbsGlhRBGGDn5jg9Ki99Bctti/LOHPmIcAdQRioF/eON/GenPWtSxit9RuXNwyoqjdxxuI9qgvIFgnCLJHIDg7x71ViUhsby2znGQxG0jPalYLMmJV2HH3j1qS3A2bGBDHk56fnTbpjHJGxfcoOSo5waltJuwvQqC1Afh9y9cg8CrtuXtZFWVd3GV3dCPrSorF9zKBu6Y7e1TOweQbEDx7cbCen0rNq+4nqBvFMnzEAf3gamWSMqJCu4E9RWbbRo1w2EIAOQrc/hUkjlrgqMqBwV6U0kK3Ql1G+lmKQsS4QYXPVRVaKKOIiSM73PPPc1fnjiNv5cSDzc5ZwcnHvWYX8hyrKwk6cn9RQ/d1Kj5D0LEswUliSfl7CrEKecgJLAKQCM1XmkRySMx89V60rzxqAkfzOwBOM07cxdr6lm7VCyxocbiBx3FRPObUFAehwMdaAQRGbokBRjI60yKMTTDA+ReWJonC60FYngJmDC4TdxxT/ALM+3zzgoDsxnoajZvLfABUHjGf1qeWQi2LeZgcL5f8AEfes7WJWhI1qLhQ0vEangepqa4uVMMNsqKDHnD9z7VWgMj/KpCD+Iv29KuqLaJcx7nlAwd/Uf4ilG7C/QgjDOwDHjPc4FPFyY45EjTBYYIbvVS6lDKf0Henf6m2+8GYjnJ5otroUvIs2xikAyBuHbvWkYIvLhV5I2cZykY5HuTXPRsUHykCQ9d1aSXfkjeu0nGCB0apW4NFm0+yIk0t0pkf/AJYqOmfU1m6hcmYkRqERewqtLcs52qdp68fyqS3DIoZuo5+oo5mnZFRWtytaAzBtse7n71R3Fu0Th8jI6EGoLWdo2YEhcfrWgrJdR4lOxx0IHH413KKtqZPQzpopJZASxLHnJHQVat71kRIZ9phXjIHP40stvIis4G5Rxupjae5Tcw564FY8uuhJpwWUV5D5kUuwnopOM0w2xtyi3BKDoGPemabN5OVjxuxghqvSpc3kRmkOUjGBn0pxlrZCvqUJVTy9ghRpCSd+cE1nixmkWZ7dGLLyY1GePWp5WUxkGTbg8ADrUttEwV/sk8iT7cMM8MKt6lp2MOaDALTuw4PA55pmniKAkzIZFbsp5rVe6/dNFcwJK+doz1FVZLNWCmJtrHtQ3psUpCRNHcud5ZE7K3UipbvTMxl7LcUxwvUgVlXLOhUd8/55p9tq5inMSu67QMuvSs22tWOztdFqVpBbwhLssqj5o9uMVLBOZQ+31796JoXuJf3LCZTjGRtJrNbdFIQTscNVPVaBuakqxqOVAb19ao387S7I1benbPak+07uGwzEcD0NNhuHsJluNiNKhyFYZU/UU0m1YaRLBKlvHy4Y9CTUM0nmsBEwC02d7e8iMiIyTszMwB+XHsKZa27IDsA3dMg5/GsmrA0lqEQZ3MMcmBnPPB//AFVfnsonhCZJcDJk9/8ACoktDDJ+82hiOD6/WnzMYyFDgoccdea0jo7spMxJ3Ni7I6Fm9PX6VoaFM98wMKhpG4EI649PrVbyEkkk84mQJyM1Czx213GbMvCw5BRuh9a0qNz1R0SjdeZs3lyqF47hShXqrcYNc3qV2Ek86AkN+hFa097DqACa1GrM7YaaM/OR0/OobzS4YG/0OaWfTs5TzBhh7EVKkluXCMY7iW92jKJFGWOCN3+Fa9urunyMVBAyCeprn9OspJGeW3Vkii/1gboPpWtbTSJGSOf9kdamT7dTOrFR2NhI/Jj2j7zDDPViwMCrNFKyvwFAPXnuB3rEa7kkIGzeQOADyKu2llcyu09syuQATHnBFEVoYNdWWbyZ7XbH5pMajC5qtC7yOS4AA56dasvMty8cUkQiIGD/AL3rUz2bceTIGTH3h2qG1eyIuhodtm6PLZ4Kgc/hViFfmUkMpHUZpsa+VJhDuZvTgipDIOzHfnvRa5Frkt3BE9qojyjj7w7/AFFZ5Q7g8rlyvGRzj61MZgG3lZCoGA3Q5qEecrxmS3fLAsjI2CR6+9HUaTKr3Ei3KeW3zY7DpU0Nyx3/AGpFkGchu45qvdWlxc3W+Kb95jHGKjktbmBWEsqK3QYHWqlvY0su5ff7PMoMbC2mByAeVP8AhUEUSreg3J8tR1Yd6yitwyZklB3HjA61K6SqoE28dlj6496LIvl8za8uO/u2WK42RgfK0nAJ7A1CjS2zNBNgN0wOap2trtQrK7iPooB5J963rWe2jtPJlsBcTOeHViCPcVTstyJWWhQVnNzllB2jADH7xrWtHQMBPENmQSpHP51BBGogLP8AMeg55BqZJSQVuU3KBw46j2qLLdkOxYnCXcokiARxxjs3/wBeoZWREIxhx/e4qBWcLhTzyxGcHHrSyhp1WS4ZhDnar7eCamW+grXZXRSGywJz2I61JLEFwsgy/oe1W7XZbvvkTzMAgYP3vQ1WGD88hLM/ODyazTKTsIlqdRljWPYkqkAnO0H61HLviLLjzEUkEpyBU0Vpv+aVikZOORziobhpguy2ZBjKgIME+9Va2pa1Kog3tvhOY1OWz1q9IDHAuee2CegqC0QW6oMgsv3geh9qsXBgmb90HFuTlc/wnuPpUqNtR+hQW3aRRtx6g9qfHFwQCEZfXvUdkT5JGeNx/nVh/viuq+tjmb1JY5ZIovJl+6TzTjNIh3QnlOc9qZfk+UD32VCv+oz320m+Ui9iK4vUkbzPKAlHUjgE0s+qmOPyxnZjJIPes2X75qvN9+L6UktbmqSLvmuQGc/Mf0qeNXUIzAgnoc1UH31HbFbumANHGGAI54NaS2FIqmTyI0kRcyochsZrPjumjupZZQTkHOBnrWlL/rmHbJ4qrAqs8mQD8hPIqE9AgUtUt4r22V7YujgZkUn9RVSyhgRl2hTIDk7u5q3B95foarSABmIAzR0Nb6WLas6SMygAdevp2pdUuEvABJEiOBjcgwT7mnWnNlNnnAP8qzYuevPNNr3bistwitY4ZYpfMBR+oHUe9WdZtbX7TEljcySs3XemABUagFmyPWtHQhmefPZDj2pxXLsXdrUwZYp4nDKpYk7cp2rYs1Z5REU2uw2gvxg1Jbf8fEn1Fb3iEA6fpzkfOQct3NZtX1Im7nL6qs9hdGCVQ2BwV5H502CRWwWXOBnFbTfPbxbvm+U9ea5+24aQDgBhUy1Ki7onuVhdwUUNgdF4zUQ060vFH2NxDcryY5T97HoaljA+zhsfNuIz3rKuDiWMjg+YOauD0saQbM3U4Jbe6VZY/LkznB6Gtl9Szpwj8k71OOvXFT6h84ct8xCnk81jy825J6g8Gokramt+dK5JpyyR5CzOFY7nQdDW4R8pPALY2lf5Gse2J2Hn0qzubenJ6+tawjdEzfMzRWNo3/eqCSMD2pwk8rBBIbtg063JMYJOTz1prAeWOB/k0n2MN3Ys2kk00gLpuXPU88+taO6SG5YAfIqgnHIAqracRMBwMr/Kui8MqrT3gZQQ0fOR15rJN3JkUJTbhgspB34Kz91PpUcUgRXjKRybjkPnlai1YAOFAwoLYFULInz5Bk4waubaRNrIuXskSQfKVOB0IrJW7fcCWPIwuOq/4VPc8hs+lVSB5PQVK7FIvNKGYbjwMHd0yKkur1BAFdBJGh+U5+7WZ0Xjiq8BzNHnnOP50lpdjsX7WHzZBtwq5yN3atO4eOJnb5S5UBSeST70y7VUbCgKMDgDFVX/AOPtPoaa3uK9xsTvLcgn5U/u471v2Uyw7ZNqhl6k/wAqwckucnPT+daFz0h9xSqXT1FMTUbwXN8ZI4vI7FVPBPrUUt3uXBBDHtnvSXgHzcdB/WqqAER5APXrTb1GlcsWWRMzzOAo4C/0rTe6lez2bsRZyI8cfWsG84ukx6/0rWsfmRt3Pyjr9KJqz0HMIvtAAhjH7p+VPUmpkidJJcFWdD90d6NEJ+3sM8ANj24qEM2Qdxzkc596lLW5Nx7XPnECSQqvQAfyp7WYiiWWJxJM4J+U8qPes+b/AI/HHbNbkHFmxHBOc0mVeyMxTBHIvn5WQHoASPxq7EiXBwcKi9eOD7Cq+s8QwMPvHIz3qS0/1We9Yt62Dpc//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lesion has a warty, tortoise shell-like, \"stuck on\" appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic keratoses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These \"stuck-on\" appearing lesions are most often confused with malignant melanoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic keratoses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Seborrheic keratoses are common, benign, yellowish to brown, raised lesions that feel slightly greasy and velvety or warty. Typically multiple and symmetrically distributed on the trunks of older people, they may also appear on the face and elsewhere.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sauer, GC. Manual of Skin Diseases, 5th Edition, JB Lippincott, Philadelphia 1985. Copyright &copy; 1985 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_38_38506=[""].join("\n");
var outline_f37_38_38506=null;
var title_f37_38_38507="Contraindications exercise test";
var content_f37_38_38507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contraindications for exercise testing in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Acute inflammatory cardiac disease (eg, pericarditis, myocarditis, acute rheumatic heart disease)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Uncontrolled heart failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute myocardial infarction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute pulmonary disease (eg, acute asthma, pneumonia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe systemic hypertension (eg, blood pressure greater than 240/120 mmHg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute renal disease (eg, acute glomerulonephritis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acute hepatitis (within three months after onset)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Drug overdose affecting cardiorespiratory response to exercise (eg, digitalis toxicity, salicylism, quinidine toxicity)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe aortic stenosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe pulmonary stenosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Serious ventricular dysrhythmia, especially when associated with significant cardiac disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coronary arterial diseases (anomalous left coronary artery, homozygous hypercholesterolemia, Kawasaki disease [acute phase])",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Severe pulmonary vascular disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Metabolic disorders (glycogenolysis types I and V)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hemorrhagic diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Orthostatic hypotension",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Washington RL, Bricker JT, Alpert BS, et al. Guidelines for exercise testing in the pediatric age group. From the Committee on Atherosclerosis and Hypertension in Children, Council on Cardiovascular Disease in the Young, the American Heart Association. Circulation 1994; 90:2166 and James FW. Exercise testing in children and young adults: an overview. Cardiovasc Clin 1978; 9:187.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_38_38507=[""].join("\n");
var outline_f37_38_38507=null;
var title_f37_38_38508="Risk classific exercise class C";
var content_f37_38_38508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk classification for exercise training: class C: those at moderate-to-high risk for cardiac complications during exercise and/or unable to self-regulate activity or to understand recommended activity level",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        This classification includes",
"individuals with any of the following diagnoses:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Coronary artery disease with the clinical",
"characteristics outlined below.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Valvular heart disease,",
"excluding severe valvular stenosis or regurgitation with the clinical",
"characteristics as outlined below.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Congenital heart disease; risk",
"stratification for patients with congenital heart disease should be",
"guided by the 27th Bethesda Conference recommendations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Cardiomyopathy: ejection",
"fraction &lt;30 percent; includes stable patients with heart",
"failure with clinical characteristics as outlined below but not",
"hypertrophic cardiomyopathy or recent myocarditis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Complex ventricular arrhythmias not well controlled.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical characteristics (any",
"of the following):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. NYHA class 3 or 4.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        2. Exercise test results",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Exercise capacity",
"&lt;6 METs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Angina or ischemic ST",
"depression at a workload &lt;6 METs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fall in systolic blood",
"pressure below resting levels during exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nonsustained",
"ventricular tachycardia with exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Previous episode of primary",
"cardiac arrest (ie, cardiac arrest that did not occur in the presence",
"of an acute myocardial infarction or during a cardiac procedure).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. A medical problem that the physician believes may",
"be life-threatening.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Activity guidelines:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Activity should be individualized, with exercise",
"prescription provided by qualified individuals and approved by primary",
"healthcare provider.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Supervision",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Medical supervision during all exercise sessions",
"until safety is established.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        ECG and blood pressure",
"monitoring:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1. Continuous during exercise sessions until safety is",
"established, usually &ge;12",
"sessions.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NYHA: New York Heart Association.",
"     <br>",
"      * Class C patients who have successfully completed a series of supervised exercise sessions may be reclassified to Class B providing that the safety of exercise at the prescribed intensity is satisfactorily established by appropriate medical personnel and that the patient has demonstrated the ability to self-monitor.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher GF, Balady GJ, Amsterdam EA, et al. Circulation 2001; 104:1694. Copyright &copy; 2001 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_38_38508=[""].join("\n");
var outline_f37_38_38508=null;
var title_f37_38_38509="Acromioclavicular injury Type III";
var content_f37_38_38509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acromioclavicular injury Type III",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 203px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Type III AC injuries represent complete rupture of both the AC and CC ligaments. This radiograph clearly shows the clavicle elevated above the normal plane of the AC joint and an increase in the coracoclavicular distance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott M. Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_38_38509=[""].join("\n");
var outline_f37_38_38509=null;
var title_f37_38_38510="Radiation survey documentation A";
var content_f37_38_38510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 592px\">",
"   <div class=\"ttl\">",
"    Radiation Incident Patient Tag",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 572px; height: 672px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_38_38510=[""].join("\n");
var outline_f37_38_38510=null;
var title_f37_38_38511="M mode mitral valve";
var content_f37_38_38511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    M mode echocardiogam of mitral valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anterior leaflet of the mitral valve opens widely at the beginning of diastole (D), reaching a peak at the end of rapid left ventricular filling (E). During diastasis, the valve leaflet floats back towards a closed position (E) and it opens again with atrial systole (A). At the end of diastole and the initiation of systole, the mitral leaflets are closed (C). The posterior leaflet is a mirror image of the anterior leaflet except that its amplitude of motion is less.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_38_38511=[""].join("\n");
var outline_f37_38_38511=null;
       